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Abstract 
Epstein-Barr Virus (EBV) is a human gamma herpesvirus that infects about 
95% of world population. The life cycle of EBV can be divided into two stages: 
latent and lytic. During latency, the virus DNA is maintained as a nuclear 
episome with minimal protein expression to avoid immune recognition. Although 
primary EBV infection in childhood is usually asymptomatic, infection with EBV 
is associated with a wide range of proliferative diseases such as post-transplant 
lymphoproliferative disease (PTLD), Burkitt’s lymphoma (BL) and primary 
effusion lymphoma (PEL). Despite EBV infection being common, less is 
understood about the host control of the lytic virus life cycle or the sequence 
diversity of the viral genome. 
This thesis investigates the reactivation of lytic EBV replication in both PEL and 
BL cell lines and whole genome EBV sequence diversity. X-box binding protein 
1 (XBP-1), a transcriptional activator that is essential for plasma cell 
differentiation, reactivates Kaposi sarcoma herpesvirus (KSHV), a closely 
related gamma herpesvirus from latency. With KSHV and EBV co-infection in 
PEL, the possibility of XBP-1 also reactivating EBV is investigated here. We 
show XBP-1 does not induce EBV into the lytic cycle in tumour B-cell 
backgrounds, either with or without protein kinase D. This contrasts previous 
observations. The lytic replication of EBV generates sequence diversity. To 
further understand EBV genomes and their association with the malignancies, a 
pipeline for sequencing EBV whole genomes using Next Generation 
Sequencing (NGS) has been developed. EBV whole genomes from mature B-
cell tumour lines, such as PEL and BL have been sequenced assembled along 
with EBV from blood samples of PTLD patients. Examining the EBV whole 
genome sequences from PTLD blood samples through time suggests dynamic 
EBV sequence evolution can be observed in vivo. We conclude that EBV 
genomes contain higher variation than previously expected, and further study is 
needed to understand the relationship between EBV and the diseases. 
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Chapter 1 
Introduction 
1.1. Human Herpesviruses 
The Herpesviridae are a large family of DNA viruses that infect nearly all 
animals, including humans. Over a hundred herpesviruses have been identified 
with hosts ranging from primates to oysters, with most species being 
susceptible to be infected by at least one type of herpesvirus. The name 
“herpesvirus” is derived from “herpein” in Latin meaning “to creep”. This 
highlights one of the most important features of this family of viruses, which is 
that infection with herpesvirus cannot be eliminated from the hosts. The viruses 
have the ability to cause latent infections and as such remain in the infected 
host for life. The latent viruses can remain silent in the infected host, with the 
ability to reactivate and produce infectious virus particles. All herpesvirus are 
double stranded DNA (dsDNA) viruses with genomes ranging between 125-290 
Kilo bases (Kb) and a characteristic virion structure (see chapter 1.1.3.1 for 
more detail). Currently, eight human herpesviruses (HHVs) been isolated and 
identified, which are divided into three sub-families; alpha-, beta- and gamma-. 
The sub-family and diseases associated with these eight HHVs are shown in 
table 1.1.1. 
This Ph.D study focuses on the gamma sub-family of HHVs consisting of two 
members: Epstein-Barr virus (EBV/HHV-4) and Kaposi’s sarcoma associated 
herpesvirus (KSHV/HHV-8). Gamma-herpesviruses are characterised by their 
limited host range, lymphocyte tropism and sequence homology. EBV and 
KSHV belong to the gamma-1 herpersvius (or lymphocryptovirus (LCV) and the 
gamma-2 herpesvirus (or rhadinovirus (RV)) respectively; the details and 
difference of these two viruses will be discussed later in the chapter. The 
gamma HHVs are the only two viruses that have been associated with tumour 
formation in different cellular backgrounds, and both have also been associated 
with more than one type of lymphoma (table 1.1.1).  
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Table 1.1.1. Summary of human herpesviruses (HHVs) and the associated diseases 
Sub-
family 
Human 
herpesvirus 
Common name Disease associations 
Alpha 
 
HHV-1 Herpes-simplex virus (HSV)-1 Oropharangeal herpes (cold sores) 
Genital herpes 
Alpha HHV-2 Herpes-simplex virus (HSV)-2 Genital herpes 
Alpha 
 
HHV-3 Varicella-Zoster virus (VZV) Varicella (chickenpox) 
Zoster (shingles) 
Gamma HHV-4 Epstein-Barr virus (EBV) Infectious mononucleosis 
Nasopharyngeal carcinoma 
Burkitt’s lymphoma 
Classical Hodgkin’s lymphoma 
Post-transplant lymphoproliferative 
diseases  
Beta HHV-5 Human cytomegalovirus 
(HCMV) 
CMV-mononucleosis 
CMV disease 
Beta HHV-6a 
HHV-6b 
 Exanthem subitum (sixth disease) 
Roseola infantum 
Encephalitis 
Beta HHV-7 
 
 Exanthem subitum (sixth disease) 
Encephalitis 
Gamma HHV-8 Kaposi’s sarcoma-associated 
herpesvirus (KSHV) 
Kaposi’s sarcoma 
Primary effusion lymphoma 
Multicentric Castleman’s disease 
 
1.1.1. Morphology of herpesvirus 
Members of the herpesviruses all share similar morphology and structure, 
despite the taxonomical divisions within the family. Figure 1.1.1 illustrates the 
structure of the virion of all herpesviruses. A typical virion consists of a core with 
linear dsDNA, packaged within an icosahedral capsid (Furlong et al., 1972; 
Nazerian, 1974). The capsid is surrounded by a layer of proteins called 
tegument proteins which are packaged by the virus envelope that forms the 
outer most layer of the virion. The envelope is a lipid membrane and is believed 
!
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to be derived from patches of altered cellular membrane (Rickinson & Kieff, 
1996). Viral glycoproteins are embedded within the lipid envelope, forming the 
“spike” look. Different herpesviruses share the same virion structure but differ in 
the size of the virion, and the glycoproteins embedded in the envelope.  
Figure 1.1.1. A) Electron microscopic picture and B) schematic diagram of the herpesvirus 
morphology. Linear dsDNA forms the core of the virus, packaged into an isocohedral capsid, 
surrounded by tegument proteins. The outer layer of herpesvirus is the envelope, which is 
covered by the glycoproteins that are important for viral entry. Adapted from (Young & 
Rickinson, 2004). 
 
1.1.2. Life cycles 
The life cycle of all HHVs can be divided into two phases; lytic and latent cycle, 
this allows the viruses to establish persistent lifelong infection and onward 
infection of new hosts. After primary infection, the virus establishes latency in 
different cell types (Roizman & Whitley, 2001), depending on the virus. During 
latency, the viral genome exists as an episome (circular DNA) in the nucleus of 
the host cell and minimal viral gene expression occur thus avoiding host 
immune surveillance. The virus enters its lytic cycle upon appropriate cellular 
signalling. During the lytic phase, viral replication occurs to produce new viral 
particles infecting new target cells. Both KSHV and EBV, as gamma 
herpesviruses establish latency in lymphoid cells, specifically in memory B-cells 
for EBV (Babcock et al., 1999; Babcock et al., 1998; Souza et al., 2005; 
Thorley-Lawson, 2001). The true latent B-cell for KSHV has yet to be 
determined. 
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1.1.3. Epstein-Barr virus (EBV) 
1.1.3.1. General background 
EBV was discovered in 1964 by M. Anthony Epstein, Bert Achong and Yvonne 
Barr (Epstein et al., 1964) via electron microscopy of cells from a Burkitt’s 
lymphoma (BL) biopsy. BL was first described by an Irish surgeon Dennis 
Burkitt, as a tumour that was common to children in equatorial africa in 1958 
(Burkitt, 1958). This tumour was subsequently named Burkitt’s lymphoma. BL 
has a distinct geographical distribution (Burkitt, 1962), however, EBV infects up 
to 90% of population worldwide (Rickinson & Kieff, 2006), the high prevalence 
earned the virus the nickname “Every Body’s Virus”. In developing countries 
EBV infection usually occurs in the early years of life, often without overt 
symptoms. Infection with EBV later in life, such as in adolescence or young 
adulthood is more common in the developed countries and often associated 
with a lymphoproliferative disease called infectious mononucleosis (IM) 
(Kuppers, 2003), also known as glandular fever. Despite primary and persistent 
EBV infection being mostly asymptomatic; it is known that the virus is able to 
transform B-cells in vitro and is associated with the development of several B-
cell lymphomas, such as Burkitt’s lymphoma (BL), Hodgkin’s lymphoma, 
primary effusion lymphoma (PEL), post-transplant lymphoproliferic diseases 
(PTLD). EBV is also associated with an epithelial tumour, nasopharyngeal 
carcinoma (NPC) (Andersson-Anvret et al., 1979). EBV was the first human 
virus to be classified as a tumour virus (Rickinson & Kieff, 2006). Recently, it is 
believed that EBV infection is also associated with higher risk of some 
autoimmune diseases, such as systemic lupus erythematosus (SLE) (James et 
al., 1997; Toussirot & Roudier, 2008), rheumatoid arthritis (Toussirot & Roudier, 
2008) and multiple sclerosis (Ascherio & Munch, 2000). EBV is transmitted 
orally, and the infectious virus can be detected in oropharyngeal secretions 
(saliva) from the IM patients and EBV seropositive individuals whether they 
were immuno-suppressed or healthy (Gerber et al., 1972; Strauch et al., 1974; 
Yao et al., 1985). 
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1.1.3.2. Epidemiology of EBV associated malignancies 
Since EBV infection at childhood often occurs with no symptoms, it is difficult to 
determine the epidemiology of the primary virus infection. However, some EBV 
associated tumours are associated with distinct geographical regions. NPC 
occurs most frequently in Southern China, Southeast Asia, the Maghrebi Arabic 
regions of Northern Africa and the Arctic and less frequently in the rest of the 
world (Bray et al., 2008; Chang et al., 2009; Chang & Adami, 2006; Hsu & 
Glaser, 2000). BL occurs most frequently in equatorial africa. Despite BL being 
diagnosed in the rest of the world, only a small proportion of the cases are 
associated with EBV infection, whereas most of the BL in equatorial africa are 
associated with EBV (Brady et al., 2008; Chan et al., 1995; Gutierrez et al., 
1992; Klumb et al., 2004; Mbulaiteye et al., 2009; Philip, 1985; Rochford et al., 
2005). The correlation between the geographic and climatic distribution of 
endemic BL and holoendemic malaria (Plasmodium falciparum malaria) have 
been well documented in equatorial africa (Booth et al., 1967; Kafuko & Burkitt, 
1970). Prior to the discovery of EBV, BL was believed to be caused by 
pathogens transmitted by mosquitoes. Intense exposure to Plasmodium 
falciparum and EBV infection are co-factors to endemic Burkitt’s lymphoma. 
Details of the relationship between BL and malaria will be discussed in chapter 
1.3.3. 
Hodgkin’s lymphoma (HL) is most common in Europe and North America, to a 
lesser extent in South Africa, and even less common in China or Africa. 
However, EBV associated HL is most frequent in Africa and South Africa, but 
only present in moderate levels around the rest of the world (Chang et al., 2009; 
Dinand & Arya, 2006; Ferlay, 1992; Weiss, 2000). Previous reports linked 
infectious mononucleosis (IM) with HL in the 1950s.  The association appears to 
be the strongest in young adults, however it is unclear if IM (primary 
symptomatic infection with EBV) or primary infection (non-symptomatic) acts as 
risk factor of HL. Details of HL is described in chapter 1.3.5. 
The reason for the three EBV associated tumours showing three different 
geographical patterns is not clear. There are many factors, such as human 
genetic variation, environmental, or other viral factors that may influence the 
geographical restriction. Studies have been carried out linking polymorphisms of 
specific EBV genes to geographical regions mostly for NPC. Little is known 
!
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about the whole virus, the association with the host genome, variation and 
association with other geographical factors.  
 
1.1.3.3. EBV Virion and Genome structure 
The general structure of herpesvirus virion has been discussed in chapter 1.1.1. 
The EBV icosahedral capsid comprises 162 capsomeres with the major capsid 
proteins 160, 47 and 28 Kilo Dalton (kDa) in size. This is similar to the major 
capsid protein of herpes simplex virus type 1 (Forman et al., 1985; Foster, 
1966). The most abundant capsid and tegument proteins of EBV are 350/220, 
and 152 kDa respectively, which differs from HSV-1 (Rickinson & Kieff, 2006). 
The major difference between EBV and other herpesviruses in virion structure is 
that EBV has predominance of a single glycoproteins gp350/220 in the outer 
envelope.  
The EBV genome DNA in the viral particle is linear, double stranded, and 172 
kilobases (kb) long and encodes 94 (type 1) and 82 (type 2) genes (Baer et al., 
1984; Rickinson & Kieff, 1996). During latency, the EBV genome exists as a 
circular episome inside the nucleus of the infected cell (Dambaugh et al., 1980; 
Lindahl et al., 1976). Figure 1.1.2 shows the simplified structure of both the 
episomal (figure 1.1.2.A) and linear genome (figure 1.1.2.B). EBV contains 
repeat regions, firstly a series of 0.5 kb terminal direct repeats (TRs) reside at 
both ends of the linear genome, which are joined in the episome (Dambaugh et 
al., 1980), and internal repeat sequences (IRs), also known as the W repeats 
that divide the genome into short (US) and long (UL) unique domains. These two 
unique domains are 15 kbp and 130 kbp long respectively. Unlike other 
herpesviruses, these two unique domains maintain their unique orientation 
relative to each other (Baer et al., 1984). During latency, EBV replicates from 
the circular DNA form via oriP, known as the plasmid replication origin (Yates et 
al., 1985). However, during the lytic cycle EBV is replicated via oriLyt 
(Hammerschmidt & Sugden, 1988). During lytic replication, the genome DNA is 
synthesized as long head-to-tail concatemers, which are cleaved and packaged 
into virus capsids. 
There are two viral elements that are responsible for maintaining episomes: the 
cis-acting sequence, oriP; and a gene encoding a trans-acting protein, Epstein-
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Barr Nuclear antigen 1 (EBNA-1) (Yates et al., 1985). The oriP sequence is 
composed of two functional elements: the dyad symmetry element (DS) and the 
Family of Repeats (FR) (Baer et al., 1984; Reisman et al., 1985). The FR 
consists of multiple copies of a 30bp repeat unit, with each unit consisting of a 
16bp palindromic sequence that constitutes an EBNA1 binding site (Ambinder 
et al., 1990). It has been shown that, unlike other repetitive sequence that alter 
in copy number during viral replication, FR maintains its copy number 
throughout the process (Fruscalzo et al., 2001), and is conserved with in strains 
of EBV. Hence the copy number of FR is distinct for each EBV strain (Ali et al., 
2009). 
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Figure 1.1.2. EBV genome shown as a double-stranded DNA episome (A) or a linear form (B), 
with the origins of plasmid replication (oriP) and lytic replication (oriLyt) indicated. The large 
solid blocks represent coding exons for each of the latent proteins and the arrows indicate the 
direction in which they are transcribed; the latent proteins include the six nuclear antigens 
(EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and the three latent membrane proteins (LMP 1, 
2A, 2B). EBNA-LP is transcribed from variable numbers of repetitive exons. LMP2A and LMP2B 
are composed of multiple exons located on either side of the TR region, which is formed during 
the circularization of the linear DNA to produce the viral episome. The open arrows at the top 
represent the highly transcribed nonpolyadenylated RNAs EBER1 and EBER2; their 
transcription is a consistent feature of latent EBV infection. The outer long-arrowed line 
represents EBV transcription during a form of latency known as latency III, where all the EBNAs 
are transcribed from either the Cp or Wp promoter; the different EBNAs are encoded by 
individual mRNAs generated by differential splicing of the same long primary transcript. The 
inner shorter arrowed line represents the EBNA1 transcript originating from the Qp promoter 
during latency I and latency II. (B) Diagram showing the location of ORFs for the EBV latent 
proteins on a BamHI restriction endonuclease map of the prototype B95.8 EBV genome. 
(Adapted from (Young & Murray, 2003) and (Tao et al., 2006)). 
 
1.1.3.4. EBV Typing 
EBV can be sub divided into two types, namely type 1 and type 2, based on 
variation in the EBNA genes. The types are also referred to as type A and B in 
earlier publications. EBV type 1 was first sequenced from the B95.8 marmoset 
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cell line, which was infected with EBV from an IM patient (Baer et al., 1984). 
The type 2 genome has been isolated and sequenced from a BL sample, 
AG876 (Dolan et al., 2006). Previous literature suggests that the type 1 strain 
infects dominantly compared to the type 2 strain (Zimber et al., 1986). However, 
a more recent study shows the possibility of EBV superinfection and co-
infection with both strains of EBV (Apolloni & Sculley, 1994; Yao et al., 1996). 
The previous methodologies of assessing EBV subtypes involve transforming 
B-cells with the EBV samples. Since EBV type 1 transforms B-cells more 
efficient than EBV type 2 (Rickinson et al., 1987), this method can introduce 
bias towards EBV type 1 when sub-typing EBV. Nevertheless, EBV type 1 
strains are more commonly found in Caucasian and Asians while type 2 strains 
are less frequent in Europe and the United States, but equally abundant as type 
1 in Africa (Lucchesi et al., 2008). EBV type 2 is not only less efficient in 
producing lymphoblastoid cell lines (LCLs) by immortalising B-cells; it also 
enters lytic cycle more readily than type 1 EBV (Brooks et al., 2000; Buck et al., 
1999; Chen et al., 1996).  
The definition of type 1 and 2 EBV indicates that these two viruses differ in four 
nuclear proteins EBNA2, EBNA3A, EBNA3B and EBNA3C. The nucleotide 
difference between the open reading frames (ORFs) of these proteins for type 1 
and type 2 are 55% (Lucchesi et al., 2008), 10%, 12% and 19% respectively 
(Sample et al., 1990). The percentage of differences is high compared to the 
non-coding region surrounding these ORFs, which is less than 5% (Sample et 
al., 1990). However, the overall difference between the two types of EBV is 
considered minor (Rickinson & Kieff, 1996). The major differences at the 
EBNA2, 3A, 3B and 3C region of EBV type 1 and 2 are known, but it is not clear 
if there are other differences in other parts of the genome. Variations in genes 
such as BZLF1 have been observed (see chapter 1.1.2.4.), however, these 
differences have not been associated with a type-specific phenotype. However, 
small type-specific differences have been discovered before in EBER genes 
(Arrand et al., 1989). 
EBV type 1 transforms and establishes latency in B-cells better than type 2 in 
vitro, which is due to the differences between the EBNA2 and EBNA3 genes 
(Sample et al., 1990). It has been shown a recombinant type 2 EBV with the 
EBNA2 coding sequence replaced by EBV type 1 EBNA2, acquires the 
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efficiency of transforming B-cells of the type 1 virus (Cohen et al., 1989). There 
are some genes that are induced more strongly by type 1 EBNA2 than type 2 
EBNA2, such as latent membrane protein 1 (LMP1), which is important in 
allowing B-cells to survive, after being driven into cell cycle by EBNA1 and –LP, 
however, this effect is only transient. Another gene that is induced more 
strongly by EBV type 1 is CXCR7, which is required for proliferation of LCLs 
(Lucchesi et al., 2008). CXCR7 has been shown previously to be essential for 
transforming endothelial cells by KSHV (Raggo et al., 2005). 
 
1.1.3.5. Variation and polymorphisms of the EBV genome 
Little is known about the variation of the EBV whole genome sequence. To date 
the variation between genomes has been specifically associated with specific 
genes but not the whole genome. Other than the variations associated with EBV 
sub-typing, polymorphisms of specific regions or genes, such as LMP1 and 
BZLF1, have been have been studied extensively.  
LMP1 contains two commonly reported polymorphisms, one is a 30bp deletion 
in the C-terminus, and the other is the loss of restriction site XhoI in the N-
terminus of the gene (Edwards et al., 1999; Nagamine et al., 2007; Saechan et 
al., 2006; Sung et al., 1998). It has been suggested that losing the 30bp region 
in the C-terminus results in a more aggressive phenotype of NPC disease 
progression and increased oncogenesis (Kingma et al., 1996; Knecht et al., 
1993). This deletion has also been reported to be a major characterristic of EBV 
strains circulating in Eastern Asian (Edwards et al., 1999), and Japan (Itakura et 
al., 1996; Mori et al., 1999). The majority of samples containing the loss of XhoI 
site are from Asia, and show higher frequency amongst cancer cases than 
controls within this region (Chang et al., 2009). Despite the similarity in 
distribution and oncogenesis, the relationship between these two variations is 
unclear. 
The polymorphisms between EBNA2 and EBNA3A, B and C have been used to 
determine the types of EBV, either type 1 or 2 (Sample et al., 1990).  The three 
EBNA3 genes share a similar gene structure.  The identified conserved region 
of EBNA3 C terminus contains three direct repeats, which remain conserved 
between EBV type 1 and 2, although the number of repeats can vary in the 
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variants (Sample et al., 1990). To date, there are five EBNA3 genes subtypes 
that have been determined from the EBV type 1 genome in addition to the B95.8 
reference genome, with samples studied from European, region, especially the 
Netherlands and Austria (Gorzer et al., 2006). With the five variants, EBNA3 
variant 5 is the most divergent but also shares the most homology with EBV 
type 2 EBNA3 genes. Previous studies have shown that intertype recombination 
within the EBNA3 genes region (Midgley et al., 2000), and the region 
surrounding the EBNA3A C terminus contain the active locus for EBV 
recombination (Gorzer et al., 2006; Midgley et al., 2003; Midgley et al., 2000). 
The basic residues stretched prior to the leucine zipper domain in the N 
terminus of the EBNA3C allows the EBNA3C protein to maintain interaction with 
RBP-J! in vivo (Radkov et al., 1997; West et al., 2004).  The variants 3 and 5 
both have contain this change in this basic domain, with Arginine being replaced 
by Lysine, although the final charges of the region remain the same.  The 
variant 4 contains only three out of the four Leucines in the zipper region, with 
Methionine replacing one Leucine (Gorzer et al., 2006). The variation between 
EBNA3 genes has also been linked to LMP1 variants, which mainy influence the 
biological functions of the virus.  
EBNA1 is known to contain large variations. One study in Australia sequenced 
the EBNA1 gene from 26 healthy individuals and 17 IM patients, resulting in 22 
distinct EBNA1 sequences with 19 different protein sequences (Bell et al., 
2008). Two major types of variation can be based on the C-terminal region, 
named prototype (P) and the variant (V). Both subtypes can be further classified 
based on the amino acid at codon 487, and further divided into sub-variants 
depending on the amino acid change (Sandvej et al., 2000; Wang et al., 2003). 
Further studies have also showed variation at the N-terminus, namely at codon 
16, 24 and 27 (Gutierrez et al., 1997; Habeshaw et al., 1999). 
The variants of BZLF1 have been identified in both coding (CDS) and non-CDS 
regions. Variation in the non-CDS region involves differences in the number of 
repeats in the first intron (Packham et al., 1993). Five variants have been 
identified from the CDS (Ji et al., 2008) in comparison to the EBV type 1 
reference genome. The promoter region of BZLF1 (Zp) also shows variation. Zp 
is a 220bp element located upstream of BZLF1 gene, containing regulatory 
domains to control BZLF1 transcription (see figure 1.1.5). Five Zp variants have 
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been identified: Zp-P represent the EBV type 1 reference sequence, Zp-V3, Zp-
V4, Zp-PV (Gutierrez et al., 2002; Martini et al., 2007) and Zp-V1, which is the 
most recently detected Zp variant (Jin et al., 2010). Zp-P is more common in the 
Americas and Europe than in China, which was believed to have predominantly 
Zp-V3 and Zp-V4 variants (Gutierrez et al., 2002; Martini et al., 2007). However, 
a recent study by Jin et al (2010) on Chinese children indicates Zp-P is the most 
prevalent strain in China, not Zp-V3 or Zp-V4. Zp-V3 is more common within 
cancer cases across geographical regions, and has been associated with 
malignancy in both immnocompetent and immunodeficient individuals (Gutierrez 
et al., 2002; Martini et al., 2007). More than one type of Zp variant has been 
found in the same individual suggesting superinfection of multiple strains of 
EBV. 
Different EBV variants have also been found in different sample types from the 
same individual (Chen et al., 1996; Edwards et al., 2004; Gutierrez et al., 1997; 
Sacaze et al., 2001; Triantos et al., 1998; Walling et al., 2003), making 
comparison of the data more difficult. Despite many studies showing 
geographical association with certain polymorphisms, it is important to bear in 
mind the heterogeneity in the study designs, non-random sampling and the 
sparsity of data for many of the geographical and disease subgroups evaluated, 
means interpretation should be tentative. 
 
1.1.3.6. Infection and Entry 
EBV can infect a variety of cell types, such as T-cells, NK cells, smooth muscle 
cells (Rickinson & Kieff, 2001) and monocytes (Savard et al., 2000), although B 
lymphocytes and epithelial cells are the two major target cells of infection. 
Figure 1.1.3 illustrates the process of EBV infection of B-cells. During the 
primary phase of EBV infection of B-cells, the B-cell specific receptor 2 (CR2) 
(also known as CD21), a cellular receptor for the C3d complement component, 
is recognized by EBV major membrane glycoprotein gp350/220 (Fingeroth et 
al., 1988; Fingeroth et al., 1984; Tanner et al., 1987). This interaction is 
responsible for viral attachment to the cell surface (Ahearn et al., 1988). 
gp350/220 has a dual nomenclature with genes expressed in two alternatively 
spliced forms, of 350 and 220 KDa each (Beisel et al., 1985; Hummel et al., 
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1984). The splice does not remove the CR2 binding domain, which is at the 
amino terminal part of the protein; and therefore does not affect the interaction 
with CR2. The interaction between CR2 and gp350/220 initiates endocytosis of 
EBV (Tanner et al., 1987) and fusion with the plasma membrane occurs leading 
to virus entry. CR2 is a B-cell surface receptor; it interacts with the cellular 
ligand C3d inducing production of the bioactive fragment of complement protein 
3 (C3), which is deposited on the surface of foreign particulate antigens during 
infection. CR2 then generates downstream signals to stimulate the humoral 
response (Guthridge et al., 2001; Sarrias et al., 2001; Szakonyi et al., 2001; 
Weis et al., 1984). EBV binding to CR2 blocks the interaction with C3d, stopping 
the signal pathway of C3 and the consequent humoral response. Therefore the 
gp350/220 and CR2 interaction not only enables attachment of EBV to B-cells, 
but also blocks the immune response. 
Fusion of the EBV envelope to the B-cell plasma membrane requires other virus 
membrane glycoproteins including gB, gH, gL and gp42. A core fusion protein, 
gB, which is 857 amino acids residues in size, allows virus fusion (Haan et al., 
2001), but is also important for virus assembly (Lee & Longnecker, 1997). The 
other two glycoproteins gH and gL form a non-covalently linked complex in the 
virus (Li et al., 1995). Removing this complex results in EBV binding but not 
penetrating the cells. Protein gH is the largest, with 708 amino acid residues, 
and gL is a 137 amino acid residue glycoprotein which is approximately 25 kDa, 
and remains anchored in the envelop by an uncleaved signal sequence (Li et 
al., 1995; Yaswen et al., 1993). EBV gH is dependent on gL for folding and 
transportation through the cell. 
EBV uses different pathways to infect epithelial cells and B-cells (Hutt-Fletcher, 
2007; Longnecker, 2009). To infect both cell types, gB, gH and gL are required; 
but to infect B-cells gp42 is also required. gp42 is a 223 amino acid protein 
which does not depend on the gH/gL complex for fusion with the cellular 
membrane. It interacts with the gH/gL complex at residue 40 and 58, with a 
trans membrane anchor which lies between residue 7 and 28 (Ressing et al., 
2005; Wang & Hutt-Fletcher, 1998). The carboxyl terminal of gp42 interacts with 
the variable region of the beta chain of HLA class II (Spriggs et al., 1996). The 
interaction between gp42 and HLA class II is essential for EBV infection, which 
has been shown by either blocking gp42 interaction with HLA class II or by 
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preventing HLA class II from interacting with gp42 (Li et al., 1997; Miller & Hutt-
Fletcher, 1988). Binding to HLA class II by gp42 also triggers the fusion process 
of EBV entry of B-cells. The infectivity of EBV alters depending on the 
production cell types, due to the level of gp42 in the viruses produced.  This 
results in switching of the preferred tropism of infection (Borza & Hutt-Fletcher, 
2002). EBV produced by epithelial cells (E-EBV) contains higher amounts of 
gp42, therefore it is more efficient in infecting B-cells than epithelial cells.  
Moreover, the EBV produced by the HLA class II positive B-cells (B-EBV), 
contains less gp42 than E-EBV, and therefore is able to infect epithelial cells 
more efficient than B-cells. The switch of tropism of infectivity and level of gp42 
in produced viruses is associated with the existence of HLA class II. This 
suggests that the infection of epithelial cells act as transient event, which allows 
a quick turnover of producing EBV that targets B-cells.  B-cells releasing 
epithelial primed EBV into saliva also allows efficient infection of epithelial cells 
in a new and naïve host (Borza & Hutt-Fletcher, 2002).  
EBV enters B-cells by endocytosis, internalised into cytoplasmic vesicles (Carel 
et al., 1990; Nemerow & Cooper, 1984; Tanner et al., 1987) with the virus 
envelope fused with vesicle membrane, releasing nucleus capsid and tegument 
proteins into the cytoplasm. This process takes place in a low-pH compartment 
(Borza et al., 2004; Miller & Hutt-Fletcher, 1992). However, EBV infection of Raji 
cells (a BL cell line) is vesicle independent, which is believed to be due to 
cytoskeleton abnormalities of the tumour cells (Seigneurin et al., 1977). EBV 
infection of epithelial cells also use a non-endocytotic mechanism (Miller & Hutt-
Fletcher, 1992) at a neutral pH. Little is known about EBV dissolution and 
genome transport to the cell nucleus. By studying models from other DNA 
viruses, it is believed that the cytoskeleton network is likely to mediate EBV 
capsid transport to the nucleus (Dales & Chardonnet, 1973). A recent study by 
Valencia and Hutt-Fletcher (2012) has shown that actin is important in 
trafficking EBV in B-cells, and in an epithelial cells. EBV requires both actin and 
the microtubule network to successfully deliver EBV to the nucleus.  
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Figure 1.1.3. The infection and replication cycle of human herpesviruses (adapted from 
Mettenleiter, 2004). Schematic diagram illustrates the herpesvirus life cycle from infection to 
either latency or production of new virion through lytic replication. 
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1.1.3.7. Latency programs  
EBV displays five different gene expression patterns, with one expressed during 
lytic reactivation and the other four expressed during the latency stage, 
depending on the stage of development of the infected B-cells. These are 
known as latency 0 (latency program), I, II (default program) and III (growth 
program). Different latent genes are expressed in the four latency programs. 
These programs were discovered in various cell lines (Amon & Farrell, 2005) 
and have been linked to the stage of primary EBV infection in vivo. Table 1.1.2 
shows the details of the four latency programs and the lytic program. It is 
understood that the EBV genes expressed during latency control B-cell 
development by mimicking the B-cell signalling pathways. EBV also uses B-cell 
transcription factors to regulate its own gene expression. 
 
Table 1.1.2. The latent and lytic programs of EBV. EBV expresses different genes during 
different latency programs, associated with different tumours and cell types during B-cell 
transformation (adapted from (Klein et al., 2010; Thorley-Lawson, 2001; Thorley-Lawson & 
Gross, 2004)) 
Transcription 
program 
Promoter 
used for 
EBNA 
Cell 
type 
Associated 
Tumour Gene expressed 
Latency III Growth 
program 
Cp, Wp Newly 
infected 
B-cells 
Immunoblastic 
Lymphomas 
EBNA1, EBNA2, EBNA3A, 
EBNA3B, EBNA3C, 
EBNALP, LMP1, LMP2A, 
LMP2B, EBER1, EBER2, 
BART1 
Latency II Default 
program 
Qp Germinal 
centre B-
cells 
Nasopharyngeal 
carcinoma 
Hodgkin’s 
lymphoma 
EBNA1, LMP1, LMP2A, 
LMP2B, EBER1, EBER2, 
BART1  
Latency I  Qp Dividing 
memory 
cells 
Burkitt’s 
lymphoma 
Primary Effusion 
lymphoma 
(PEL) 
EBNA1, EBER1, EBER2, 
BART1 
(PELs also express EBER 
and LMP2A) 
Latency 0 Latency 
program 
 Resting 
memory 
cells 
 EBER1, EBER2, BART1 
Lytic     Lytic protein cascade 
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EBV in the natural context manipulates B-cell development process during 
infection, which is achieved by the expression of different latency programs. in 
newly infected B-cells, the viruses express latency type III (growth) program and 
drives the B-cells into formation of germinal centre B-cells, at which the latency 
program expressed is switched from III to II. GC B-cells further develop into 
dividing B-cells, and the EBV latency program switches into I and finally, when 
the B-cells developed into resting memory B-cells, EBV enters the final latency 
program, latency 0. The details of how EBV B-cell process will be discussed in 
chapter 1.2.5. 
The latency 0 program is also known as the true latency program; and it is the 
program that expresses the least of the EBV latent genes, with no detectable 
latent mRNA or proteins. This presumably allows EBV to avoid immune 
surveillance and remain silent in the host. This latency program has only been 
identified in resting memory B-cells, and currently there has been no disease 
linked with this latency program. 
The latency I program is commonly found in EBV positive BL. This program 
involves the expression of EBV encoded RNAs (EBERs) and the BamHI-A 
rightward transcripts (BARTs). The expression of Qp promoter induced EBV 
nuclear antigen-1 (EBNA1) is also observed (Figure 1.1.4). However none of 
the other EBNAs or the latent membrane proteins -1, 2A and -2B (LMP1, 
LMP2A and 2B) are expressed during this program. 
The latency II (default program) can be found in NPC, and EBV positive HLs. 
LMP 1 and 2A/B are expressed, along with the Qp-driven EBNA1. However, the 
other EBNA genes are not expressed (figure 1.1.4.b). The latency II program 
can differ depending on the expression level of LMP2. For example, in gastric 
carcinoma, a low level of LMP2 is expressed; and in HL, a high level of LMP1 
and 2 are expressed while both define type II latency. LMP1 and 2 expression 
level can also vary in the same type of malignancy (Rowe et al., 2009).  
Latency III, also known as the growth program, is typically found in 
Lymphoblastoid cell lines (LCLs) and PTLD. LCLs are generated by in vitro EBV 
infection of B-cells. In this program, EBV expresses the full spectrum of the 
latent genes. The EBNA 1, 2, 3A, 3B, 3C and -LP are all expressed, which are 
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spliced from a single poly-cistronic transcript from the Cp/Wp promoter (figure 
1.1.4.). 
EBNA and LMP genes are both expressed during latency. Unlike the LMP 
genes, which are all transcribed from individual promoters; mRNA of EBNA 
genes are spliced from a long transcript which is primarily produced by either 
the Cp or the Wp (Bodescot & Perricaudet, 1986; Bodescot et al., 1987; Sample 
et al., 1986; Speck & Strominger, 1985). During latency I and II, the only EBNA 
protein expressed is the episome maintaining EBNA1, which is transcribed from 
an alternative promoter Qp (Nonkwelo et al., 1996; Schaefer et al., 1995) (figure 
1.1.4), with the Wp and Cp silent. During latency III, all six EBNA proteins are 
expressed, the transcription of the genes occurs following a promoter switch. In 
newly infected B-lymphocytes Wp is selectively activated post infection (Alfieri 
et al., 1991; Woisetschlaeger et al., 1990). However, despite the transcript from 
Wp encoding for all six EBNA proteins, only EBNA2 and EBNA-LP are 
expressed. EBNA2 and EBNALP proteins are the first two viral proteins 
expressed (Allday et al., 1989; Rooney et al., 1989a). The expression of these 
two EBNA proteins leads to activation of Cp and induces the expression of all 
the rest of the EBNAs (Rooney et al., 1992; Sung et al., 1991; Woisetschlaeger 
et al., 1991); and also upregulate the promoters of the LMP genes (Abbot et al., 
1990; Fahraeus et al., 1990; Wang et al., 1990b; Zimber-Strobl et al., 1991). 
The switch of promoters from Wp to Cp is driven by EBNA2 and a cellular 
transcription factor RBP-J!. EBNA2 does not directly interact with DNA, and 
RBP-J! recognised EBNA2 response element in Cp. Therefore EBNA2 and 
RBP-J! together drive the induction of Cp and leads to the expression of the 
other EBNA and LMP genes (Woisetschlaeger et al., 1991). 
Although the switch of EBNA promoters from Wp to Cp has been previously 
described (Alfieri et al., 1991; Schlager et al., 1996; Woisetschlaeger et al., 
1991; Woisetschlaeger et al., 1990; Yoo & Speck, 2000), it is unclear of how 
Wp becomes repressed post Cp activation. Previous studies have suggested 
that the methylation state of Wp is associated with the promoter switch. Wp 
becomes methylated post infection with reduced activity of the promoter 
(Tierney et al., 2000b). Other studies also indicated that methylating the Wp 
does not initiate the Wp silencing, but merely maintaining the silent state, also, 
methylating downstreams of the Wp sequence has a negative affect on Cp 
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transcription (Paulson & Speck, 1999). An important protein that is expressed 
after the promoter switching is EBNA1, which is essential for maintaining EBV 
latency by binding to oriP and initiates DNA replication of the EBV episome. 
EBNA1 is also a transcriptional activator. OriP locates just upstream of Cp and 
when EBNA1 binds to oriP it upregulates transcription from Cp (Puglielli et al., 
1996; Reisman & Sugden, 1986; Sugden & Warren, 1989). The expression of 
EBNA2 also induces transcription of LMP1 gene. EBNA1 interacts with the 
LMP1 promoter (LMP1p) via RBP-J! or PU.1. Unlike with Cp, where the 
interaction with EBNA2 is completely dependent on RBP-J!, the interaction 
between EBNA2 and LMP1p is partially dependent on RBP-J! (Johannsen et 
al., 1995). EBNA 2 is able to induce LMP1 transactivation without RBP-J! 
(Fahraeus et al., 1990; Fahraeus et al., 1993), which suggests different 
mechanisms are involved in transactivation of Cp and LMP1p.  Previous studies 
have shown that other factors such as PU.1 are involved in inducing LMP1 
transactivation. PU.1, a PU-box binding protein, is a B-cell specific transcription 
activator. It is believed that EBNA2 transactivates LMP1p via interaction with 
PU.1 protein and a POU domain protein, instead of RBP-J! (Sjoblom et al., 
1995).  
EBNA1 is expressed in all of the latency I, II and III programs; however, the 
transcription of EBNA1 switches from Cp in latency III, to Qp in latency II and I. 
It is believed that the change between latency programs is controlled by the 
cellular transcription factor OCT2 and EBNA1 together (Werner et al., 2007). 
Previous studies have shown OCT2, in association with members of the 
Groucho (Grg/TLE) family of proteins, acts as inhibitor of Cp (Almqvist et al., 
2005; Malin et al., 2005). Werner et al. (2007) had proposed that Cp was 
switched on by EBNA1 and switched off by OCT2, in combination with Grg/TLE; 
whereas Qp is switched off by EBNA1, which is otherwise on. The expression 
level of these two proteins allows EBV to express different latency patterns 
(Werner et al., 2007). 
It is also known that the type of EBV latency program can switch when cell lines 
have been cultivated for a long period of time. BL cell lines normally exhibit the 
same type of latency program as the original tumour in vivo, however, after long 
passages of them within tissue culture, the BL cell lines can drift and tend to 
display type III latency (Gregory et al., 1990; Rowe et al., 1987). Despite the 
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classification of the latency programs and the gene expression during these 
programs, these are not definitive (Kelly et al., 2002). The latency profile does 
not include the expression of viral micro-RNAs in the EBV infected B-cells and 
epithelial cells. While B-cells are able to support all three latency programs, 
non-B-cells only display either latency program I or II. This is because part of 
the Wp/Cp promoter activation in latency III is regulated by a B-cell specific 
transcription factor, PAX-5, which is involved in transactivating the Wp 
immediately after infection of B-cells (Tierney et al., 2007).  
The EBV positive BLs are known to establish latency I, with occasions of 
latency III, however, there are at least two other types of latent gene expression 
profiles that are associated with BL. In one case, BL shows expression of all six 
EBNAs but not LMP1 or LMP2, which may be the very rare consequence of 
EBV integration into the cellular chromosome (Kelly et al., 2006). The other type 
of EBV latency exhibited in BL is known as the Wp-restricted BL (see figure 
1.1.4.b.), which shows the expression of all the EBNAs except EBNA2, also 
with no expression of LMP1 or LMP2. Wp-restricted BL is common and may be 
found in about 15% of the endemic BL cases (Kelly et al., 2002; Kelly et al., 
2006; Kelly et al., 2005). The EBNA2 gene is not silent but deleted from the viral 
episome in this type of BL cells. The Wp promoter, instead of the Qp promoter, 
is then used to activate the EBNA gene expression, although the exact 
mechanism of this is still unclear. Wp-restricted BLs also express BHRF1, a 
homologue of cellular Bcl-2 (Cleary et al., 1986; Henderson et al., 1993), a viral 
protein not previously associated with latency (Kelly et al., 2009).  
 
 
 
 
 
 
!
 
35 
 
Figure 1.1.4. EBV protein expression during different latency programs. A) a schematic 
diagram of the EBV genome, indicating the location of the coding exon regions for EBNA1, 
EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNALP (red arrow), BHRF1 (homologue of bcl-2) 
(green arrow), and the latent membrane proteins LMP1, LMP2A and LMP2B (blue arrow). The 
origin of latent replication (OriP), BamHI W repeats and terminal repeats (TR) are also shown 
on the diagram. (B) shows the structures of viral mRNA transcripts expressed in different 
latency programs. Latency 0 is not shown as there is no protein expression. The promoter is 
shown in black thin arrow, with coding exons coloured and non-coding exons unshaded. 
Latency I, expressed in most BL tumours and dividing memory B-cells, is characterised by only 
expressing EBNA1 from Qp. Latency II is commonly found in Nasopharyngeal carcinoma and 
Hodgkin’s lymphoma. Latency II is also found in EBV positive germinal centre B-cells. Qp 
transcribed EBNA1 and the LMP family proteins are expressed during latency II. The latency III 
program commonly found in LCLs or newly infected B-cells is characterised by expression of all 
latent proteins. However with the EBNA family mRNAs transcribed as a long primary transcript 
and generated by alternative splicing, this is either initiated from the repeated W promoter (Wp) 
or the C promoter upstream. BHRF1 is also expressed from Wp initiated transcripts. LMP family 
proteins are transcribed from separate promoters. Wp-restricted latency, the most newly 
discovered latency program, only expresses the EBNA1, EBNA3A, EBNA3B, EBNA3C, 
EBNALP and BHRF1 proteins, with no EBNA2 and the LMPs. As the name suggests, the long 
primary transcripts of EBNA proteins are initiated from Wp only, and this can only be found in a 
subset of BL tumours with EBNA2 deletions (Rowe et al., 2009). !
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1.1.3.8. Latent genes 
Unlike other genes expressed during viral replication, the EBV genes expressed 
in latency have no homolog in the genomes of the other human herpesvirus. 
There are two families of proteins that are mainly expressed during latency: 
Epstein-Barr nuclear antigen (EBNA) and latent membrane proteins (LMP).  
EBNA1 is a DNA binding protein (Jones et al., 1989; Rawlins et al., 1985), and 
is essential for EBV persistence in infected cells during cell division (Yates et 
al., 1984). It controls the genome partition during cell division via binding to the 
origin of latent replication (oriP) (Rickinson & Kieff, 2001) and to the host EBP2 
protein, which is associated with mitotic chromosomes (Kapoor et al., 2005; 
Shire et al., 1999; Wu et al., 2002). EBNA1 also contains the AT-hook domain, 
and it is proposed that via this domain, EBNA1 can bind to the scaffold-
associated metaphase chromosomes without EBP2 (Sears et al., 2004). 
EBNA2 in the most variable EBV gene between EBV type 1 and type 2. Along 
with EBNALP, this is one of the two first viral proteins to be expressed. In vivo, 
EBNA2 is only expressed for a short period of time immediately after the virus 
infects the tonsillar B-cells (Kurth et al., 2003) during latency III infection. The 
transcription of EBNA2 mRNA was originated by Wp, and then switched to Cp 
in latency III program. EBNA2 does not bind to DNA directly, but in a complex 
with PU.1 (Johannsen et al., 1995) or RBP-J! (Grossman et al., 1994; Henkel 
et al., 1994; Yalamanchili et al., 1994), it acts on both cellular and viral 
promoters inducing cell proliferation (Sinclair et al., 1994). EBNA2 interacts with 
Cp in combination with RBP-J!, and participates in the promoter switching in 
latency II, and also drives the LMP gene transactivation with PU.1. Details of 
promoter switching and EBNA2 interaction with various promoters were 
discussed in detail in chapter 1.1.3.7.  
The EBNA3 family of proteins consists of three members: EBNA3A, EBNA3B 
and EBNA3C. The three proteins share 30% sequence homology and are 
transcribed as alternatively spliced transcripts (Rickinson & Kieff, 2001). 
EBNA3A and 3C are indispensible for viral transformation of B-cells in vivo 
(Tomkinson et al., 1993) and in vitro (Sims, 2010). However, EBNA3B is not 
necessary for B-cell transformation in vivo (Tomkinson & Kieff, 1992) or in vitro. 
EBV with EBNA3B deletion can also induce fatal lymphoproliferative disease 
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(Gottschalk et al., 2001). A recent study by White et al. (2012) suggests that 
EBNA3B acts as a tumour suppressor and restrains proliferation of EBV 
transformed B-cells. EBNA3B is responsible for changes in host gene 
expression, which leads to alteration in cell surface markers, expression and 
growth behaviour of infected B-cells. Knocking down EBNA3B (EBNA3BKO) in 
humanised mice results in formation of a more aggressive and immunoevading 
monomorphic diffuse large B-cell lymphoma (DLBCL) like tumours. Despite the 
fact that EBNA3BKO helps to prime T-cells against EBV infection, EBNA3BKO 
B-cells also show reduced chemoattraction to T cells. This is due to reduced 
secretion of chemokine CXCL10, although the mechanism which associates 
EBNA3BKO and reduce expression of CXCL10 in unclear. The cytotoxic T 
lymphocytes (CTLs) used in treating EBV-specific lympoproliferated diseases 
consistently express CXCR3, which is the receptor for CXCL10 (Pule et al., 
2008); thus decreasing the expression of CXCL10 allowing developing tumours 
to undergo immuno escape (White et al., 2012). 
The EBNA3 family of proteins are transcription regulators. EBNA3C can induce 
both cellular and viral gene expression, such as CD21 and LMP1 (Allday & 
Farrell, 1994). EBNA3C does not bind to DNA directly, but targets promoters via 
association with the RBP-J! transcription factor (Robertson et al., 1995b), which 
is also a DNA-binding partner with EBNA2. Previous studies have shown that 
EBNA3A and EBNA3C repress RBP-J!-EBNA2 activated transcription (Le 
Roux et al., 1994; Waltzer et al., 1996). It can also repress Cp promoter function 
(Radkov et al., 1997) despite the transcript being induced by Cp promoter 
activity, thereby forming a negative feedback loop; therefore EBNA3C acts as 
negative regulator of EBNA2. However, recent studies using a conditional virus 
have shown that inactivating EBNA3C does not result in increasing the 
expression of both viral and cellular genes, such as LMP1 and c-myc 
respectively, that are regulated by EBNA2 (Maruo et al., 2006) and therefore 
does not antagonise the function of EBNA2. The difference between these 
studies could be due to the fact that the earlier studies have carried out 
experiments in either transient or constant transfection assays. EBNA3C was 
not expressed at the physiological levels but overexpressed. The promoter 
assays were also carried in cellular background that is not B-cell. These 
differences in the protein expression levels and/or cell type are possible 
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reasons for the differences between the studies. EBNA3C can also interact with 
pRb to promote transformation (Parker et al., 1996). EBNA3C interacts with 
human histone deacetylase (HDAC) 1 (Radkov et al., 1999) and HDAC 2 
(Knight et al., 2003) indicating that EBNA3C associates with chromatin re-
modelling complexes. It has also been shown that EBNA3C is involved in cell 
cycle regulation, by decreasing the level of p27 (Knight et al., 2005a; b) and 
pRb (Knight et al., 2005a) in rat cells. However, the pRb level does not alter in 
LCLs (Maruo et al., 2006) in response to the expression of EBNA3C. 
EBNALP, also known as the EBNA leader protein, is encoded by the leader of 
the EBNA mRNA, the size of which varies depending on the number of BamHI 
W repeats that is encoded in the virus genome (Rickinson & Kieff, 2001). 
Previous studies have shown that EBNALP, although is not required for 
transforming B-cells in vitro, it is required for cell proliferation (Allan et al., 
1992). EBNALP also enhances the EBNA2 mediated transcriptional activation 
(Harada & Kieff, 1997; Nitsche et al., 1997; Peng et al., 2004). 
Latent membrane protein (LMP) 1 is only expressed in either latency II or III, 
and is the major transforming protein during EBV infection of B-cells. LMP1 is 
essential for EBV induced B-cell transformation (Kaye et al., 1993; Wang et al., 
1985). Expressing LMP1 induces the production of cell surface adhesion 
molecules and activation markers (Wang et al., 1990a). LMP1 expression also 
upregulates Bcl-2, an anti-apoptosis protein, (Henderson et al., 1991) and 
stimulates the production of the cytokines IL-6 and IL-8 (Eliopoulos et al., 1999). 
By functioning as a constitutively active tumour necrosis factor (TNF) receptor, 
LMP1 aggregates in the membrane, and interacts with the TNF receptor 
associated factors (TRAFs) and TNFR-1-associated death domain protein 
(TRADD). This activates both NF-!B and c-Jun amino-terminal kinase (JNK) 
(Eliopoulos et al., 1999; Kieser et al., 1997; Kilger et al., 1998). Both LMP1 and 
LMP2A are important for the survival of latency III tumours, knocking down 
either of the latent membrane proteins leads to NF-!B down regulation and 
apoptosis (Guasparri et al., 2008). Many of the functions of LMP1 overlap with 
CD40, a member of the TNFR family. CD40 is a co-receptor of activated Ig 
receptors, which are important for B-cell development and differentiation. By 
fusing LMP1 with the CD40 C-terminus, LMP1 mimics CD40 and activates NF-
!B signalled growth signals (Baxendale et al., 2005; Busch & Bishop, 1999). 
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The LMP2 gene encodes for two proteins, -2A and -2B. These two proteins only 
differ in the first exon, resulting in LMP2A having a 119 amino acid cytoplasmic 
amino terminal domain. Neither LMP2A or 2B are essential for B-cell 
transformation in vitro (Longnecker, 2000). The main function of LMP2B is to 
regulate LMP2A in maintaining latency (Rechsteiner et al., 2008; Rovedo & 
Longnecker, 2007). LMP2A encodes an immunoreceptor tyrosine-based 
activation motif (ITAM) (Fruehling & Longnecker, 1997). When ITAM is 
phosphorylated, it recruits an activated src family of protein tyrosine kinases 
(PTKs) and Syk PTKs and with the B-cell surface receptor (BCR) mediates B-
cell differentiation and proliferation. LMP2A mimics BCR signalling pathway, the 
expression of LMP2A in B-cell results in proliferation and survival without BCR 
signalling (Caldwell et al., 1998). 
 
1.1.3.9. Lytic cycle and reactivation 
EBV reactivation has been extensively studied in vitro. It is well known that 
treating latently infected B-cells in tissue culture with chemicals that alter certain 
intracellular pathways can trigger lytic reactivation of EBV. Such chemicals 
include phorbol esters, such as 12-O-tetradecanoyl-phorbol 13-acetate (TPA); 
calcium ionophores; histone deacetylase (HDAC) inhibitors, such as sodium 
butyrate and valporic acid; and DNA demethylating agents, such as 5-
azacytidine. Cross-linking the cell-surface immunoglobulin (Takada & Ono, 
1989; zur Hausen et al., 1979) of latently infected B-cells also induces the EBV 
lytic cycle.  
A previous study by Laichalk and Thorley-Lawson (2005) showed that the 
differentiation of peripheral memory B-cells into plasma cells in the tonsils is 
associated with production of infectious virus particles; which can then transfer 
into the lympho-epithelium and secrete virus into saliva (Hadinoto et al., 2009; 
Laichalk & Thorley-Lawson, 2005). It is suggested that the EBV positive 
memory B-cell returns to the Waldeyer’s ring at the tonsils and adenolds, 
undergoes plasma cell differentiation and therefore viral replication. The viruses 
produced from plasma cells infect the basolateral surface of epithelial cells of 
the Waldeyer’s ring, which continuously shed viruses into saliva. 
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Two viral proteins, BZLF1 (ZTA) and BRLF1 (RTA), mediate reactivation from 
latency via direct binding of EBV DNA (Amon et al., 2004; Chang & Liu, 2000; 
Yuan et al., 2006). BZLF1 is an immediate early protein and a transcription 
factor that initiates the EBV lytic cycle. BZLF1 belongs to the basic-leucine-
zipper (bZIP) family of transcription factors, this family also contains cellular 
transactivators such as c-Fos and c-Jun (Farrell et al., 1989; Flemington & 
Speck, 1990b; Kouzarides et al., 1991), which can dimerise to form the AP-1 
transcription factor that upregulates genes involved in proliferation and 
differentiation. BZLF1 contains three functional domains: the amino terminal 
non-acidic transactivation domain, the basic DNA binding domain and the 
dimerisation domain (Farrell et al., 1989; Lieberman & Berk, 1990). B-cell 
surface receptor (BCR) cross-linking activates the BZLF1 promoter (Zp) and 
this leads to BZLF1 expression. The BRLF1 promoter (Rp) is then subsequently 
activated (Amon et al., 2004). BRLF1 is also a sequence specific DNA binding 
transcriptional activator, with three functional domains: an acidic transactivation 
domain, a DNA-binding domain and a homodimerization domain (Manet et al., 
1991). BRLF1 activates transcription in part through direct binding to Rta-
responsive elements (RREs) (Manet et al., 1991).  BZLF1 is the key 
immediately early protein in EBV (Bryant & Farrell, 2002; Countryman & Miller, 
1985) and BZLF1 expression alone is sufficient to initiate the entire EBV lytic 
cycle in permissive cell types (Countryman & Miller, 1985; Rooney et al., 
1989b). Once BZLF1 is expressed it transactivates the Rp promoter leading to 
the expression of BRLF1, as well as transactivating its own promoter, Zp. 
Together these two proteins orchestrate the rest of the EBV lytic gene 
expression cascade (Takada et al., 1986). Some studies have shown that 
BRLF1 can also trigger the lytic cycle cascade alone, but this only occurred in 
some cell lines (Ragoczy et al., 1998; Zalani et al., 1996). Knocking down of 
either BZLF1 or BRLF1 prevents the virus lytic cycle (Feederle et al., 2000).  
EBV DNA replication is controlled by oriLyt, which is different from the control of 
EBV episome replication during latency, controlled by oriP (Hammerschmidt & 
Sugden, 1988). BZLF1 and five other EBV proteins are essential for the function 
of oriLyt (Fixman et al., 1992). OriLyt contains seven BZLF1 binding sites in four 
clusters which are essential for replication (Fixman et al., 1992; 
Hammerschmidt & Sugden, 1988; Sarisky et al., 1996; Schepers et al., 1993a; 
1996; Schepers et al., 1993b). BZLF1 is not only the viral lytic origin binding 
!
 
41 
protein, it also facilitates the recruitment of the EBV helicase-primase complex, 
a lytic replication complex (Gao et al., 1998). 
 
1.1.3.10. Regulation of lytic reactivation 
The BZLF1 gene consists of three exons and one intron that contains a set of 
29bp repeats. The expression is derived from three exon transcripts starting 
from the BZLF1 promoter (Zp) (figure 1.1.5.A). The BRLF1 reading frame is 
upstream of Zp and both are transcribed in the same orientation. Unlike Zp, 
which only produces one type of transcript, Rp can lead to three different 
alternatively spliced mRNAs (Manet et al., 1989). Two larger mRNAs encode 
BRLF1 and the third one produces a BZLF1/BRLF1 fusion protein called RAZ. 
RAZ contains the BRLF1 amino-terminus, and the BZLF1 DNA binding and 
dimerisation domain (Furnari et al., 1994; Manet et al., 1989), this fusion protein 
inhibits BZLF1 transactivation, although not via acting as the dominant-negative 
protein to BZLF1. During latency, the expression of BZLF1 and BRLF1 are not 
detectable. 
The Zp can be sub-divided into various elements (figure 1.1.5.B). The ZV 
element, which is near the transcription start site, binds to the transcriptional 
inhibitor ZEB1. ZEB1 induces repressed chromatin through recruiting a 
CoREST-CtBP corepressor complex (Kraus et al., 2001). The ZEB binding to 
ZV maintains Zp silencing during latency (Binne et al., 2002; Feng et al., 2007; 
Kraus et al., 2001; Kraus et al., 2003; Yu et al., 2007b). The myocyte-specific 
enhancer factor 2D (MEF2D) also recruits HDAC to Zp, which maintains the 
promoter as an inactive chromatin structure further maintaining the silent state 
of Zp (Gruffat et al., 2002; Liu et al., 1997b). This explains how HDAC inhibitors 
such as sodium butyrate, can activate EBV into the lytic cycle. Rp contains CpG 
dinucleotides, which are highly methylated during latency (Bhende et al., 2004), 
contributing to the silencing of Rp during latency. 
There are sequence related elements other than ZV assigned to Zp, namely 
ZIA, ZIB, ZIC, ZID, ZII, ZIIIA and ZIIIB (figure 1.1.5.B). Many cellular factors 
have been identified which bind to these Zp elements. MEF2D has been shown 
to bind to ZIA, ZIB and ZID elements. BCR cross-linking, shown to induce EBV 
reactivation, leads to modification of MEF2D via the phosphatidylinositol 3-
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kinase/Ca2+ pathway, allowing other factors bind to ZI elements (Bryant & 
Farrell, 2002). SP1 and SP3 are both ubiquitous transcription factors and can 
bind to ZIA, ZIC and ZID elements (Liu et al., 1997a; Liu et al., 1997b). CREB, 
ATF-1, and a ATF2/c-Jun hetrodimer can bind to the ZII element (Adamson et 
al., 2000; Flemington & Speck, 1990c; Liu et al., 1998; Wang et al., 1997). The 
ZIII elements interact with BZLF1 (Flemington & Speck, 1990a) with ZIIIB 
having higher affinity binding to BZLF1 than the ZIIIA element. Binne et al., 
(2002) indicated that the ZIIIA element still has a key role in Zp activation, 
following BCR cross-linking activation, however this effect is mediated via 
unknown cellular factor, and not directed by BZLF1 binding (Binne et al., 2002). 
Therefore ZIIIA is essential for Zp activation without BZLF1. ZIIIB, with the 
higher affinity binding of BZLF1, is not required at the very immediate stage of 
promoter activation after BCR cross-linking, but at the later induction stage, 
which happens at about the same time as BZLF1 expression. There are many 
factors that have been studied and previously reported to activate Zp, such as 
TGF-" (Fahmi et al., 2000; Liang et al., 2002) and XBP-1 (Bhende et al., 2007; 
Lai et al., 2011; Sun & Thorley-Lawson, 2007), which will be discussed in 
further detail in chapter 3. 
EBV genomes are not methylated when entering the cells, but gradually 
became methylated during immortalisation and during establishment of latency 
(Li & Minarovits, 2003; Tao & Robertson, 2003). Methylation of DNA is 
associated with inhibition of gene expression, by association of specific methy-
CpG-binding proteins with methylated DNA, and leads to transcriptional 
silencing and chromotin remodelling (Klose & Bird, 2006). DNA methylation is 
therefore involved in regulation of EBV reactivation. Previous studies suggest 
that BZLF1 is able to bind to DNA even is CpG methylated (Bhende et al., 2004; 
Dickerson et al., 2009; Karlsson et al., 2008a), which indicates BZLF1 is able to 
transactivate Zp during latency when the genome is methylated. BZLF1 is able 
to interact directly to sequence specific DNA which is referred to as the Z 
response elements (ZREs) (Sinclair & Farrell, 1992), which can be sub-divided 
into three classes (Karlsson et al., 2008b). Class I ZRE does not contain a CpG 
motif and therefore the interaction with BZLF1 is not associated with 
methylation status. Class II ZREs contain a CpG motif and is able to interact 
with BZLF1 when non-methylated; however the interaction is enhanced when 
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the ZREs are methylated. Class III ZREs contains one or more CpG motifs. This 
class of ZREs are not able to or poorly interact with BZLF1 when non-
methylated, but are recognised by BZLF1 when methylated (Karlsson et al., 
2008b). Therefore, BZLF1 is able to bind to Class III ZREs when the viral 
genome is methylated. The ZIIIA and B domains of the Zp have been identified 
to interact with BZLF1 (Flemington & Speck, 1990a); however, it is unclear if 
these two regions contain any class III ZREs. 
 
 
 
Figure 1.1.5. Schematic diagrams of A) BZLF1 genes. BZLF1 contains three exons and one 
intron, which consists numbers of 29 bp repeats. The nucleotide coordination is according to 
EBV type 1 reference sequence from Genbank. B) Diagram of Zp, the promoter of the Epstein-
Barr virus BZLF1 gene. Cis-active regulatory sites and proteins that bind these sites are 
identified. The location of the Zp polymorphisms described in section X is indicated below the 
diagram of Zp (Miller & El-Guindy, 2002) 
 
1.1.3.11. EBV replication in latency 
Replication of EBV during latency differs from EBV replication during lytic cycle. 
During latency, EBV DNA is in the closed circular episome form and the genes 
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required for replication are silent. The replication of the EBV episome is 
associated with the host DNA replication. The EBV episome is packaged with 
the cellular histones (Dyson & Farrell, 1985), and replicates only once with the 
host DNA during the S phase of the cell cycle (Adams, 1987). The two copies of 
EBV DNA are then divided into the daughter cells during the mitosis phase 
(Kirchmaier & Sugden, 1995). EBV replication during latency initiates from OriP, 
and only one protein EBNA1 is involved in the process. Since EBNA1 has no 
helicase activity (Frappier & O'Donnell, 1991), genome replication is dependent 
on cellular factors. OriP contains two clusters of EBNA1 binding sites, in the FR 
and DS regions. It is believed that the 20 EBNA1 binding sites in FR are 
associated with tethering the viral episome to human chromosomes, allowing 
the replicated DNA to be retained in the daughter cells (Kanda et al., 2001; 
Kirchmaier & Sugden, 1995). The DS region contains two pairs of EBNA1 
binding sites flanked by telomere repeat factor (TRF) binding sites (Bashaw & 
Yates, 2001; Deng et al., 2002; Rawlins et al., 1985; Yates et al., 2000). The 
TRF binding sites contribute to DNA replication efficiency and episome 
maintenance, and have also been shown to recruit the origin recognition 
complex (ORC) in an RNA dependent manner (Atanasiu et al., 2006; Norseen 
et al., 2008). The TRFs are also responsible for recruiting cellular factors 
involved in DNA recombination and repair (Palm & de Lange, 2008). ORC is a 
cellular initiation factor, which has been shown to interact with OriP by binding 
either to or close to the region of DS elements (Schepers et al., 2001). 
Minichromosome maintenance complex (MCM) is another cellular initiation 
factor, that has been shown to bind to OriP (Chaudhuri et al., 2001). ORC and 
MCM form a pre-replication complex, and initiate replication with OriP. 
 
1.1.4. Kaposi Sarcoma associated herpesvirus (KSHV) 
KSHV is a gamma-2-herpesvirus and first member of the genus Rhadinovirus 
found to infect humans (Moore et al., 1996; Neipel et al., 1998). The most 
closely related human virus to KSHV is EBV. 
KSHV is the most recently discovered member of the Herpesvirus family; first 
identified in 1994 in AIDS associated Kaposi’s sarcoma (KS) (Chang et al., 
1994). KS was first described at 1872 by Moritz Kaposi, a Hungarian 
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dermatologist, who found that six patients with multifocal brown–red or blue–red 
nodules or plaques on the feet and hands (Kaposi, 1872). It was initially called 
“Idiopathisches multiples Pigmentsarcoma der Haut” (multiple idiopathic 
sarcoma of the skin). However it was not until 1994, Chang et al., (1994) using 
the technique called representational difference analysis (RDA), successfully 
identified KSHV from AIDS associated KS samples. KSHV has been shown to 
be the aetiological agent of KS, the most common malignancy (10%) found in 
regions of sub-Saharan Africa (Dedicoat & Newton, 2003). KSHV is also 
associated with two types of B-cell lymphomas: Primary Effusion Lymphoma 
(PEL) (Cesarman et al., 1995a) and multicentric Castleman’ disease (MCD) 
(Soulier et al., 1995). KSHV is also associated with 4% of all AIDS related non-
Hodgkin lymphomas (Carbone & Gloghini, 2008), thus KSHV is the most 
common cause of cancer among those with untreated HIV infection (Beral et al., 
1990; Boshoff & Weiss, 2002).  
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Figure 1.1.6. Schematic diagram showing the KHV/HHV-8 genome. Human cells latently 
infected with KSHV harbour multiple copies of the episomes. As indicated above, the circular 
episome represents a fusion of the terminal repeats at the both ends of the linear genome. The 
episome is approximately 140 kilobase pairs in length and contains open reading frames which 
code for viral proteins which mediate latent infection as well as modulate cellular processes 
(adapted from (Cotter & Robertson, 2002). 
 
 
 
1.1.4.1. KSHV Genome 
As with other HHVs, KSHV is a double stranded DNA (dsDNA) virus, with a 
whole genome of 165-170 Kbp (Renne et al., 1996a), consisting of a long 
unique region (LUR) which is approximately 140-145 Kbp in length. The 
genome exists in circular dsDNA episome form during latency. During lytic 
replication, linear dsDNA genome is produced in reactivated cells and virions 
(Renne et al., 1996b).  
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The LUR encodes all the viral open-reading frames (vORFs) (Russo et al., 
1996). The LUR is flanked at each end by a series of non-coding GC-rich 
terminal repeats (TRs), which are 801 base pairs (bp) long. Typically, the TR 
DNA content is about 20-25 Kb in total. However, the number of TRs in different 
genomes ranges widely between 16-75, which accounts for the variation that 
can be seen in the isolates of KSHV (Lagunoff & Ganem, 1997). There are 81 
ORFs which are larger than 100 amino acids in LUR. 66 of these ORFs have 
homologues in herpesvirus simirae (HVS), another gamma-2 herpesvirus that 
infects old world monkeys. KSHV encodes unique proteins such as K1-K15 and 
also encodes 11 microRNAs (miRNAs) (Cai et al., 2005; Pfeffer et al., 2005; 
Samols et al., 2005).  
Unlike EBV, only two gene expression profiles have been defined for KSHV: 
lytic and latent. The genes expressed during KSHV latency are dependent on 
the cell line. For example, eight different latent genes are expressed during 
latency in PELs: (vFLIP/ORF71 (Low et al., 2001), v-cyclin/ORF72 (Platt et al., 
2000), LANA/ORF73 (Rainbow et al., 1997), vIL-6/ORFK2 (Staskus et al., 
1999), LNAN2/ORFK10.5 (Rivas et al., 2001), vIRF2/ORFK11.1 (Burysek & 
Pitha, 2001), Kaposin/ORFK12 (Muralidhar et al., 2000) and K15/ORFK15 
(Glenn et al., 1999); as compared to four in KS (vFLIP/ORF71 (Sturzl et al., 
1999), v-cyclin/ORF72 (Reed et al., 1998), LANA/ORF73 (Rainbow et al., 1997) 
and Kaposin/ORFK12 (Zhong et al., 1996). Currently, there is no further sub-
typing of the latency depending on the level of latent gene expression. 
KSHV reactivation can also be induced by various reagents, such as TPA by 
activating the protein kinase C (PKC) pathway (Renne et al., 1996b); HDAC 
inhibitors i.e. valporic acid (VPA) and sodium butyrate (NaBut) (Miller et al., 
1997); or by DNA methylation inhibitors (Chen et al., 2001). RTA of KSHV (K-
RTA) is analogous to BZLF1 of EBV, but KSHV does not encode a protein that 
is equivalent of BRLF1. The expression of K-RTA induces and leads to the 
completion of the KSHV lytic cycle. K-RTA is often referred to as the “switch” for 
the KSHV lytic cycle, since its expression is suppressed during latency and only 
activated to induce the lytic cycle. RTA is therefore necessary (Lukac et al., 
1998) and sufficient (Gradoville et al., 2000) to activate the KSHV lytic cycle. It 
is encoded by the ORF50 gene and like EBV protein BZLF1, can transactivate 
its own promoter (Deng et al., 2000). 
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1.1.4.2. KSHV diversity 
The majority of the KSHV genome is highly conserved, but there are some 
regions of KSHV such as ORF K1 and K15 that are highly variable. This has 
lead to classification of the virus into five different sub-types A, B, C, D and E 
(Hayward & Zong, 2007). The general viral nucleotide differences between 
these sub-types are about 3%, compared to 15-30% of variation at the K1 
region. The variation can reach up to 60% at the two hypervariable regions V1 
and V2, at ORF K1 region (Zong et al., 2002; Zong et al., 1999). It is unclear 
what causes the variability in the K1 region,; however, there are epitopes for 
cytotoxic T cells (CTLs) present at the V1 region, indicating K1 variation could 
be due to CTL evasion (Stebbing et al., 2003). 
The sub-types of KSHV can be further divided depending on the ORF K15 
region, with variants known as P (prototype), M (minority) (Poole et al., 1999), N 
and Q (Zong et al., 2002). However, these four variations can only be found in 
the KSHV sub-type A and C, and are believed to arise from recombination with 
a progenitor herpesvirus (Zong et al., 1999). KSHV genome typing is correlated 
with the geographical and/or ethnic origin with the possibility that the sub-types 
arise due to geographical isolation of the host population (Hayward, 1999; Zong 
et al., 2002).   
 
1.1.4.3. Epidemiology 
The prevalence of KSHV can be divided by geographical regions and also 
associated with HIV prevalence. North America, North Europe and Asia have 
the lowest prevalence of KSHV (between 1-7%); Mediterranean, Middle East 
and Caribbean have about 5-25% prevalence. The highest percentage (over 
50%) of KSHV infection can be found in sub-Sahara Africa and the Amazon 
basin. The sub-types of KSHV clades A and C are predominantly isolated from 
individuals from Europe, the United States, Asia and the Middle East; sub-type 
B can be found in sub-Saharan Africa; sub-types D and E are predominately 
isolated from South Asia, Australia, the Pacific and Brazilian Amerindians 
(Biggar et al., 2000; Cook et al., 1999; McGeoch & Davison, 1999; Meng et al., 
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1999; Zong et al., 1999). The transmission route and risk factors for KSHV are 
not fully understood. 
 
1.1.5. Interactions between KSHV and EBV  
Primary effusion lymphoma is defined as a KSHV positive body cavity based 
lymphomas (Nador et al., 1996); however, 80% of PELs are also co-infected 
with EBV. EBV and KSHV in dually infected PELs have been shown to interact 
with each other as well as with the host cell (Fan et al., 2005; Groves et al., 
2001; Krithivas et al., 2000; Xu et al., 2007). 
EBV is known to enhance the tumourigenecity of the dually infected PELs in 
SCID mice, increasing the kinetics of tumour development and the vascularised 
tumour growth, in comparison to the EBV negative PELs (Trivedi et al., 2004). 
Also, dually and singly infected PELs express different sets of cellular genes 
(Fan et al., 2005). The KSHV LANA gene activates EBV LMP1 by directly 
transactivating LMP1 promoter (Groves et al., 2001) but reduces EBNA1 
expression, and repress EBNA2 activation (Krithivas et al., 2000). Previous 
studies showed that in dually infected PEL cell line BC1, adding both TPA and 
butyrate, inducing agents of both herpesviruses, only induces KSHV but not 
EBV into lytic reactivation (Miller et al., 1997; Sun et al., 1998). Under the dually 
infected environment, EBV BZLF1 and KSHV RTA (K-RTA) co-localise and 
interact in vivo. This interaction is associated with the leucine heptapeptide 
repeat region of K-RTA and the leucine zipper region of BZLF1. K-RTA inhibits 
the expression of EBV BZLF1. Both K-RTA and EBV BZLF1 co-localise and 
physically interact. During EBV lytic reactivation, BZLF1 and BRLF1 interact 
and synergistically activate EBV lytic reactivation. Since BZLF1 physically 
interact with K-RTA, this synergistic activity is inhibited by K-RTA, leading to 
inhibition of EBV lytic gene expression (Jiang et al., 2008). The inhibition 
between EBV and KSHV is mutual. EBV BZLF1 also inhibits KSHV lytic gene 
expression (Jiang et al., 2008). The mechanism of the mutual inhibition is 
unclear. Since BZLF1 and K-RTA both require multimerization for their function 
(Bu et al., 2007; Sinclair, 2003), it has been suggested that the interaction 
between the two proteins affects the multimerization process, and therefore 
inhibits the function of each protein (Jiang et al., 2008). 
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KSHV and EBV in PELs also interact via not only the immediate early genes, 
but also the latent gene LMP1. K-RTA in EBV latency cells induces LMP1 in an 
EBNA2 independent manner at the RNA level, K-RTA binding to the LMP1 
promoter at the ISRE region and transactivates the promoter (Xu et al., 2007). 
Overexpressing LMP1 inhibits chemically induced KSHV lytic replication in PEL. 
LMP1 is commonly expressed in dually infected PELs and LMP1 inhibits EBV 
lytic reactivation (Adler et al., 2002; Prince et al., 2003), by reducing the EBV 
BRLF1 gene via upregulation of NF-!B. NF-!B is known to down regulate 
KSHV and EBV lytic activity. Therefore, EBV inhibits KSHV lytic replication in 
PELs, via LMP1 (Xu et al., 2007). 
 
1.2. B-cell development  
B-cell development is a highly regulated process, producing functional 
peripheral B-cell subsets from haematopoietic stem cells (HSC), in the foetal 
liver before birth, or bone marrow after birth. B-cell development can be 
summarized in several simple stages as shown in figure 1.2.1. These steps can 
be divided into three major stages: firstly the antigen independent stage leads to 
generation of mature B-cells; secondly the encounter of antigen activates the B-
cells; and thirdly the antigen-driven generation of either memory B-cells or 
plasma cells. Each B-cell developmental stage can be distinguished by the cell 
surface markers and the status of immunoglobulin (Ig) genes. Each stage of 
development is influenced by external factors, and also regulated closely by the 
complex B-cell intrinsic transcription factor network. In this chapter, particular 
attention is paid to the final stage of this development, especially the 
development of plasma cells, which is associated with EBV and KSHV lytic 
reactivation. 
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Figure 1.2.1. Schematic diagram representing the major stages of B-cell developmental starting 
from the lymphoid progenitor (Haematopoietic stem cells) to Mature B-cell, antigen naive cells; 
to antigen encounter and driven into either memory or plasma cells 
 
1.2.1. From Haematopoietic stem cells to Mature B-cells 
Human B-cells originate from the haematopoietic stem cells (HSC) in the bone 
marrow of adults, where the antigen independent phase occurs. The 
commitment of HSC to the B-cell lineage is shown by CD45 expression (Allman 
et al., 1999), on progenitor (pro) B-cells. Pro B-cells are the first stage in the 
long development process driven by stimulation of various factors including 
stromal cell-derived growth factor 1 (SDF-1) (Nagasawa et al., 1996), stem-cell 
factor (SCF) (McNiece et al., 1991) and IL-7 (Lee et al., 1988), which are 
secreted by surrounding cells. B-cell development is therefore dependent on the 
non-lymphoid stromal cells of bone marrow. Pro B-cells bind to vascular cell 
adhesion molecule 1 (VCAM-1) on stromal cells through the integrin very late 
antigen 4 (VLA-4) and also interact through cell-adhesion molecules (CAM) 
which promote the binding of Kit and SCF. Growth of early B-cell progenitors is 
stimulated by SCF which interacts with the cell-surface receptor tyrosine kinase 
Kit leading to the proliferation of pro-B-cell.  
CD19, the major determinant of B-cells is first expressed during the pro B-cell 
stage. The expression of CD19 is upregulated by B-cell specific activation 
protein (BASP) which is encoded by Pax-5 (Adams et al., 1992; Kozmik et al., 
1992). BASP also represses the alternative lineage choice for HSC (Nutt et al., 
1999) ensuring the confirmation of B-cell lineage. MicroRNAs have also been 
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shown to maintain the B-cell lineage at the pro B-cell stage of development 
(Chen et al., 2004). 
One of the important features of the B-cell is the variability of B-cell surface 
receptors (BCR) and hence the ability to recognise a wide range of antigens. 
The diversity of the BCR repertoire is created by the rearrangement of the 
immunoglobulin (Ig) chains, starting at the pro B-cell stage. The BCR consists 
of two heavy (H) and two light (L) chains joined by disulfide bonds, with each 
chain containing variable (V) and constant (C) regions. During B-cell 
development, both the H and L chains undergo somatic recombination resulting 
in the specific VDJ domains of each BCR. During the pro B-cell stage, only the 
H chain undergoes re-arrangement. Firstly, the diversity (D) and joining (J) gene 
segments of the immunoglobulin H (IgH) chain are joined together (Hardy & 
Hayakawa, 1991). Recombination at the V region of the DJ segment completes 
the IgH gene. This is referred to as VDJ rearrangement, and is catalysed by 
recombinase-active genes (RAG) 1 and 2 (Oettinger et al., 1990) and terminal 
deoxynucleotide transferase (TdT) (Bassing et al., 2002; Komori et al., 1993). 
The cells then undergo positive selection for IgH rearrangement, depending on 
their ability to associate with protein V#5 and VpreB. These two proteins form a 
structure known as the surrogate light chain (SLC) (Cherayil & Pillai, 1991), 
which is similar structurally to the immunoglobulin light chain (IgL). SLCs have 
the ability to associate with heavy chains (Karasuyama et al., 1990). The pro B-
cell with the rearranged IgH forms a complex known as the pre B-cell receptor 
and the Igµ heavy chain associates with the SLC, allowing B-cell maturation 
and a proliferation burst (Hardy & Hayakawa, 1991).  
Post positive selection with the pre BCR is the pre B-cell stage. With the H 
chain rearranged, this stage is characterised by the rearrangement of the L 
chain. Both ! and # gene segments of the L chain can undergo rearrangement. 
However, the # segment only rearranges if the rearrangement in the ! loci fails 
(Mehr et al., 1999). Either only !, or both ! and # rearrangements result in IgL 
production. The expressed IgL binds to the Igµ heavy chain leading to IgM 
expression, resulting in an immature BCR complex with association of Ig$ and 
Ig" (Ollila & Vihinen, 2005). If the association is successful, the cells undergo 
negative selection and clonal deletion. Association occurs if the cells have high 
affinity towards self antigen (Nemazee & Burki, 1989), or the light chains of the 
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BCR are edited (Tiegs et al., 2011) or B-cells became anergic (Goodnow et al., 
1989). Figure 1.2.2 shows the summary of the light and heavy chain 
rearrangement during both pro and pre B-cell stages. 
 
Figure 1.2.2. Summary of events in B-cell development in bone marrow. In pro B-cells, the 
immunoglobulin heavy chain undergoes rearrangement and undergoes positive selection. Once 
cells enter the pre B-cells stage, rearrangement of immunoglobulin light chain occurs. The ! 
gene undergoes rearrangement before the # genes, which only rearrange if the ! gene fails. 
After positive selection, the immature B-cells express surface IgM. (Adapted from (Janeway et 
al., 2001)) 
 
The development of immature B-cells to mature B-cells occurs either in the 
bone marrow or via migration and maturation in the periphery (Allman & Pillai, 
2008). Immature B-cells have a short half-life and a tendency to apoptosis post 
BCR engagement instead of proliferating (Allman et al., 2001; Norvell et al., 
1995). Only 30% of the immature B-cells develop into mature B-cells (Allman et 
al., 1993; Levine et al., 2000). It is believed that the majority of the losses occur 
during the migration stage, whereas nearly all the migrated immature B-cells 
successfully develop into mature B-cells (Melchers et al., 2000). During the 
development from immature B-cells to mature B-cells, the cells can be further 
divided into several distinct subsets. Originally this “transitional” B-cell stage 
was divided into T1 and T2 stages (Loder et al., 1999) with T2 containing 
significant amounts of marginal zone B-cell precursors (MZPs) (Srivastava et 
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al., 2005). However, a new model has suggested there are at least three 
subtypes during the transitional stage, suggesting a stepwise maturation 
process (Allman et al., 2001). The three subtypes T1, 2 and 3 all express the B-
lineage precursor marker CD93/AA4 with different levels of CD21 and IgM, only 
the T1 subset does not express CD23 (Allman et al., 2001). These three 
subsets of immature B-cells then undergo a series of negative and positive 
selections resulting in mature B-cells. Continuous BCR expression is necessary 
for survival of mature B-cells (Wasserman et al., 1998) that also been 
suggested that BCR signalling plays a key role in determining the maturation 
into the subsets of mature B-cells (Allman & Pillai, 2008). 
Naïve B-cells can be further divided into three different subsets: the follicular B2 
cells, marginal zone (MZ) B-cells and the B1 cells, with the follicular B2 cells 
being the most common subset and the focus of chapter 1.2.2. The strength 
and quality of BCR signals influences the division of subsets of B-cells 
(Okkenhaug & Vanhaesebroeck, 2003). The follicular B2 cells circulate between 
the follicles in the spleen, lymph nodes and bone marrow, and are not further 
differentiated until they encounter an antigen. Both B1 and MZ B-cells are able 
to secret “natural antibodies” when they encounter an antigen even without 
previous antigenic experience (Martin et al., 2001). Figure 1.2.3 shows the 
multiple stages of B-cell development. 
A low affinity for BCR signalling drives the formation of MZ B-cells (Cariappa et 
al., 2001). Both notch and NF-!B signalling are involved during the 
development of this subset of immature B-cells (Pillai & Cariappa, 2009). MZ B-
cells circulate in humans in the same manner as the circulating memory B-cells, 
both cell types are also populated in the splenic marginal zone. The circulating 
IgM+ memory B-cells carry similar somatic mutations in the IgM genes as the 
MZ B-cells (Weller et al., 2004). With elevated levels of a transcription factor B-
lymphocyte induced maturation protein-1 (BLIMP-1), MZ B-cells differentiate 
into plasmablast rapidly, providing a fast immune response against blood-borne 
antigens (Zandvoort & Timens, 2002). 
B1 cells are another subset of B-cells producing “natural antibodies” (Shapiro-
Shelef & Calame, 2005). Despite being the minority subset of B-cells in adult life 
(Dono et al., 1996), B1 cells are the majority subset in the foetal life (Bhat et al., 
1992). B1 cells are mainly found in the peritoneal, pleural cavities and the gut 
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lamina propria. Other than producing natural antibodies, B1 cells can respond to 
bacterial antigens, and have a BCR repertoire biased towards recognising T-cell 
independent type II antigens and self antigens (Martin et al., 2001). B1 cells 
secret antibodies in the same (B-lymphocyte-induced maturation protein 1 
(BLIMP-1) dependent manner as MZ B-cells, however the IgM produced by B1 
cells is not mutated. B1 cells are long lived and are also capable of self-renewal 
(Fairfax et al., 2007). 
 
1.2.2. The Humoral immune response: B-cell activation 
Antigen specific memory B-cells and antibody secreting plasma cells are 
essential features of the adaptive immune response, and can be derived from 
follicular B2 cells. Firstly the follicular B2-cells are attracted by B-lymphocyte 
chemokines and enter follicles of a secondary lymphoid organ (Gunn et al., 
1998). They develop into IgM+ and IgD+ mature B-cells, with the self-reactive 
B-cells which fail to develop into mature B-cells being removed under clonal 
deletion (Russell et al., 1991). The activation of naïve and antigen specific B-
cells requires two sets of signals (Lanzavecchia, 1985). Firstly, BCR signalling 
is required, usually initiated by either naïve or antigen specific B-cells 
encountering antigen that is presented by antigen presenting cells (APCs) 
(Gunn et al., 1998; Lanzavecchia, 1985; Russell et al., 1991). 
The activation of B-cells is dependent on the binding strength and avidity of the 
antigen. This can be increased by inducing the formation of BCRs clusters and 
allowing successful BCR stimulation (Harwood & Batista, 2008). BCR activation 
recruits in expression of different signalling molecules, such as spleen tyrosine 
kinase (SYK) and the kinase LYN, which induces B-cells to internalise the 
antigen (Batista et al., 2001). Once internalised the antigen is processed and 
presented at the cell surface as part of the MHC II complex (Lanzavecchia, 
1985). This complex is recognised by the T cell receptor (TCR) of a specific 
population of T-helper cells that has been clonally expanded by recognition of 
the same antigen. The interaction between MHC II complex and the TCR of T-
helper cells serve as the second signal for B-cell activation, and drives the cells 
to further proliferate and differentiate (Lanzavecchia, 1985). 
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Other than the two main signals, there are several co-stimulatory signals that 
are also required for the B-cell activation process, which occur between the 
BCR and the ligands on either T-helper cells or the APCs (Bishop & Hostager, 
2001). CD40, a member of the tumour necrosis factor (TNF) receptor family, is 
expressed on all B-cells, with the CD40 ligand expressed on T-helper cells. 
CD40 and CD40 ligands are essential for class switching recombination (CSR) 
and germinal centre (GC) formation. OX40 and OX40 ligands are also essential 
for CSR (Murata et al., 2000), with CD27-CD27 ligand promoting plasma cell 
differentiation (Jacquot et al., 1997). Once activated, B-cells proliferate into 
plasmablasts, and can either differentiate into short live plasma cells for 
antibody production, or undergo a GC reaction with the help of T cells and 
further differentiate into either plasma cells or memory B-cells (figure 1.2.3).  
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Figure 1.2.3. The multiple pathways of B-cell development (adapted from (Shapiro-Shelef & 
Calame, 2005) by Dr. Sam Wilson). Schematic diagram represents the multiple pathways of B-
cell development from the three subsets of naïve B-cells. 
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1.2.2.1. Germinal centre reaction 
The activated proliferating B-cells form germinal centres (GC) which displace 
resting B-cells within the follicles of the peripheral lymphoid tissue into a 
surrounding mantle zone. GC consist of a dark zone of proliferating centroblasts 
and a light zone, formed by non-cycling centroblasts. Affinity maturation and 
class-switch recombination of immunoglobulin occurs during this stage of B-cell 
development, resulting in production of both plasma cells, that produce high 
affinity antibody, and long-lived memory B-cells, which provide protection 
against second challenge of antigens (Klein & Dalla-Favera, 2008; Schmidlin et 
al., 2009). 
Once in the germinal centre, cells undergo clonal expansion and somatic 
hypermutation (SHM) (Berek et al., 1991; Jacob et al., 1991), which modify the 
genes encoding the variable regions of immunoglobulin heavy and light chains. 
SHM, facilitated by activation induced cytidine deaminase (AID) (Muramatsu et 
al., 2000; Revy et al., 2000; Stavnezer & Schrader, 2006), introduces 
substitutions, deletions and insertions into the VDJ recombination sites of Ig 
(Goossens et al., 1998). The affinity for specific antigen alters due to the 
mutation at the BCR variable region, with approximately one mutation 
introduced per cell division (McKean et al., 1984). GC B-cells with high affinity 
antigen receptors outcompete the low affinity GC B-cells, differentiate into non-
dividing centrocytes and migrate into the light zone of germinal centre.  The GC-
B-cells with low affinity antigen receptors undergo apoptosis (Takahashi et al., 
1999). The light zone also contains follicular dendritic cells (FDCs), T-cells and 
macrophages that help select GC B-cells with high affinity towards the antigen. 
Class switching recombination (CSR) may occur in the light zone at this stage 
(Toellner et al., 1996), allowing B-cells to change the surface immunoglobulin 
from IgM to IgD, A, G or E.  The different IgH constant regions are arranged 
sequentially in the human genome; with CSR inducing non-homologous end-
joining recombination between the switch regions upstream of the heavy chain 
constant regions, resulting in different IgH gene expression without modifying 
the variable region (Stavnezer & Schrader, 2006). This process is linked to 
SHM and requires AID to increase antibody diversity (Hackney et al., 2009; 
Longerich et al., 2006; Ta et al., 2003). Uracil-N-glycosidase (UNG) is also 
required for CSR (Rada et al., 2002). 
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The GC B-cells travel between the light and the dark zone of the GC, 
undergoing further clonal expansion, SHM and CSR, a process refered to as 
affinity maturation. Eventually, the centrocytes that survive all the GC reactions 
migrate from the GC and further differentiate into memory B-cells, or 
plasmablasts (pre antigen-produced plasma cell) (Allen et al., 2004). The signal 
required for centrocytes to exit the GC is unclear, as are the signals required for 
GC B-cell differentiation. Previous studies indicated that the production of 
memory B-cells by the germinal centre reaction is random (Blink et al., 2005). 
High affinity BCR however drives the post GC-B-cells to differentiate into 
plasma cells (Phan et al., 2006), which is controlled and regulated by 
transcriptional factors. 
The transcription factor B-cell lymphoma 6 (BCL-6) is present at high levels in 
GC B-cells (Cattoretti et al., 1995) and is required for GC formation (Dent et al., 
1997). BCL-6 acts as a transcriptional repressor and downregulates the genes 
involved in growth suppression and apoptosis. This allows cells in GC to 
proliferate and undergo SHM and CSR (Parekh et al., 2007; Shaffer et al., 
2000). BCL-6 also suppresses the gene required for T-cell dependent B-cell 
activation, preventing immature differentiation of B-cells (Shaffer et al., 2000). 
The most important feature of BCL-6 is the suppression of B-lymphocyte-
induced maturation protein 1 (BLIMP-1) expression which allows the GC 
reaction to continue before differentiation into plasma cells (Fearon et al., 2002; 
Shaffer et al., 2000) BCL-6 represses positive-regulatory-domain-containing-1 
(Prdm1) which encodes BLIMP-1. See figure 1.2.4. for detail. The metastasis-
associated 1 family member 3 (MTA3) is required for BCL-6 mediated 
repression of BLIMP-1. 
However, with continuous BCL-6 expression, GC B-cells cannot differentiate 
into plasma cells. BCR signalling has been shown to suppress BCL-6 
expression via proteasome mediated degradation of BCL-6. This alone is not 
sufficient to induce GC B-cells into plasma cell differentiation and other signals 
may be required for this process (Schliephake & Schimpl, 1996; Shapiro-Shelef 
& Calame, 2005). CD40 signalling is able to down regulate BCL-6 
(Panagopoulos et al., 2004), suggesting an involvement of T-cells in the final 
stages of plasma differentiation. 
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Figure 1.2.4. Transcription factors involved in regulating the terminal differentiation into plasma 
cells from GC B-cells. 
 
1.2.3. Memory B-cells 
Memory B-cells are long-lived non-dividing cells, which circulate either in the 
blood (Benner et al., 1977) or colonise the MZ of the spleen (Liu et al., 1988). 
Memory B-cells can rapidly proliferate and differentiate into plasma cells at the 
second encounter with the original antigen (Arpin et al., 1997; Mitchell et al., 
1972) or respond to polyclonal stimulation through pattern recognition and T-cell 
help (Bernasconi et al., 2003; Bernasconi et al., 2002). Interestingly, naïve B-
cell do not respond to this signal (Bernasconi et al., 2003). This allows memory 
B-cells to maintain the memory pool in the absence of an antigen. 
All memory B-cells are IgD-, with CD27 being identified as the memory B-cell 
marker (Klein et al., 1998), and can be divided into subsets according to the Ig 
isotype expressed. The locations of memory B-cell subsets are also restricted to 
facilitate a good immune response, for example memory B-cells expressing 
inhibitory receptor Fc receptor like 4 (FCRL4) are restricted to mucosal tissues 
and amesenteric lymph nodes (Ehrhardt et al., 2005). The memory B-cell is 
long-lived and can persist for the lifetime of a host, through high expression of 
anti-apoptotic factors such as Bcl-2, A1 and Mcl-1 compared with naïve B-cells 
(Good et al., 2009). However the full mechanism for memory persistence 
remains unclear. 
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Although BCL-6 is an important factor for preventing GC B-cells from 
differentiating into plasma cell and memory B-cells, Toyama et al. (2002) 
showed that memory B-cells are still able to be produced in BCL-6 deficient 
mice, despite them being unable to form GC. Nevertheless, over-expression of 
BCL-6 leads to maintenance GC B-cells and prevents differentiation into 
memory cells (Kuo et al., 2007). Therefore; the differentiation from GC B-cells to 
memory B-cells involves other transcription factors. Post GC memory B-cells 
can be sub-divided into two subsets: the CD45+ memory B-cells, which are 
highly proliferative (Bleesing & Fleisher, 2003), and the CD40- pre-plasma 
memory B-cells, which are less proliferative but can differentiate into plasma 
cells quickly (Driver et al., 2001; McHeyzer-Williams et al., 2000). B-cells 
deficient in BLIMP-1 expression, resulting in high-level expression of BCL-6, 
can only develop into post GC memory cells, but not pre plasma memory cells. 
This suggests a linear memory cell development with post GC memory B-cells 
upstream of pre-plasma memory B-cells (Shapiro-Shelef et al., 2003). However, 
further investigation is required to support this model. 
 
1.2.4. Plasma cells 
Plasma cells are non-dividing effector cells of the B-cell lineage. B-cells 
eventually terminally differentiate into plasma cells and are able to syntheses 
and secrets large amounts of immunoglobulin against a specific antigen, acting 
as an essential feature of both innate and adaptive immunity. Plasma cells can 
be differentiated from many different B-cell stages, including follicular B2 cells, 
GC B-cells, and memory B-cells, depending on the nature of the antigen and 
the location of the encounter. This process is tightly regulated by many 
transcription factors as shown in figure 1.2.4.  
B-lymphocyte-induced maturation protein 1 (BLIMP-1) is a five-zinc-finger-
containing protein that was first identified as a repressor of the human 
interferon-# (IFN-#) promoter (Keller & Maniatis, 1991) and was the identified as 
an induced transcript when BCL-1 lymphoma cells differentiate into antibody 
secreting cells after cytokine treatment (Turner et al., 1994). Exogenous 
expression of BLIMP-1 in mature B-cells or cell lines can induce plasma cell 
differentiation. BLIMP-1 knock out mice do not develop plasma cells (Shapiro-
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Shelef et al., 2003; Turner et al., 1994). BLIMP-1 regulates three transcription 
factors (Shaffer et al., 2002); BLIMP-1 directly down regulates paired box 
protein 5 (PAX5) (Lin et al., 2002) and BCL-6 (Shaffer et al., 2002), and 
indirectly activates XBP-1 and BLIMP-1. BLIMP-1 acts upstream of XBP-1 
which is required for terminal differentiation. However, if BLIMP-1 is deficient in 
cells, over-expression of XBP-1 alone cannot induce plasma cell differentiation 
(Shapiro-Shelef et al., 2003). Many of the genes required for regulating terminal 
differentiation of plasma cells are regulated by both BLIMP-1 and XBP-1 
proteins (Shaffer et al., 2004). 
PAX5 is also known as B-cell-lineage-specific activator protein (BSAP), and 
regulates many genes involved in Ig transcription, BCR signalling and B-cell 
identity, via binding to DNA by a bipartite paired domain, and can function as 
either a transcriptional activator or a repressor (Nutt et al., 2001). Similar to 
BCL-6, PAX5 represses GC B-cell terminal differentiation of plasma cells. One 
of the main functions of PAX5 is the direct repression of XBP-1 transcription 
(Reimold et al., 1996). PAX5 is also able to down regulate the expression of 
IgH, IgL and the J chain. Since expression of Ig can also induce XBP-1 
expression, by repressing the expression of the Ig, PAX5 also indirectly blocks 
XBP-1 expression. 
 
1.2.4.1. Unfolded protein response 
The terminal differentiation of B-cells into plasma cells occurs through a 
transcription factor mediated development chain. During this process, the B-
cells expand their secretary apparatus (Shaffer et al., 2004; Shapiro-Shelef & 
Calame, 2005) ready for large scale Ig secretion. This process involves the 
activation of transcription factors associated with the unfolded protein response 
(UPR); an inducible stress response that is able to increase the capacity for 
protein folding in the endoplasmic reticulum (ER) (Schroder & Kaufman, 2005) 
whilst decreasing synthesis of proteins and decreasing cell cycle arrest and 
apoptosis (Gass et al., 2004). Some functions during the UPR such as ER 
stress have been related to many diseases, such as diabetes, inflammation, 
autoimmunity and neurodegenerative disorders; whereas other functions of 
UPR, such as decreasing protein synthesis, have not. Therefore it has been 
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suggested that terminal differentiation of plasma cells is through a 
“physiological” UPR, rather than the “stress induced” UPR (Blond-Elguindi et al., 
1993; Gass et al., 2002; Shaffer et al., 2004). The UPR in mammalian cells is 
more complex than yeast, where it was originally discovered, and involves three 
branches of signalling, initiated by three different ER integral membrane 
proteins: activating transcription factor-6 (ATF6), protein kinase RNA (PKR)-like 
ER kinase (PERK) and IRE-1$. The signalling pathways between these three 
branches cross talk and contain various positive and negative feedbacks. The 
production of unfolded proteins in the ER initiates the UPR and it is sensed and 
mediated through BiP (also known as GRP78), an IgH binding protein (Haas & 
Wabl, 1983). BiP binds to the short hydrophobic motifs that reside in the interior 
of soluble proteins in the ER, but with low affinity (Blond-Elguindi et al., 1993; 
Flynn et al., 1991). This enables BiP to be recruited by the unfolded protein and 
removed from its usual binding partners, such as PERK, IRE1 or ATF6. This 
initiates the UPR. Figure 1.2.5 shows the detail of the UPR in mammalian cells. 
PERK and IRE-1$ both contain transmembrane serine/threonine kinase 
cytoplasmic domains (Bertolotti et al., 2000). Following dissociation with BiP, 
both PERK and IRE-1$ undergo homodimerisation and autophosphorylation. 
PERK then phosphorylates eularyotic initiation factor-2$ (eIF-2$) (Harding et 
al., 1999) causing translation attenuation, thereby preventing further 
accumulation of proteins in the ER. However, certain protein translation such as 
ATF4, which is required for recovering from cellular stress is active and requires 
phosphorylation of eIF-2$ (Harding et al., 2000; Harding et al., 2003; Lu et al., 
2004). Expression of ATF4 upregulates genes involved in amino acid synthesis 
and also activates C/EBP homologous protein (CHOP), which is a pro-apoptotic 
transcription factor (Harding et al., 2000). CHOP expression induces the 
expression of growth arrest and DNA damage inducible protein 34 (GADD34), 
leading to dephosphorylation of eIF-2$ via protein phosphatase 1 (PP1). CHOP 
expression is also induced by ATF6. CHOP also inhibits the expression of Bcl-2 
(Zinszner et al., 1998); Bcl-2 is important in switching the signalling of UPR from 
pro-survival to apoptotic (Rutkowski et al., 2006). Hence ATF4 acts as a 
negative feedback regulator of PERK mediated inhibition of translation, relieving 
the cells from the translational cell repression, allowing cells to express proteins 
that are required for cellular recovery (Marciniak et al., 2004).  
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Figure 1.2.5. ER stress and activation of the UPR signalling pathways. Accumulation of 
misfolded or unfolded protein aggregates in the ER lumen, a condition known as ER stress, 
leads to activation of three ER transmembrane proteins, PERK, IRE1, and ATF6. GRP78, a 
ubiquitous ER chaperone that is normally bound to these ER stress sensors and keeps them 
inactive, dissociates from them in order to assist with the folding of proteins in the ER lumen. 
However, this dissociation leads to activation of the 3 UPR pathways. (1) PERK 
homodimerization and autophosphorylation results in the subsequent phosphorylation of the ! 
subunit of eIF2 which by inhibiting global protein synthesis reduces the ER protein load. ATF4 
expression, however, increases upon eIF2! phosphorylation which translocates to the nucleus 
allowing for transcription of UPR target genes by binding to the UPR response element (UPRE). 
These genes include CHOP, a pro apoptotic transcription factor that results in cell death if ER 
stress conditions persist, and GADD34, which acts as a negative regulator of the PERK 
pathway by dephosphorylating eIF2!. (2) IRE1 is activated in a similar manner to PERK by 
homodimerization and autophosphorylation. Additionally, interaction of misfolded or unfolded 
proteins with the luminal domain of IRE1 can also further promote its activation. XBP1 mRNA is 
an IRE1 substrate that undergoes splicing to produce XBP1s, encoding a transcription factor 
that can lead to upregulation of ER chaperones and other UPR target genes. (3) ATF6 
activation leads to its translocation to the Golgi where it is sequentially cleaved by site 1 and site 
2 proteases. This leads to the release of the N-terminal ATF6 fragment which translocates to 
the nucleus, binds to the ER stress response element (ERSE) thereby activating UPR target 
genes. (Basseri & Austin, 2012) 
 
ATF6 is comprised of two transmembrane bZIP transcription factors, ATF6$ 
and ATF6" (Haze et al., 1999). Under normal conditions, these two factors are 
held together in the ER with BiP. After dissociation from BiP, these two factors 
migrate to the Golgi and are cleaved by site 1 and site 2 proteases, releasing  
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the N-terminal domain of ATF6 (Ye et al., 2000). ATF6" has a minimal role in 
the UPR (Thuerauf et al., 2004); however ATF6$ entry into the nucleus 
activates many UPR target genes, such as XBP-1, CHOP and ER chaperons. 
With both ATF6 and XBP-1 being bZIP transcription factors, formation of either 
homodimers or hetrodimers of these two proteins are possible (Newman & 
Keating, 2003). ATF6 activates the genes via inducing transcription from the 
promoters containing ER stress responsive elements (ERSEs), resulting in 
expression of BiP and protein disulphide isomerase (PDI), which increases the 
folding capacity of ER, and activates the genes involved in ER associated 
protein degradation (ERAD) (Okada et al., 2002; Yamamoto et al., 2007). ERAD 
allows unfolded proteins to be translocated from the ER lumen into the cytosol, 
and degraded by the proteasome, reducing the amount of unfolded protein in 
the ER. Other than promoting unfolded protein degradation and inducing XBP-1 
expression, ATF6 is also important in ER expansion and lipid biosynthesis 
(Bommiasamy et al., 2009). As well as sensing ER stress through BiP 
disassociation, ATF6 can also sense ER stress via alternative pathway. ATF6 
contains three glycosylation sites; and once glycosylated, it promotes 
interaction with calreticulin. This interaction allows ATF6 to anchor in the ER, 
whereas the unglycosylated ATF6 migrates to the Golgi (Hong et al., 2004) and 
initiates UPR. This alternative activation pathway of ATF6 could allow UPR to 
be activated by different stress signals.  
IRE-1$ also undergoes homodimerization and autophosphorylation following 
BiP dissociation, which activates both kinase and endoribonuclease activity of 
IRE-1$ (Hosoi et al., 2010). Unfolded proteins may also directly bind to IRE-1$ 
and induce homodimerisation and autophosphrylation (Credle et al., 2005; 
Gardner & Walter, 2011; Kimata et al., 2007) without dissociation from BiP. IRE-
1$ can then bind to tumour-necrosis factor (TNF)-receptor-associated factor 2 
(TRAF2) which then activates JNK signalling via apoptosis signal regulating 
kinase-1 (ASK-1) (Nishitoh et al., 2002; Urano et al., 2000). Activation of JNK 
results in activation of autophagy, which removes damaged organelles and 
aggregated proteins (Bernales et al., 2006; Ogata et al., 2006), and apoptosis of 
the cells that are unable to recover from ER stress (Yoneda et al., 2001). IRE-
1$ in UPR is linked to apoptosis through several members of Bcl-2 family such 
as BAX, BAK and “BH3 only”, there have been shown to interact with IRE-1$, 
!
 
66 
resulting in apoptosis (Hetz et al., 2006; Klee et al., 2009). IRE-1$ expression 
also induces mRNA degradation via the endoribonuclease domain, reliving the 
pressure of ER. The function of ATF6, IRE-1$ and PERK highlights two 
proposes of UPR: firstly attempted recovery and secondly, if homeostasis 
cannot be restored, induce apoptosis. 
 
1.2.4.2. XBP-1 in plasma cell differentiation 
The transcription factor X-box binding protein 1 (XBP-1) is a bZIP transcription 
factor identified by its ability to bind to the X-box, which is a conserved 
transcriptional element in the human leukocyte antigen (HLA)-DR$ promoter 
(Liou et al., 1990). Expression of XBP-1s is essential for terminal differentiation 
of plasma cells (Reimold et al., 2001). Over expressing XBP-1 in post GC B-
cells or plasmablasts drives the cells to express transcriptional profiles of 
plasma cells (Shaffer et al., 2004; Wilson et al., 2007). Expression of XBP-1 
mRNA is induced by ATF6 (Yoshida et al., 2000), IL-4 (Iwakoshi et al., 2003) 
and BLIMP-1-dependent repression of PAX5 expression (Shapiro-Shelef et al., 
2003). XBP-1 is expressed retaining a 26 nucleotides (nt) intron (XBP-1u, 
unspliced) that results in a frame shift preventing the translation of an active 
transcription factor. Under ER stress and B-cell terminal differentiation, the 26nt 
intron of XBP-1u mRNA is removed to allow the translation of the full length 
stable and active form of XBP-1s (XBP-1 spliced) (Calfon et al., 2002). The 
splicing event of XBP-1 mRNA is facilitated by IRE-1$ (Calfon et al., 2002) and 
is dependent on the increased IgH expression during the UPR (Iwakoshi et al., 
2003). XBP-1 induces expression of p58IPK, which negatively regulates PERK 
expression, indicating further cross talk between the UPR pathways (Yan et al., 
2002). The inactivated XBP-1u acts as dominant-negative regulator of XBP-1s 
by occupying the binding sequence of target promoters (Lee et al., 2003). 
Accumulation of XBP-1u during ER stress recovery also blocks XBP-1s nuclear 
entry (Yoshida et al., 2006). Hence XBP-1u acts as negative regulator of XBP-
1s and degradation of XBP-1u is essential for XBP-1s activity.  
In B-cells, XBP-1 induces the gene expression involved in targeting of proteins 
to ER, translocation into the ER, folding of proteins, degradation of misfolded 
proteins, glycosylation of proteins, trafficking between ER and the Golgi, 
trafficking in the ER pathway, and targeting secretary vesicles to the plasma 
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membrane (Shaffer et al., 2004). XBP-1 also induces the expansion of 
mitochondria mass, ER, cell size, lysosomal content, ribosomal content, and 
total protein synthesis (Shaffer et al., 2004); suggesting the main function of 
XBP-1 is to facilitate the development of secretory apparatus in plasma cell 
differentiation. Recent studies have indicated that XBP-1 activation is 
differentiation dependent and occurs prior to UPR during B-cell terminal 
differentiation (Hu et al., 2009; Todd et al., 2009). 
 
1.2.5. EBV control of B-cell development 
EBV is known to be able to manipulate B-cell development, and can transform 
B-cells into immortal LCLs in vitro. Despite life-long EBV latent infection in the 
memory B-cells, EBV actively infects naïve B-cells in vivo and manipulates 
cellular factors by mimicking certain aspects of B-cell differentiation thereby 
driving the infected cell towards a memory cell phenotype (Souza et al., 2005; 
Thorley-Lawson & Babcock, 1999). Figure 1.2.6 shows a side-by-side 
comparison model of the EBV manipulation of B-cell differentiation after 
infection of naïve B-cells. EBV establishes different latency programs 
throughout the differentiation in different type of B-cell, which is shown in table 
1.1.2. 
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Figure 1.2.6. B-cell development and EBV (adapted from (Thorley-Lawson, 2005) by Dr. Sam 
Wilson). A diagrammatic representation of normal and EBV-driven B-cell differentiations. EBV 
gene expression programs are highlighted in grey. 
 
1.2.5.1. Infection of resting naïve B-cells 
EBV is transmitted through saliva and infects IgD positive naïve B-cells in the 
nasopharyngeal lymphoid tissue (Joseph et al., 2000). Upon immediate 
infection, EBV enters an initial burst of lytic replication. Virus particles are 
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produced during this period. This early lytic cycle is important and contributes to 
the establishment of latency and transformation of B-cells (Halder et al., 2009). 
Naïve B-cells express Pax-5 which binds to and activates the Wp of EBV which 
induce the expression of EBNA2 (Tierney et al., 2000a). EBNA2 then activates 
other viral genes, including the rest of the EBNA family proteins and the LMP 
family proteins (Abbot et al., 1990), allowing EBV to establish the latency III 
program (growth program). This mimics the affect of antigen encounter and 
activates the B-cells (Wang et al., 1987), driving them to follicles where they 
undergo germinal centre like reactions and the EBV gene expression profile is 
switched to latency II. 
Interestingly, despite the importance of LMP proteins in transforming B-cells 
(see section 1.2.5.2.), the number of W repeats in EBV genome can affect the 
ability of virus transformation. EBV with lower numbers of W repeats is reported 
to have impaired ability in B-cell transformation compared to a virus with more 
W repeats (Tierney et al., 2007). EBV with one W repeat is virtually incapable of 
transforming B-cells; the ability to affect transformation reaches a peak at 5 
copies of W repeats (Tierney et al., 2011). The number of W repeats directly 
affects the function of Wp, which encodes EBNA2, EBNALP and BHRF1 at the 
Wp-initiated transcript. It has been suggested that the difference in 
transformation ability is due to the suboptimal levels of Wp transcription from 
the incoming virus genome, and therefore suboptimal levels of EBNA2 and 
EBNALP, two key transactivators of both viral and cellular gene expression. 
EBV impaired transformation ability due to small number of W repeats can be 
rescued by over expressing both full length EBNA2 and EBNALP proteins 
(Tierney et al., 2011). However, other studies have also shown that EBNALP 
with two repeat domains could efficiently co-activate the Cp and LMP1 promoter 
(Rickinson & Kieff, 2006; Shannon-Lowe et al., 2009).  
 
1.2.5.2. Germinal centre B-cells 
Latency program II is the program expressed in the GC cells and is also known 
as the default program, with only three viral genes expressed: EBNA1, LMP1 
and LMP2. It is suggested that the switch between Latency III and II programs 
may be caused by EBNA2 hyperphosphorylation (Yue et al., 2004) which 
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downregulates EBNA2, although further evidence is required for the hypothesis. 
In EBV free B-cell development, GC B-cells undergo a series of somatic 
hypermutation and class switching recombination which are signalled by 
antigen encounter and T helper cells. In EBV positive B-cells, LMP1 and 2 
mimic these signals in the GC reaction.  
LMP1 mimics the signals generated through CD40-CD40 ligands provided by T-
helper cells (Kilger et al., 1998; Zimber-Strobl et al., 1996), via ligand 
independent recruitment of tumour necrosis factor (TNF) receptor-associated 
factors (TRAFs). LMP1 also upregulates the expression of BAFF and induces 
ligand-independent CSR (Bleesing & Fleisher, 2003). LMP2A mimics BCR 
signalling through association with the tyrosine kinase Lyn (Burkhardt et al., 
1992), and has been shown to be able to drive B-cells into GC formation 
independent of antigen in transgenic mice (Casola et al., 2004). LMP1 also 
inhibits expression of BCL-6, which signals the B-cells to leave the germinal 
centre and enter the memory cell pool. 
 
1.2.5.3. Peripheral blood memory B-cells 
EBV positive post GC B-cells can either differentiate into memory B-cells or 
plasma cells after exiting the GC reaction. The differentiation into memory B-
cells is associated with EBV achieving life-long persistency. The circulating EBV 
positive B-cells express latency I/0 profiles, with minimal viral protein 
expression. Differentiation into plasma cells is associated with EBV reactivation. 
Studies have shown EBV could be reactivated by XBP-1s expression alone or 
in combination with protein kinase D (PKD) during terminal differentiation into 
plasma cells (Bhende et al., 2007; Laichalk & Thorley-Lawson, 2005). Other 
studies suggested ER stress induces EBV into lytic reactivation (Taylor et al., 
2011). More details on EBV reactivation and plasma cell differentiation will be 
discussed in chapter 3. 
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1.3. Gamma Herpesvirus Associated tumours 
1.3.1. B-cell tumourigenesis 
Different B-cell tumours have been associated with B-cells arrested at different 
stages of the developmental process. Fundamental understanding of each B-
cell development stage will help future studies of these tumours. Since EBV is 
capable of transforming and affecting gene expression in B-cell development, it 
has also been suggested that EBV infection may contribute towards formation 
of B-cell tumours. A hypothesis suggested is that EBV negative lymphomas 
lose EBV after the lymphoma has formed. Sporadic BL without detectable 
EBNA1 had been found to contain detectable partial EBV genomes (Razzouk et 
al., 1996). It has been suggested that EBV had an initiating role in 
tumorigenesis.  Despite losing EBV later on in the process, the cells had 
acquired other mutations during the progression of malignancy, and these 
mutations compensated for the lost of EBV. This therefore leads to lymphomas 
being clinically presented as EBV negative (Vereide & Sugden, 2011). Here we 
review some of the B-cell malignancies that have been associated with EBV or 
herpesvirus infection, with the exception of NPC, which is of epithelial origin but 
is associated with EBV infection. 
 
1.3.2. Primary Effusion Lymphoma 
Primary effusion lymphoma (PEL) is a neoplasm of large B-cells usually 
presenting as serous effusions without detectable tumour masses, usually in the 
cavity of human body, and was thus initially referred to as body cavity based 
lymphoma (BCBL) (Knowles et al., 1989). However, cases of isolated solid 
lymph-node associated PEL have been discovered since (Chadburn et al., 
2004). With KSHV being associated with BCBL (Cesarman et al., 1995b), PEL 
was redefined as a KSHV positive lymphoma (Nador et al., 1996). 80% of PEL 
are also EBV positive. PEL accounts for about 3% of the AIDS-related non-
Hodgkin’s lymphomas (Knowles, 2003); the majority of PEL patients are HIV 
positive and immune-suppressed (Komanduri et al., 1996), however PEL can 
also occur in HIV negative individuals (Nador et al., 1996). The only difference 
between PEL in HIV positive and negative individuals is the latter tends to occur 
later on in life (Carbone et al., 1996; Nador et al., 1996).  
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Despite being of B-cell origin, PEL does not express CD19 on the cell surface. 
PEL expresses CD138, CD30, CD38, CD45 and CD71, which is similar in 
immune phenotype to the cycling plasmablast. Most PELs have hypermutated 
immunoglobulin (Ig) gene, which suggests that they have passed through the 
germinal centre reaction (Fais et al., 1999; Matolcsy et al., 1998). The gene 
expression profiles of PELs indicate that they are arrested in the stage of a 
plasmablast in B-cell development (Jenner et al., 2003; Klein et al., 2003); 
however, PELs do not express Ig on the cell surface (Nador et al., 1996). 
CD138 expression is typically seen in either pre-B-cell or plasma cells and no 
other lymphomatous effusion (Gaidano et al., 1997), and can therefore be used 
as a marker to diagnose PEL.  
 
1.3.3. Burkitt’s Lymphoma 
Burkitt’s Lymphoma (BL) is named after Dr. Denis Parsons Burkitt who first 
described the disease in equatorial Africa; it is also the tumour where EBV was 
first discovered. BL is a highly aggressive lymphoma that often presents at 
extranodal sites, or as acute leukaemia. It contains monomorphic medium-sized 
B-cells with basophilic cytoplasm and numerous mitotic figures. BL shows the 
same pattern of immunoglobulin gene hypermutation as germinal centre B-cells 
and memory B-cells (Klein & Zachau, 1995), but has the cellular phenotype of a 
germinal centre B-cell (Gregory et al., 1987). EBV often establishes latency type 
I program in BL cell lines.  
BL can be divided into three variants: endemic, sporadic and immunodeficiency 
associated variants. The endemic variant of BL occurs in equatorial Africa and 
is associated with EBV. The sporadic variant of BL occurs worldwide, and only 
about 15% of sporadic BL are EBV positive (Rickinson & Kieff, 2001); however, 
it is suspected that EBV infection contributes to the formation of sporadic BL but 
the cells then lose the infection later on in the tumour formation process 
(Razzouk et al., 1996; Vereide & Sugden, 2011). AIDS is often associated with 
BL however only 30-40% of AIDS related BLs are EBV positive (Diebold, 2001).  
Endemic BL (eBL), with or without EBV infection, has been long associated with 
holoendemic Plasmodium falciparum malaria geographically (Burkitt, 1958; 
Dalldorf et al., 1964) and also has a molecular link to holoendemic malaria 
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(Chene et al., 2007). Previous studies have shown the cysteine-rich interdomain 
region 1! (CIDR1!) of the malaria protein P falciparum erythrocyte membrane 
protein 1 (PfEMP1), which is expressed at the surface of parasite positive red 
blood cells, activate B-cells, especially the membrane B-cells, where EBV 
remains latent (Chene et al., 2007; Donati et al., 2006). However, the 
interactions between EBV infection, risk of BL and malaria infection remain 
unclear and require future study. 
 C-myc is a transcription factor that is involved in many cellular progresses such 
as cell growth, proliferation and apoptosis. The common feature of all BL is the 
c-myc chromosomal translocation occurs most frequently at chromosome 8q24 
to the Ig heavy chain region on chromosome 14q32, which deregulates the 
expression of c-myc oncogene (Klein, 1983; Leder, 1985; Manolov & Manolova, 
1972). This accounts for about 85% of the c-myc translocation in BL. The 
remaining 15% is made up of either translocations at chromosome 2q8 or 8q22, 
at the kappa or lamda IgL region. The translocation leads to high level of c-myc 
expression (Klein et al., 1968). Li et al. (2003) have shown that c-myc binds and 
is involved in the regulation of large number of gene promoters in BL and 
promoties tumorigenesis. 
 
1.3.4. Post-transplant lymphoproliferate disease (PTLD) 
PTLD is a lymphoid proliferation or lymphoma that develops as a consequence 
of immunosuppression in a recipient of a solid organ or bone marrow allograft. 
PTLD refers not to a single disease but to a wide range of lymphoproliferations, 
ranging from early EBV driven polyclonal proliferations resembling infectious 
mononucleosis (IM), to EBV positive or negative lymphomas of predominantly 
B-cells, or less commonly, T-cells. PTLD can affect nearly all organ system and 
is able to form a heterogeneous group of tumours, ranging from B-cell 
hyperplasia to immunoblastic lymphoma. Approximately 90% of the PTLD are 
B-cell origin, and 90-95% contain EBV (Harris et al., 2001). However, the 
association of PTLD with EBV is dependent on many factors such as the type of 
organ allograft, the patient population (adult or paediatric), and the 
immunosuppressant regiment (Nalesnik, 1996; 1998). 
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The frequency of PTLD varies with the type of graft. It is estimated that PTLD 
accounts for 2% frequency in solid organ transplant recipients (Nalesnik, 1996; 
1998). With the lowest incident in renal transplant, which is around 1%, patients 
receiving lung, heart and liver transplant have higher incident frequency of 
developing PTLD, which is around 5% (Harris et al., 2001). Paediatric patients 
have higher frequency of developing PTLD than adults (Dror et al., 1999; 
Harmon & Dharnidharka, 1999; Ho et al., 1988; Pickhardt et al., 1998). The 
general frequency of children under 15 developing PTLD post solid organ 
transplant is about 8% (Pickhardt et al., 2000). The frequency of paediatric 
PTLD post liver transplant is 4-15%, lung and heart transplant is 7.7-19.5% and 
1-8% in kidney transplant (Boyle et al., 1997; Cox et al., 1995; Dror et al., 1999; 
Harmon & Dharnidharka, 1999; Malatack et al., 1991; Newell et al., 1996; 
Pickhardt et al., 1998; Younes et al., 1999). The majority of the EBV in PTLD 
after solid organ transplant is of host origin, with a minority (less than 10%) of 
donor origin. However, this also varies depending on the type of grafts. Majority 
of the patients receiving bone marrow transplant developed PTLD of donor 
origin EBV. Increased levels of immunosuppression allows greater EBV 
expansion; therefore a high level of immunosuppression is another risk factors 
for developing PTLD, especially when treating rejections (Cox et al., 1995; 
Harmon & Dharnidharka, 1999; Newell et al., 1996). 
Since PTLD represents a large number of lymphoproliferative diseases, the 
America Society of Haematopathology has outlined three general categories for 
PTLD according to the morphology (Harris et al., 1997). Early lesions: which 
include plasma cell hyperpasia and infectious-mononucleosis-like-PTLD. This 
type of PTLD shows preservation of the nodal architecture (Harris et al., 2001; 
Pickhardt et al., 2000). Polymorphic PTLD are defined as destructive lesions 
composed of immnuoblasts, plasma cells, and intermediate sized lymphoid 
cells. This type of PTLD also shows destruction of the nodal architecture and 
locally invades the involving organs (Pickhardt et al., 2000). The third type of 
PTLD is referred to as monomorphic PTLD, which is characterised by nodal 
architecture effacement and/or invasive tumour growth in extra nodal sites with 
confluent sheets of transformed cells (Harris et al., 2001). This type of PTLD 
can be further divided according to histopathological features by using standard 
lymphoma nomenclature, such as diffused large B-cell lymphoma, Burkitt’s 
lymphoma or multiple myeloma. 
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1.3.5. Hodgkin’s lymphoma 
Hodgkin’s Lymphoma can be further divided into Nodular lymphocyte 
predominant Hodgkin lymphoma (NLPHL) and classic Hodgkin’s lymphoma 
(CHL), depending on the morphology, immunophenotype, immunoglobulin 
transcription and the composition of the cellular background. EBV infection can 
only be found in the CHL. 
CHL accounts for 95% of the HLs, and has a bimodal age curve, the first 
between ages 15-35 and the second one later on in life.  It is a monoclonal 
lymphoid neoplasm composed of mononuclear Hodgkin cells and 
multinucleated Reed-Sternberg (HRS) cells. It resides in an infiltrate containing 
a variable mixture of non-neoplasmic small lymphocytes, plasma cells, 
fibroblasts and collagen fibres. EBV can only be found in a population of CHL, 
with HIV often being associated with EBV positive CHLs.  Previous reports have 
associated patients with infections mononucleosis with higher incidence of CHL 
(Mueller, 1999). EBV positive CHL expresses the latency type II program (Stein, 
2001).  
 
1.3.6. Nasopharyngeal Carcinoma  
Nasopharyngeal carcinoma (NPC) is a tumour of epithelial cells in the 
nasopharynx. As discussed earlier in this chapter, it is more common in Asia. 
NPC, according to the classification by the World Health Organisation (WHO), 
can be divided into three types. Type I is referred to as the squamous cell 
carcinoma, type 2 is the Keratinizing undifferentiated carcinoma, and type III is 
the nonkeratinizing undifferentiated carcinoma. Type III accounts for 80% of the 
NPC cases and is strongly associated with EBV. There are several aetiological 
factors associated with NPC, firstly genetic susceptibility, secondly, an early 
exposure to chemical carcinogens and finally, association with EBV latent 
infection (Busson et al., 2004; Chan & Lo, 2002). EBV in NPC arises from a 
single EBV infected progenitor cell (Raab-Traub & Flynn, 1986). The 
progression of NPC requires accumulation of many changes, either genetic or 
epigenetic in the host genome (Lo & Huang, 2002). 
EBV is in latency II within the NPC cells, with expression of high level of LMP2A 
(Brooks et al., 1992), and LMP1 (Chen et al., 1995). Low level of lytic replication 
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can also be detected in NPC cell lines (Cochet et al., 1993). Previous studies 
have suggested that, unlike other EBV associated B-cell lymphomas where the 
virus is considered to be the initial factor of the tumour progression. In NPC the 
EBV infection only acts to facilitate or promote the tumour progression. EBV 
infection of healthy epithelial cells does not lead to NPC development, whereas 
EBV infection in epithelial cells unable to differentiate (due to other factors such 
as genetic or chemical carcinogens) provides the cells with growth and survival 
advantages, eventually leading to development of NPC (Shah & Young, 2009).  
 
1.4. Next Generation Sequencing 
It is becoming clear that the understanding of host and virus biology 
increasingly needs the determination of the host and pathogen genome, 
especially in virus tumours. Currently studies of viral and host interactions focus 
on single genes and their effect in infection or the disease progression. Little is 
known about the how the whole genomes interact with the host, and the 
interactions between multiple genes. Furthermore, current studies focus on the 
coding regions of the viral genome and little is known about the promoter and 
non-coding sequence of the viral genome, Lacking information of the whole viral 
genomes prevents further understanding of how the viruses truly interact with 
the host. Next Generation Sequencing (NGS) now allows further study of the 
whole viral genome; therefore it provides more information about variations in 
viral genomes which allows a fuller understanding of how virus function. 
DNA sequencing has been a powerful and widely used tool in biological 
research. In 1977, Sanger et al. developed the dideoxynucleotide sequencing 
that led to modern capillary based methods used widely and almost exclusively 
in the last 30 years (Sanger et al., 1977a). Sanger sequencing, (also known as 
dideoxy sequencing), uses both dideoxynucleotides (ddNTPs) and normal 
nucleotides (NTPs) in the process. ddNTP differs from NTP by containing a 
hydrogen group at the 3’ carbon, instead of a hydroxy group (OH), this 
substitution prevents ddNTP from further incorporation with other NTP which 
results in the termination of the DNA chain. The resulting DNA fragments vary in 
length depending on the location of ddNTP incorporation. In capillary 
sequencing, different fluorescent dyes are used to label the ddNTP which 
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makes it possible to determine the nucleotide based on the termination position. 
The DNA sequence is determined by running the DNA fragments through size 
separating gel electrophoresis to separate by DNA length, and then using a 
laser to excite the fluorescent labels which provide the readout and DNA 
sequence. The Sanger sequence can achieve a DNA read length of to up 
1000bp. 
Following Sanger capillary sequencing of the Human Genome, many different 
approaches to sequencing have been developed in the last decade which aim 
to improve the rate and reduce the cost of sequencing. Improvements in other 
fields, such as computational data analysis, also enabled the development of 
the so called “Next Generation Sequencing” (NGS). Currently, NGS is used to 
refer to procedures developed using the cyclic-array sequencing technology, 
such as 454 sequencing (used by Roche Applied Sciences), Solexa technology 
(used by Illumina, referred to as Illumina sequencing), the SOLiD platform (used 
by Applied Biosystems), the Polonator and the HeliScope Single Molecular 
Sequencer technology (used by Helicos) (Shendure & Ji, 2008), with 454 and 
Illumina being the most commonly used platforms.  
When compared with the traditional Sanger sequencing, there are several 
advantages associated with Next Generation Sequencing. Firstly, the array-
based sequencing allows a higher degree of paralysation than the capillary 
based sequencing. Because the DNA fragments are immobilized to a planar 
surface during array-based sequencing, they can be manipulated with a single 
reagent volume, which lowers the cost of reagents. Secondly, array-based 
sequencing also allows deeper sequencing per base, which allows accurate 
base calling. Although 454 and Illumina are the most commonly used Next 
Generation Sequencing technologies, they rely on different PCR strategies to 
produce material for sequencing. 
  
1.4.1. Illumina Sequencing 
Prior to constructing the library for sequencing, DNA needs to be sheared to 
several hundred base pairs in length and ligated to adaptors. The Illumina 
sequencing relies on the bridging PCR method to generate amplicons. Both 
forward and reverse primers are tethered to a solid substrate at 5 prime ends by 
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a flexible linker, alternative cycles using Bst polymerase and denaturation with 
formamide after hybridisation results in clusters of PCR products, which consist 
of around 1000 clonal amplicons in each cluster (Figure 1.4.1.a). Several million 
clusters can be amplified in distinct locations with the eight independent “lanes” 
on a single Illumina flow cell, hence 8 independent libraries can be sequenced 
in parallel in the same run. After forming the clusters, the amplicons are 
denatured to single strands, allowing hybridisation of sequencing primers. 
Mixtures of four modified nucleotides along with the modified polymerase are 
added at each cycle of PCR. The modified nucleotides are also referred to as 
reversible terminators, due to the chemically cleavable moiety at the 3’ hydroxyl 
position, which prevents further binding and incorporation of other nucleotides 
(Turcatti et al., 2008). An image of the four channels is taken after each single 
base extension, then both modified moieties are cleaved chemically prior to 
next cycle (figure 1.4.2.b) (Shendure & Ji, 2008). The base calling depends on 
the image showing the location of the florescent label. With Illumina 
sequencing, the original read pairs generated by Solexa technology generate 
short reads at around 36 bps. Every strand of DNA is sequenced twice, in the 
positive and negative senses, resulting in a read-pair. However, with recent 
models such as the Illumina HiSeq system, the read pairs generated are much 
longer to 100bps. 
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Figure 1.4.1. Illumina sequencing base on Solexa technology. a) The Illumina technology relies 
on bridge PCR (Adessi et al., 2000; Fedurco et al., 2006) (aka 'cluster PCR') to amplify clonal 
sequencing features. In brief, an in vitro–constructed adaptor-flanked shotgun library is PCR 
amplified, but both primers densely coat the surface of a solid substrate, attached at their 5' 
ends by a flexible linker. As a consequence, amplification products originating from any given 
member of the template library remain locally tethered near the point of origin. At the conclusion 
of the PCR, each clonal cluster contains 1,000 copies of a single member of the template 
library. Accurate measurement of the concentration of the template library is critical to maximize 
the cluster density while simultaneously avoiding overcrowding. (b) Each sequencing cycle 
includes the simultaneous addition of a mixture of four modified deoxynucleotide species, each 
bearing one of four fluorescent labels and a reversibly terminating moiety at the 3' hydroxyl 
position. A modified DNA polymerase drives synchronous extension of primed sequencing 
features. This is followed by imaging in four channels and then cleavage of both the fluorescent 
labels and the terminating moiety. Adapted from (Shendure & Ji, 2008). 
 
1.4.2. 454 platform 
The 454 platform developed by Roche was the first generation new sequencer 
to be commercialised. Any method that produces short-adaptor-flanked 
fragments can be used to generate the library. In contrast to the Illumina 
platform, clonal amplification is generated by emulsion PCR (Dressman et al., 
2003) with amplicons captured onto the surface of 28 µm beads. The primers 
are tethered to the beads at 5’ end in an oil and water emulsion PCR. Post 
amplicon caption, the untethered strands are removed from the beads. The 
beads covered with amplicons are hybridised to the sequencing primer (figure 
1.4.2.a). Sequencing of 454 platform is performed by the pyrosequencing 
method (Ronaghi et al., 1996), again using Bst polymerase. The beads are 
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deposited onto a microfabricated array of picoliter scale of wells, with diameters 
that only allow one bead per well. Smaller beads containing immoblized 
enzymes such as ATO sulfurylase and luciferase are the added to the array. 
These enzymes are essential for pyrosequencing. One side of the array acts as 
the flow cell for introducing or removing sequencing reagents, with the other 
side attached to a fibre-optic bundle for charge couple device (CCD) based 
signal detection. A single type of unlabelled NTPs is added to the array and, 
during the incorporation, pyrophosphate is released which acts via ATP 
sulfurylase and luciferase and results in burst of light detectable by CCD (figure 
1.4.2.b). 454 technology allows generation of read-pairs which are 200-300 bps 
long. 
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Figure 1.4.2. Next Generation Sequencing of 454 platform. a)The 454 platform relies on 
emulsion PCR (Dressman et al., 2003) to amplify clonal sequencing features. In brief, an in 
vitro–constructed adaptor-flanked shotgun library (shown as gold and turquoise adaptors 
flanking unique inserts) is PCR amplified (that is, multi-template PCR, not multiplex PCR, as 
only a single primer pair is used, corresponding to the gold and turquoise adaptors) in the 
context of a water-in-oil emulsion. One of the PCR primers is tethered to the surface (5'-
attached) of micron-scale beads that are also included in the reaction. A low template 
concentration results in most bead-containing compartments having either zero or one template 
molecule present. In productive emulsion compartments (where both a bead and template 
molecule is present), PCR amplicons are captured to the surface of the bead. After breaking the 
emulsion, beads bearing amplification products can be selectively enriched. Each clonally 
amplified bead will bear on its surface PCR products corresponding to amplification of a single 
molecule from the template library. b) clonally amplified 28 µm beads generated by emulsion 
PCR serve as sequencing features and are randomly deposited to a microfabricated array of 
picoliter-scale wells. With pyrosequencing, each cycle consists of the introduction of a single 
nucleotide species, followed by addition of substrate (luciferin, adenosine 5'-phosphosulphate) 
to drive light production at wells where polymerase-driven incorporation of that nucleotide took 
place. This is followed by an apyrase wash to remove unincorporated nucleotide. Adapted from 
(Shendure & Ji, 2008) 
 
1.4.3. Post Next Generation Sequencing analysis 
Next Generation Sequencing is able to generate extremely large amounts of 
data. The bioinformatic analysis carried out to assemble the reads is crucial for 
successfully obtaining the sequence, and there are many different tools that can 
be used for this purpose. The choice of bioinformatics software depends on the 
purpose of the project. For whole genome virus sequencing, there are currently 
no reliable tools for carrying out de novo assembling, so more than one 
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software package is required to carry out the data processing. More details 
regarding analysis of data will be discussed in Chapter 4. !!
!
 
83 
1.5. Aims of this Thesis 
Despite the high prevalence of EBV and the multiple types of diseases that it 
can cause, little is known about the authentic cues that lead to the cellular 
induction of EBV replication and production of infectious virus in saliva. Since 
the virus establishes and maintains latency in non-proliferating memory B-cells, 
the signal to initiate the lytic cycle is unlikely to be from the virus (Hochberg et 
al., 2004). Previously Laichalk and Thorley-Lawson (2005) have showed that 
terminal differentiation of B-cells into plasma cells can initiate the lytic cycle of 
EBV in vivo. If this occurs in the lymphoid tissue of the oropharynx, it would 
allow infectious virus to be shed into saliva (Yao et al., 1989).  
Previously, we and others have shown that XBP-1s is sufficient to initiate the 
lytic cycle of KSHV in PEL cell lines (Dalton-Griffin et al., 2009; Sun & Thorley-
Lawson, 2007; Wilson et al., 2007). XBP-1s transactivates the promoter of 
KSHV immediate early protein RTA (ORF 50). Interestingly previous studies 
have also suggested that XBP-1s is able to bind to and transactivate the EBV 
BZLF1 promoter. However, XBP-1s may not be sufficient to reactivate EBV by 
itself since other studies have shown that protein kinase D (PKD) is also 
required (Bhende et al., 2007). It has also been suggested that EBV and KSHV 
mutually inhibit each other. It is therefore interesting to further investigate the 
reactivation of EBV in mature B-cell backgrounds by XBP-1, with and without 
KSHV infection. 
There have been many studies regarding the polymorphisms of EBV genes, 
either associated geographically, or with oncogenesis. However, little is known 
about the variations between EBV whole genomes. With limited numbers of 
whole genome sequence in Genbank, all either sequenced from a tumour 
sample, or after transforming B-cells; there is no EBV whole genome sequence 
from an EBV positive individuals with no malignancy. This thesis also 
investigates methods that have been developed to determine the EBV and/or 
KSHV full genome sequence from various different samples, via Next 
Generation Sequencing and further analysis the polymorphisms and variants 
from these EBV sequences. 
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Chapter 2 
Materials and Methods 
2.1. General Molecular Biology Techniques 
2.1.1. Preparation of Competent bacteria 
Two types of Escherichia coli (E. coli) were used in this study, XL-blue 
(Stratagene) and HB101. Either XL-blue or HB101 were streaked onto Luria-
Bertani (LB)-agar plates with no antibiotic, and incubated at 37oC for 16 hours. 
A single colony was picked and used to inoculate 5ml LB-broth starter culture 
and shaken at 37oC for 16 hours. The starter culture was then added into 200ml 
LB-broth, and shaken at 30oC until the absorbance at 595 nm was between 0.5 
and 0.6. The culture was divided into 50ml falcon tubes and put on ice for 10 
minutes, before being centrifuged at 3,500 rpm, for 10 minutes at 4oC. The 
bacteria pellet was then re-suspended in 20ml cold TFB1 (30mM potassium 
acetate, 100mM rubidium chloride, 10mM calcium chloride, 50mM manganese 
chloride and 15% Glycerol) and incubated at 4oC for 5 minutes. The bacteria 
was then centrifuged again at 3,500 rpm for 10 minutes, at 4oC, re-suspended 
in 2ml TFB2 (10mM PIPES (pH 6.5), 75mM calcium chloride, 10mM rubidium 
chloride and 15% glycerol) and incubated at 4oC for another 10 minutes. The 
bacterial suspension was quick frozen with liquid nitrogen in 100$l aliquots, and 
stored at -80oC. 
 
2.1.2. Introduction of plasmid DNA into E. coli by heat shock 
1-200ng of plasmid was mixed with 100$l of competent XL-blue or HB101 E. 
coli, which was thawed on ice, and incubated on ice for 10 minutes. The mixture 
was then heat shocked at 42oC for 45 seconds and immediately placed on ice 
for another 2 minutes. 200$l of LB-broth was added to the mixture, and 
incubated at 37oC for 30 minutes with shaking at 250 rpm. 100$l of the culture 
was plated on LB-agar plates containing 50$g/ml ampicillin or kanamycin. 
Plates were incubated upside down at 37oC for 16 hours. 
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2.1.3. Plasmid DNA midi-preps (Qiagen kit) 
Midi-preps of plasmid DNA were produced from 50ml overnight cultures from 
either transformed XL-blue or HB101 E. coli, using the Plasmid Midi Kit 
(Qiagen) according to manufacturer’s instructions. 
 
2.1.4. Plasmid DNA mini-preps (Qiagen kit) 
Mini-preps of plasmid DNA were produced from 3ml overnight cultures from 
either transformed XL-blue or HB101 Escherichia coli, using the Plasmid Mini 
Kit (Qiagen) according to manufacturer’s instructions. 
 
2.1.5. Molecular cloning 
KOD hot start polymerase (Merck) with proof-reading activity was used for 
cloning. GoTaq polymerase with no proof-reading activity (Promega) was used 
for general PCR amplification. Restriction endonucleases were purchased from 
Promega. Calf intestinal alkaline phosphatase and T4 ligase were purchased 
from Promega. All were used in accordance with the manufacturer’s 
specifications.  
 
2.1.6. Cloning using the pGEM-T-EASY vector system (Promega) 
The desired region was PCR amplified using 1 unit of KOD Hot start 
polymerase (Merck) in a 50µl reaction volume buffered with KOD Hot start 
polymerase 10x buffer. PCR conditions involved 20-100ng of template DNA and 
10picomoles of each oligonucleotide primer. In addition, the reaction was 
supplemented with a final concentration of 0.2 mM dNTPs (Merck) and between 
1.5 mM Mg++ (Merck). Cycling conditions were used in accordance with the  
manufacturer’s instructions. 
The desired PCR product was purified using a Qiagen gel extraction kit 
(Qiagen). Briefly 500μl of QC buffer was added directly to PCR reaction mix. 
10μl of isopropanol was added and mixed well before all 650μl were applied to 
the column. The manufacturer’s instructions for gel extraction were followed and 
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the final PCR result were eluted in 32μl. Poly-A tails were added to the purified 
PCR product prior to ligation to the pGEM-T-EASY vector system. The purified 
PCR product was incubated for 10 minutes with 1.5 units GoTaq polymerase 
and 1.6μl of 5nM dATPs in 8μl of GoTaq buffer with MgCl2 and 28μl of PCR 
product at 72oC. 
The correct molecular weight product was separated by electrophoresis and 
visualised using 10mg/ml ethidium bromide (Sigma Aldrich). TAE buffered 
agarose gel with a percentage between 1-2% depending on the size of 
expected product was used. The product was subsequently excised and 
extracted using the MinElute gel extraction kit (Qiagen) in accordance with the 
manufacturer’s instructions. 
The following ligation reaction was used with the pGEM-T easy vector system 
(Promega). Negative controls were used by substituting dH2O with PCR-
amplified DNA and ligated in parallel. 
5 μl 2x ligation buffer 
1 μl T4 DNA ligase 
0.5 μl pGEM-T-Easy linear DNA 
3.5 μl MinElute extracted PCR product 
 
Ligation reactions were transformed as described in chapter 2.1.2. Restriction 
enzyme digestion or PCR screening were used to confirm the positive colonies. 
 
2.1.7. Sub-cloning 
Primers were designed to contain restriction endonuclease sites to subclone the 
gene of interest from pGEM-T-Easy vector into appropriate expression 
construct or lentiviral vector. Vectors were digested overnight with appropriate 
restriction endonucleases in accordance with the manufacturer’s instructions 
and treated with calf intestinal alkaline phosphatase (Promega) before being 
purified using the MinElute gel extraction system (Qiagen), according to the 
manufacturer’s instructions. The pGEM-T Easy vector containing the gene of 
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interest was checked by digestion overnight with appropriate expression vector. 
Ligations were carried out using the following reaction. 
5 µl 2x ligation buffer 
1 µl T4 DNA ligase 
1 µl linear alkaline phosphatase treated vecto DNA 
3 µl MinElute extracted PCR product 
 
2.2. Plasmid 
2.2.1. pXBP1sG  
The lentiviral vector construction of pXBP1sIG had been described previously 
(Wilson et al., 2007). In brief, the pXBP1sG construct was developed by C. 
Tsantoulas, who generated it during an MSc project at the Kellam laboratory 
under the supervision of Dr. S. Wilson. The pXBP1sG construct encodes XBP-
1s tagged with a c-terminal His-tag, cloned in the IRES-Em vector. XBP-1s 
tagged with a c-terminal His-tag cloned in pCDNA3 (GIBCO) was also supplied 
by S. Wilson.  
 
2.2.2. pIG 
The pIG plasmid is also referred to as pCSBX containing a IRES-Emerald 
encoding sequence, which is a kind gift from Y. Ikeda. 
 
2.2.3. pPKDm-IG 
The lentiviral vector for activated PKD, pPKDm-IG, was produced from the 
pHA.PKD.S738A/S742A plasmid kindly supplied by Alex Toker (Storz & Toker, 
2003) (Addgene). The mutations at position 738 and 742 ensured the PKD was 
constitutively active once expressed. Briefly, BamHI and XhoI were used to 
clone the HA.PKD.S738A/S742A insert into the lentiviral vector pIG to produce 
the pPKDm-IG construct.  
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2.2.4. pZ-promoter-luciferase and pR-promoter-luciferase 
The pZ-promoter-luciferase construct is a kind gift from Prof. Paul J. Farrell 
(Bryant & Farrell, 2002). The pR-promoter-luciferase construct is a kind gift of 
Prof. Shannon Kenney (Bhende et al., 2007). 
 
2.2.5. pBZLF1 and pBRLF1 expression construct 
The pBZLF1 construct is a kind gift from Prof. Paul J. Farrell.(Amon et al., 2004) 
and the pBRLF1 construct is a kind gift from Prof. Shannon Kenney (Bhende et 
al., 2007; Bhende et al., 2004). 
 
2.2.6. Short hairpin RNA 
The lentiviral vector expressing the short hairpin RNA (shRNA) of XBP-1 
(Wilson et al., 2007) and luciferase (Dalton-Griffin et al., 2009) was generated 
previously. Briefly, the primers used for XBP-1 were (5%-CGA AAA AGA CTG 
CCA GAG ATC GAA AGA AGG CGA ACC TTC TCT CAA TCT CCG GCA GTC 
GGT GTT TCG TCC TTT CCA CAA GAT-3% and T7 oligonucleotide 5%-TAA TAC 
GAC TCA CTA TAG GG-3%) and Luciferase (5’-CGA AAA AGG TGG CTC CCG 
CTG AAT TGG AAT CGA AAT CCC AAT CCA-3’ and 5’-GCG AGA GCC ACC 
GGT GTT TCG TCC TTT CCA CAA GAT ATA TAA AG-3’). Primers were used 
to PCR amplify a shRNA expression cassette using the plasmid 
pGEMU61Linker. The amplicon was subcloned into the pGEM-T-Easy vector 
system. Once the sequence was verified, it was cloned via EcoR1 restriction 
into an antibiotic resistance modified version of pCSPW namely the puromycin 
acetylase (Pac) encoding pHR-SIN-CSPW. 
 
2.3. Cell Culture 
All the cell culture work was carried out in class II biosafety cabinets, with sterile 
equipment. All the plates and containers used in this study were from Techno 
Plastic Products (TTP). 
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Table 2.1 The following B-cell lines were used in this study 
Cell line B-cell tumour Viruses Reference 
JSC-1 Primary effusion lymphoma KSHV and EBV (Cannon et al., 2000) 
HBL-6 
Cro-Ap6 
Cro6 clone 2 
Primary effusion lymphoma 
Primary effusion lymphoma 
Primary effusion lymphoma 
KSHV and EBV 
KSHV 
KSHV and EBV-GFP 
(Gaidano et al., 1996) 
(Carbone et al., 2000) 
(Trivedi et al., 2004) 
BC3 
BC3 clone 6 
Primary effusion lymphoma 
Primary effusion lymphoma 
KSHV 
KSHV and EBV-GFP 
(Arvanitakis et al., 1996) 
(Trivedi et al., 2004) 
Akata Burkitt’s lymphoma EBV (Takada, 1984; Takada 
et al., 1991) 
Raji 
Mutu I 
Daudi 
Burkitt’s lymphoma 
Burkitt’s lymphoma 
Burkitt’s lymphoma 
EBV 
EBV 
EBV 
(Pulvertaft, 1964) 
(Gregory et al., 1990) 
(Klein et al., 1967) 
B95.8 LCL EBV (Miller et al., 1972) 
DG75 Burkitt’s lymphoma Negative (Ben-Bassat et al., 
1977) 
 
 
All the B-cell lines used in this study are grown in complete medium, Roswell 
Park Memorial Institute (RPMI) – 1640 medium (GIBCO, Invitrogen) with 10% 
foetal calf serum (FCS, BioSera) and 100units/ml penicillin plus 100$g/ml 
streptomycin (P/S, GIBCO, Invitrogen). With the exception of Cro6 clone 2 and 
BC3 clone 6, which are both grown in 20% FCS, with 1mg/ml and 2.5mg/ml G-
418 sulphate (GIBCO, Invitrogen) respectively. All the cell lines were cultured at 
37oC and in 5% CO2. The cells were split 1:10 or 1:20; depending on the 
density and the growth rate, twice a week. 
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Table 2.2 Cell lines of non-B-cell origin used in this study 
Cell line Description Reference 
HEK 293  293 cells containing SV40 T-antigen, 
a temperature sensitive gene 
(DuBridge et al., 1987) 
HeLa Eptheloid cervix carcinoma (Masters, 2002) 
 
HEK 293 cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM. 
GIBCO, Invitrogen) with 15% FCS and P/S, incubated at 37oC and in 10% CO2. 
HeLa cell line was grown using the same conditions as above except in 10% 
FCS and 5% CO2.  These cells were passaged three times a week and split at 
either 1:4 or 1:6. 
 
2.3.1. Freezing cells 
Cells were centrifuged at 325 x g (1200 rpm) for 5 minutes, and resuspended in 
cold FCS with 10% dimethyl sulphoxide (DMSO, Sigma), with a concentration at 
5x106 cells/ml. Cells were then aliquoted into cryovials (Nunc) and cooled to      
-80oC in an isopropanol cryo-container (Nalgene) before being transferred and 
stored in liquid nitrogen. 
 
2.3.2. Thawing cells 
After removing the cells from liquid nitrogen, either 10ml of RPMI-1640 medium 
(for suspension cells) or DMEM medium (for adherent cells) with 10% foetal calf 
serum (FCS, BioSera) and 100 unit (U)/ml penicillin and 100$g/ml streptomycin 
(Invitrogen) was added to the cells. Cells were then pelleted at 325 x g for 5 
minutes and resuspended in suitable volume of cultured medium, depending on 
the cell number. 
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2.4. Transient Transfection 
2.4.1. Transient transfection of HEK 293 cells to make lentiviral vectors 
Lentiviral vectors were produced as previously described by Besnier et al. 
(2002). HEK 293 cells were seeded such that 10cm dishes were confluent on 
the day of transfection. 10$l of FuGENE-6 (Roche) was added to 200$l of Opti-
MEM (Invitrogen). 1$g of p8.91, 1$g of pMDG and 1.5$g of vector-genome 
encoding plasmid DNA were made up to 15 $l in Opti-MEM and added to the 
FuGENE-6 and Opti-MEM mixture. The mixture was incubated at room 
temperature for 30 minutes and then added to confluent HEK 293 cells in 8ml 
fresh DMEM medium (with 10% FCS), 100 units/ml penicillin and 100$g/ml 
streptomycin, drop wise and evenly distributed on the plate. 
The plate was incubated at 37oC in 10% CO2 overnight and the medium was 
changed after 24 hours of incubation. The lentiviral vector containing 
supernatants were harvested at 48 and 72 hours post-transfection, and passed 
through a 0.45$M filter before being stored at -80oC. 
 
2.5. Lentivirus transduction and titration 
2.5.1. Purification and concentration of lentivirus 
The lentiviral vector containing medium was purified and the vectors were 
concentrated using polythylene glycol (PEG) 8000 (Sigma). After the lentiviral 
vector containing medium was passed through a 0.45$m filter, PEG 8000 and 
sodium chloride solution (5M, Sigma) were added to the solution with a final 
concentration of 5% and 0.15M respectively. The mixture was kept at 4oC for a 
minimum of 24 hours to a maximum of 7 days. The virus was pelleted at 2000g 
at 4oC for 10 minutes and the supernatant was discarded. The virus pellet was 
re-suspended in RPMI (10% FCS, 100 U/ml penicillin and 100$g/ml 
streptomycin) to 1/10th of the original volume and kept at -80oC.  
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2.5.2. Lentiviral vector titration of infectious units by GFP expression in 
adherent cells 
1x105 HEK 293 cells were seeded per well in a 6-well plate and cultured 
overnight at 37oC and in 10% CO2, in 1ml of medium (DMEM containing 10% 
FCS, 100 U/ml penicillin and 100$g/ml streptomycin). The lentiviral-vector 
containing supernatant was diluted 1 in 3 in a serial dilution five times, starting 
with 250$l. 15$g/ml polybrene (Sigma) was also added to the cell-lentiviral 
vector mixture and the cells were incubated at 37oC and in 10% CO2 for 48 
hours. The percentage of GFP expressing cells was determined by flow 
cytometry relative to total number of cells.  
 
2.5.3. Lentiviral vector titration of infectious units by GFP expression in 
suspension cells 
0.5x105 JSC-1 cells was seeded per well in a 24-well plate and cultured at 37oC 
and in 5% CO2 in 0.5ml of medium (RPMI containing 10% FCS, 100 U/ml 
penicillin and 100 $g/ml streptomycin). The lentiviral-vector containing 
supernatant was diluted 1 in 3 in a serial dilution five times, starting with 100$l. 
The supernatant was then mixed with RPMI medium to a total level of 500$l 
before adding to the JSC-1 cells. 15$g/ml polybrene (Sigma) was also added to 
the cell-lentiviral vector mixture, which was spun at 500x g for 1 hour at room 
temperature. The cells were then incubated at 37oC, in 5%CO2 for 48 hours. 
The percentage of GFP expressing cells was determined by flow cytometry 
relative to total number of cells.  
 
2.4.4. Flow cytometry  
The FACS analysis was carried out on FACScan flow cytometers with Cellquest 
software (Becton Dickinson). A total of ten thousand events were collected. 
Infectious units were plotted against $l of supernatant. The absolute titre of the 
lentiviral vector was determined by extrapolating the infectious units per ml 
(IU/ml) using the straight-line equation of the above plot. 
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2.4.5. Preparation of live cells for flow cytometry 
48 hours post infection; the adherent cells were washed once with PBS, and 
incubated with trypsin-EDTA (GIBCO, Invitrogen) at room temperature for 1 
minute. The trypsin was quenched with DMEM supplemented with 10% FCS 
and P/S and transferred to capped FACS tubes (Falcon). The cells were 
pelleted and re-suspended in PBS with 3.3% paraformaldehyde. The 
suspension cells were washed with PBS once and re-suspended with PBS with 
3.3% paraformaldehyde. Both adherent and suspension cells were kept on ice 
prior to analysis. 
 
2.4.6 Antibiotic selection following lentiviral vector transduction 
72 hours post transduction, the medium was removed and replaced with 
medium supplemented with 28µg/ml puromycine dihydrochloride (Sigma 
Aldrich) or 750µg/ml hygromycine B (GIBCO, Invitrogen), depending on the 
encoded resistance. The medium was removed and replaced with fresh 
medium supplemented with the appropriate antibiotic, every 2-3 days until non-
transduced cells in parallel cultures were no longer viable. The antibiotic 
selected cells were then cultured normally in medium supplemented with the 
respective antibiotic. 
 
2.6. Immunoblotting 
48 hours after transduction (with no antibiotic selection), the samples were 
lysed with the mixture of DTT and sample buffer (1:3 ratio) (0.2M Tris-CL pH6.8, 
5.2% SDS, 20% Glycerol and bromophenol blue), then sonicated and heated to 
95oC for 5 minutes. Protein concentration was normalised by blotting with 
housekeeping protein. Samples were resolved by 10% SDS poly-acrylamide 
gels and SDS-PAGE running buffer (10X in 50 litres: 50g SDS, 150g Tris, 720g 
glycine). The separated proteins were then transferred to a polyvinylidene 
fluoride membrane (PVDF) (GE healthcare) with either semi-dry or wet transfer 
apparatus using transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol).  
The membrane was blocked with 5% non-fat dried milk powder (NFDM) in TBS 
solution containing 0.1% Tween 20 (Sigma) (TBS-T) for 1 hour. The membrane 
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was then probed with primary antibody; BZLF1; BZ-1 diluted 1:2000 (Bryant & 
Farrell, 2002); Tubulin: anti-alpha Tubulin clone DM1A (Sigma), diluted 
1:40,000; K-RTA: polyclonal, kind gift of Don Ganem (Lukac et al., 1998), 
diluted 1:40,000; PKD: PKC $ (D-20): sc-935 (Santa Cruz), diluted 1:2000; 
BRLF1, anti-EBV transcription factor R (Argene) diluted 1:2000; BMRF1, EBV 
early antigen diffuse (Vector Labororatories) diluted 1:2000; XBP-1s, a kind gift 
from Giovanna Roncador (Maestre et al., 2009), diluted 1:50), all in 1% NFDM 
in TBS-T solution at 4oC overnight. We optimised the dilution of antibodies. The 
membrane was then incubated with appropriate HRP conjugated secondary 
antibodies (GE Healthcare) in 1% NFDM TBS-T solution for 1 hour at room 
temperature. The blots were washed 5 times for 5 minute periods in TBS-T 
before developing and visualising using ECLTM Western blotting detection 
reagents or ECL Advanced Western blotting detection reagents (GE 
Healthcare). 
 
2.7. 96-well plate Luciferase assay 
HEK 293 cells or HeLa cells were plated at a density of 2x104 cells per well in 
96 well plates. Cells were transfected the next day with 20ng of the appropriate 
reporter and expression constructs using fuGNENE-6 (Roche). The ORF50 
reporter plasmids were a kind gift from Erle Robertson (Robertson & Ambinder, 
1997). The BZLF1 promoter and expression vectors have been described 
before (Bryant & Farrell, 2002) and the BRLF1 promoter and expression 
constructs were a kind gift from Shannon Kenney (Bhende et al., 2007). The 
pXBP1sIG and pIG plasmid were described previously (Wilson et al., 2007). Co-
transfection of 2ng of Renilla expression vector was also used for monitoring 
transfection efficiency. After 48 hours, the relative light units and the expression 
of Renilla construct were determined using the luciferase Stop & Glo reagents 
according to the manufacturer’s instructions. Data was read using a GloMaz96 
microplate luminometer (Promega) with single injector.  All assays were 
performed in triplicate. 
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2.7.1. Methylation of plasmids 
Luciferase plasmids containing BZLF1 and BRLF1 were methylated using CpG 
methyltransferase (M. SssI) (New England BioLabs). 1$g DNA was mixed with 
1$l of M. SssI (4 units/$l), 160 nM of S-adenosylmethionine (SAM) and buffer, 
according to the manufacturer’s instructions. The mixture was then incubated at 
37oC for 1 hour. After incubation, 500$l of QC buffer from the gel extraction kit 
(Qiagen) was added to the mixture, with 100$l iso-propanol and following the 
manufacturer’s instruction to extract the methylated DNA. 
 
2.7.2. Methylation status of plasmids 
The methylation of the plasmids was confirmed by performing restriction 
enzyme digestion with methylation sensitive enzymes. The Zp was digested 
with BamH1 and XhoI; and the Rp was digested with BgII and MlnI. 
 
2.7.3. Dual luciferase system 
HEK 293-T cells or HeLa cells were plated at a density of 2x104 cells per well in 
96 well plates. Cells were transfected the next day with 20ng of the appropriate 
reporter and expression constructs using fuGNENE-6 (Roche). The ORF50 
reporter plasmids were a kind gift from Erle Robertson (Robertson & Ambinder, 
1997). The BZLF1 promoter and expression vectors have been described 
before (Bryant & Farrell, 2002) and the BRLF1 promoter and expression 
constructs were kind gift from Shannon Kenney (Bhende et al., 2007). The 
pXBP1sIG and pIG plasmid were described previously (Wilson et al., 2007). Co-
transfection of 2ng of Renilla expression vector were also used for monitoring 
transfection efficiency. After 48 hours, the relative light units and the expression 
of Renilla construct were determined using the luciferase Stop & Glo reagents 
according to the manufacturer’s instructions. Data was read using a GloMaz96 
microplate luminometer (Promega) with single injector.  All assays were 
performed in triplicate. 
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2.8. Detecting virion-associated genome copies using quantitative PCR 
2.8.1. Inducing EBV and KSHV into lytic cycle  
Cells were cultured at 2 x 105 /ml and treated with chemical stimuli: sodium 
butyrate (NaB) (Sigma) at 3mM; valporic acid (VPA) (Merck) at 1.5mM; and 12-
O-tetradecanoyl phorbol 13-acetate (TPA) (Sigma) at 20ng/ml. Goat anti-human 
IgG and anti-human Ig-M (Sigma) were both used at 5ug/ml. All but NaB were 
incubated overnight at 37oC, NaB was washed off after 1 hour incubation. 
 
2.8.2. DNA extraction 
The DNA was extracted from 2-10 x 105 cells using QIAmp DNA extraction kit 
(Qiagen) according to the manufacturer’s protocol. 200µl of saliva samples or 
concentrated virus supernatant were used to extract viral DNA using QIAmp 
blood DNA extraction kit (Qiagen) according to the manufacturer’s protocol. 
10ug of salmon sperm DNA (ssDNA) was added to the sample prior the 
extraction as a carrier for some samples. The total elution volume was 32µl.  
 
2.8.3. Quantitative PCR (q-PCR) 
Viral load was measured by quantitative PCR (q-PCR) using SensiMix dU kit 
(Bioline) with 5mM MgCl2. The primers were used at 20pmol (EBV forward 
primer 5’-GGC CAG AGG TAA GTG GAC TTT AAT-3’, EBV reverse primer 5’-
GGG GAC CCT GAG ACG GG-3’); the probe was used at 10pmol (EBV probe: 
5’ FAM-TCT TCT CAA AGG CCA CCG CTT TCA AGT C-TAMRA 3’). The 
primers were a kind gift from Dr. Paul Grant and target the EBNALP gene. The 
reactions were run on an ABI 7000 thermocycler with an initial 10 minutes 
incubation at 37°C for UNG, then followed by another 10 minutes incubation at 
95°C, followed by 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. 
Every sample was run in duplicate and the viral copy number per µl was 
calculated using a standard curve that was run alongside the samples. The 
standard curve of EBV was calculated by using samples with a known copy 
number of EBV and its relationship with Ct numbers. 
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2.9. RT-PCR 
2.9.1. RNA extraction and DNase treatment 
RNA was extracted using the Trizol reagent (GIBCO, Invitrogen). 1x106 cells 
were lysed per ml of Trizol reagent in accordance with the manufacturer’s 
instructions. The cell lysate was stored at -80oC until used for RNA extraction. 
The frozen cell lysates were thawed on ice prior to repeated chloroform 
extraction. The RNA was extracted and purified using RNeasy mini extraction 
kit (Qiagen) after an on-column DNase (Promega) digestion. Both were carried 
out in accordance with the manufacturer’s instructions. RNA was quantified 
using ND-1000 spectrophotometer (Nanodrop Technologies) 
 
2.9.2. cDNA synthesis 
The reverse transcription reaction was carried out using Omniscript Reverse 
Transcriptase (Qiagen), in accordance with the manufacturer’s instructions. The 
starting quantity of total RNA was between 1-2µg. 
 
2.9.3. Detecting messenger RNA 
2.9.3.1. XBP-1 PCR, Pst I digestion and resolution 
PCR amplification was performed across the atypical sliced junction of XBP-1 
by using primer XBP-1 short fwd (5’-CCT TGT SGT TGA GAA CCA GG-3’) and 
XBP-1 short rev (5’-CAG AAT GCC CAA CAG GAT ATC-3’) at 20pmol. Total 
PCR reaction volume was 50$l with 5 units of GoTaq polymerase and 5x 
GoTaq polymerase flexi buffer (Promega). The reaction was hotstarted at 95oC 
for 2 minutes, followed by 35 cycles at 95oC for 30 seconds, 58oC for 30 
seconds and 72oC for 1 minute. 
Following the PCR amplification, the 50$l reaction was halved to 2 x 25$l 
samples. One was added to 1$l dH2O and the other to 20 units of PstI 
restriction enzymes. Both were incubated at 37oC for 1 hour. 3% agarose gel 
with TAE buffer was used to resolve the PCR products, at 5 volts/cm at room 
temperature. 
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2.9.3.2. q-PCR to detect messenger RNA level 
Copies of messenger RNA (mRNA) were measured by q-PCR after reverse 
transcription (q-RT-PCR). The experiments were carried out using SyBr Green 
PCR kit (Qiagen) according to the manufacturer’s protocol. All the primers used 
are listed below in table 2.3 and were used at 5mM. The reactions were run on 
an ABI 7000 thermocycler at 95oC for 15 minutes, followed by 40 cycles of 95oC 
for 15 seconds, and 60oC for 60 seconds. Known copies of the viral DNA were 
run alongside each experiment to create a standard curve. This was correlated 
with the Ct number, from which the viral copy number was calculated. All the 
samples were run in duplicate and the copy number of mRNA was normalised 
to L32, a house-keeping gene. 
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Table 2.3. list of primers used in q-RT-PCT 
Name of primers Sequence (5’- 3’) Reference 
Z-F 
(BZLF1 qPCR forward primer) CTATCAGGACCTGGGAGGGC 
(Schelcher et al., 
2005) 
Z-R 
(BZLF1 qPCR reverse primer) CACAGCACACAAGGCAAAGG 
(Schelcher et al., 
2005) 
R-F 
(BRLF1 qPCR forward primer) AATTTACAGCCGGGAGTGTG (Chia et al., 2008) 
R-R 
(BRLF1 qPCR reverse primer) AGCCCGTCTTCTTACCCTGT (Chia et al., 2008) 
M-F 
(BMLF1 qPCR forward primer) GGACCTGCCGTTGGATCTTA 
(Schelcher et al., 
2005) 
M-R 
(BMLF1 qPCR reverse primer) TCTTCGGAGGCGTGGTTAAA 
(Schelcher et al., 
2005) 
ORF50-F  
(ORF50 qPCR forward primer) TTGGTGCGCTATGTGGTCTG 
(Caselli et al., 
2005) 
ORF50-R  
(ORF50 qPCR reverse primer) GGAAGGTAGACCGGTTGGAA 
(Caselli et al., 
2005) 
L32-F  
(house-keeping qPCR forward 
primer) CAACATTGGTTATGCAAGCAACA 
(Schelcher et al., 
2005) 
L32-R  
(house-keeping qPCR reverse 
primer) TGACGTTGTGGACCAGGAACT 
(Schelcher et al., 
2005) 
 
2.10. Sample preparation for deep sequencing 
2.10.1. Gardella gel 
The Gardella gel consists of 2 parts, the running gel (0.75% agarose gel) and 
the lysis gel (0.8% agarose gel, 2% SDS and 1mg/ml protease K), which 
contains the wells for sample loading. 2 x 106 cells were re-suspended in 50µl 
loading buffer (15% Ficoll in TBE buffer, 40µg/ml RNase A and 0.01% 
bromophenol blue). 25µl samples were loaded per well and the gel was run in 
TBE buffer at 4oC, 40 volts for 2 hours and 160 volts for 15 hours. The gel was 
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then soaked with TBE buffer containing 0.5ng/ml ethidium bromide (EtBr) for 2 
hours, before being exposed under UV light to determine the location of 
episomal DNA. The running of the gel was repeated and instead of soaking the 
gel with EtBr TBE buffer, the running gel was cut into 0.5cm length, and soaked 
with 200µl dH2O to elute the episomal DNA. 
 
2.10.2. Phi29 PCR 
Phi29 DNA polymerase (GE healthcare) and EBV specific primers (designed by 
Dr. Dan Frampton), with no cross-link with either human or KSHV genome 
(table 2.4) were used. 1$l DNA (approximate 10 ng) were used, with a 4$l 
primer mix (see table X, 5 $M/ml) and 5$l annealing buffer (80mM Tris-HCL, pH 
8.0 and 20mM MgCl2). The mixture was incubated at 95°C for 3 minutes then 
cooled at 4°C for 1 minute. After incubation, 1$l Phi29 DNA polymerase 
(Fermentas), 2$l 10X buffer, 1$l pyrophosphtase (0.025 units/ $l), 1$l BSA and 
5$l of dNTP (25 mM) were added. The final mixture was incubated at 30oC for 
12 hours, 60oC for 10 minutes and 4oC for 5 minutes. The EBV copy number 
was determined by q-PCR. 
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Table 2.4. Primers used in Phi29 PCR 
Primers and position Sequence (5’- 3’) 
EBV-142 GGTGGCGGTCACAACGGTACTAA*C*T 
EBV-2158  CATCTCCACGCGAAGCACGTACG*T*G  
EBV-47323  GAGCGTAACTCGCCTCGTCTTCG*G*T  
EBV-62291  GTCACCGTATACGCGGAGACCAA*C*C  
EBV-9178 CTGTGTAGCTACCGATAAGCGGA*C*C 
EBV-54317 CATCGTGAGCGAGTACGTGGATC*G*G 
EBV-58831 CACATATACCGCTCGGCGGAGAT*C*T 
EBV-70342 GTCATATCGGATGCCTCACGCGA*A*G 
EBV-87302 CAGCTCATCGTCCGAGGACTCTA*G*C 
EBV-92587  CAACGACGCATGTTCCATCGCGT*G*C  
EBV-100664 CTCGCAGTTCGCCGACCAAGACA*T*G 
EBV-124903 CCTGAGTCGTATGACGGATGGCA*A*G 
EBV-125359  GATAACGCCGAGTAGAAGCCGAC*G*C  
EBV-134002 GGCTATTGACTGGCGCGCTTCCT*T*G 
EBV-153457  GATCCACGACCGCATCCAGTACG*T*C 
EBV-155710 GAAGGTCACGCGCCGTTCCATTA*T*G 
EBV-159157 CATCGAGCCGAGCGACTGGATAG*A*G 
EBV-164663 GACACGCACGTACGGCTCATCAT*C*A 
 
 
2.10.3. Genomiphi (Whole Genome Amplification) 
The quantity of DNA samples was increased using Illustra GenomiPhi V2 DNA 
Amplification Kit (GE healthcare) in accordance to the manufacturer’s protocol 
and purified using Zymoclean Genomic DNA Clean & ConcentratorTM (Zymo 
Research Corp.).  
 
2.10.4. SureSelect Target Enrichment 
Overlapping 120-mer RNA baits (5x coverage) spanning the length of the 
positive strand of the reference genomes were designed using Agilent eArray 
software. The specificity of all baits was verified by BLASTn searches against 
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the Human Genomc + Transcript database. The bait library consists of two sets 
of baits from EBV type 1 and EBV type 2 reference genomes each. 
DNA preparations of 3$g were sheared for 6x60 seconds using a Covaris E210 
(duty cycle 10%, intensity 5 and 200 cycles per burst using frequency 
sweeping). End repair, non-templated addition of 3%-A, adaptor ligation, 
hybridization, enrichment PCR and all post-reaction cleanup steps were 
performed according to the SureSelect Illumina Paired-End Sequencing Library 
protocol (Version 1.0) observing all recommended quality control steps. 
However, the Sanger institute multiplex 10bp tag was used at the end of the 
process.  
 
2.11. Sequencing 
2.11.1. DNA Sequencing 
DNA Sanger capillary sequencing was used to confirm PCR and cloning 
product, and was carried out by either Cogenics (Lark) or the University College 
London sequencing facility. The results were analysed by using DNA dynamo 
program. 
Table 2.5. Primers used to confirm the majority consensus sequence generated by Next 
Generation Sequencing. 
Primers Sequence (5’- 3’) 
BRLF1-1 F ATGAGGCCTAAAAAGGATGG 
BRLF1-1 R CTAAAATAAGCTGGTGTCAAAAATAG 
BRLF1-2 F GCTACTCGGAGTCCGGACAG 
BRLF1-2 R GTAAAAGCATGAAACTGTCCGG 
BMRF1 F ATGGAAACCACTCAGACTCTC 
BMRF1 R TTAAATGAGGGGGTTAAAGGCC 
BZLF1 F ATGATGGACCCAAACTCGAC 
BZLF1 R TTAGAAATTTAAGAGATCCTCGT 
BDLF3.5 F TCAATCGGCCTTGGTCTGAC 
BDLF3.5 R ATGTCTGCCCCCGGATGC 
EBNA2 F TCTGCTATGCGAATGCTTTB 
EBNA2 R AGAGGGTGCATTGATTGGTC 
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2.11.2. Second generation sequencing (deep sequencing) 
Second generation sequencing was carried out with an Illumina machine, at the 
Welcome Trust Sanger Institute, Hinxton, Cambridge, UK. All the cell line 
samples were sequenced using the Illumina GAIIx system, and the PTLD and 
saliva samples were sequenced using the Illumina HiSeq system, six samples 
per lane.  
 
2.11.3. Computational Analysis of Second Generation sequencing Data 
For each dataset, all duplications were removed from the read-pairs, then 
subject to quality control using QUASR v7 pipeline 
(http://sourceforge.net/projects/quasr/). Firstly the 3’ end of the reads were 
trimmed to ensure that the median Phred quality score of the last 15 bases 
exceeded 30, and subsequently to remove the read-paired if either the read of 
the median Phred quality score was below 30 or less than 50bp in length. The 
remaining read-pairs were mapped back to the according reference genome 
using the Burrow-Wheeler Alinger (maximum insert 50 bases, maximum 
distance between paired ends 500) (Li & Durbin, 2009), generating SAM files 
containing all mapped and unmapped reads. The SAM files were processed 
using SAMTools (Li et al., 2009) to produce pileup files for consensus sequence 
generation and SNP calling using VarScan v.2.2.7 (--min coverage 3, --min 
reads2 3, --p value 5e-02) (Koboldt et al., 2009). The unmapped read paired 
were extracted from SAM files and BLASTn searches used to determine the 
proportion mapping to the reference genome.  
 
2.11.4. Phylogenetic tree 
Both type 1 and type 2 EBV majority consensus sequences and EBV GD1, GD2 
(HQ020558) sequences were aligned against EBV type 1 reference sequence 
(NC_007605.1) using Base-By-Base software and Gendoc. Repeated regions 
of the sequences were removed according to the location on EBV type 1 
reference genome. The coding region was extracted according to the location of 
EBV type 1 reference genome. The heterogeniety site model was determined 
using JModelTest with default setting, and Baysian skyline coalescent model 
(Drummond et al., 2005) was used to construct two trees with forced roots, 
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relaxed longitudinal and relaxed exponential clock models, both sampling 
lengths ranging between 20-50 millions. Both relaxed clock models were run on 
default setting (initial value 1, lower value 0, upper value 1). The outcome of the 
relaxed longitudinal tree was used to determine if strict clock tree was more 
suitable. A second method using a distance based method: Neighbour joining 
was used to generate an unrooted tree, using MEGA software in default setting. 
This method was a bottom-up clustering method. The possibility of 
recombination between the sequences was examined using Recombination 
Detection Programe v3.3.1 (RDP3) software (Martin et al., 2010), including 
RDP, BOOTSCAN, Chimaera, MaxChi and SiScan methods (Gibbs et al., 2000; 
Martin & Rybicki, 2000; Martin et al., 2005; Posada & Crandall, 2001; Smith, 
1992). 
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Chapter 3 
Results: XBP-1 expression and the effect on EBV reactivation 
in B-cell Lymphomas  
3.1. Introduction 
EBV lytic reactivation is mediated by two immediate early viral proteins: BZLF1 
(ZTA) and BRLF1 (RTA) (Amon et al., 2004; Chang & Liu, 2000; Yuan et al., 
2006). The Z promoter is activated after BCR cross-linking, but this is reported 
not to activate the R promoter (Rp) directly (Amon et al., 2004), indicating that 
BZLF1 is the first protein that is expressed after reactivation of EBV from 
latency. BZLF1 expression is also sufficient to initiate the entire EBV lytic cycle 
(Countryman & Miller, 1985; Rooney et al., 1989b). KSHV-RTA is the virus 
immediate early replication and transcription activator protein, and has a similar 
role to EBV BZLF1. KSHV-RTA is also sufficient and necessary to activate the 
virus lytic cycle and transactivate its own promoter, which leads to the KSHV 
lytic gene expression cascade (Lukac et al., 1998). 
XBP-1 spliced (XBP-1s) is a B-cell terminal differentiation transcription factor 
and is essential to transform B-cells into plasma cells at the final stage of B-cell 
development. EBV lytic replication is induced in plasma cells (Laichalk & 
Thorley-Lawson, 2005), however, in the environment where XBP-1s is 
expressed abundantly, such as multiple myeloma cell lines, infection by EBV 
does not result in lytic reactivation (Anastasiadou et al., 2009).  
Previous work carried out by us and others has shown that XBP-1s is sufficient 
to initiate the lytic cycle of KSHV in PEL cells (Dalton-Griffin et al., 2009; Sun & 
Thorley-Lawson, 2007; Wilson et al., 2007). XBP-1s transactivates the KSHV 
immediate early promoter ORF50, leading to reactivation from latency. Here we 
investigate further the role of XBP-1s in reactivation of EBV in a mature B-cell 
background, namely PEL and BL cell lines. Other studies have shown that 
murine XBP-1s can induce BZLF1 protein expression in vivo, by transactivating 
the BZLF1 promoter (Sun & Thorley-Lawson, 2007). However it has also been 
shown that the reactivation of EBV requires not only XBP-1s expression, but 
also the expression of protein kinase D (PKD) (Bhende et al., 2007). In this 
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chapter, we investigate the interactions between human XBP-1s and EBV lytic 
reactivation.  
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3.2. Results 
3.2.1. Over expressing XBP-1s in PEL and BL cell lines 
Over-expression of XBP-1s protein was used to examine its effect on the 
reactivation of latent gamma-herpes virus in PEL and BL cell lines. 
Transduction using lentiviruses containing XBP-1s was used for over-
expression. This lentiviral vector contains XBP-1s (pXBP1s-GFP) and was 
constructed by a previous group member in the laboratory and has shown 
successful XBP-1s over-expression in PEL cells, i.e. JSC-1 cells (Wilson et al., 
2007). This lentiviral vector expresses XBP-1s from the SFFV promoter with an 
internal ribosome entry site (IRES) immediately after XBP-1s and before the 
GFP gene (Wilson et al., 2007). FACS analysis was used to determine the rate 
of transduction of PELs and BLs  
 
 
Figure 3.1. FACS analysis of lentiviral transduction, showing the percentage of A) JSC1 (PEL 
cell line) and B) Mutu I (BL cell line) that is GFP positive, after transduction of XBP-1s GFP 
lentivirus.  
 
3.2.2. Determining the expression of BZLF1 and KSHV-RTA  
In order to determine whether XBP-1s induced the lytic cycle of EBV, the 
expression of BZLF1 was used as an indicator of initiation of the EBV lytic 
cycle. Several different methods have been used to determine BZLF1 and K-
RTA protein expression in both PEL and BL cell lines, such as FACS analysis. 
However, intra-cellular staining for the immediate early proteins with various 
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antibodies did not give clear results of the protein expression, either by FACS or 
confocal microscopy. Western blot analysis was used to show the expression of 
the viral proteins from the chosen cell lines. Daudi, a EBV positive BL cell line 
was been treated with TPA to reactivate EBV and therefore expressed BZLF1. 
The BL cell line DG75, both EBV and KSHV negative, was used as a negative 
control for the Western blot analysis. A lentiviral construct containing KSHV 
ORF50 was transfected into HEK-293 cells to express the K-RTA protein. 
Figure 2 shows clear BZLF1 and KSHV RTA protein expression from the 
Western blot. 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Using Western blot analysis to determine reactivation of EBV and KSHV. BZLF1 
and K-RTA (RTA in lane 3) are immediate early protein of EBV and KSHV respectively. The 
expression of these two proteins can be detected using Western blot analysis, which indicate 
induction of lytic cycle. 
 
3.2.3. XBP-1s over-expression in PEL cell lines results in KSHV RTA 
expression but not EBV BZLF1 expression  
Over expressing XBP-1s in PEL cell lines (single or dually infected) induced K-
RTA expression, was previously described by Wilson et al. (2007) and is also 
shown in figure 3.3. XBP-1 is unspliced and inactivated in the PEL cell lines, 
which can be induced into splicing by ER stress. Wilson et al (2007) have 
shown that in both JSC1 and BCP1 PEL cell lines XBP-1s is able to induce K-
RTA expression by transactivating the ORF50 promoter. K-RTA expression 
alone is sufficient to induce KSHV into lytic cycle. In dually infected PELs, the 
effect of XBP-1s expression on EBV BZLF1 protein expression was not known. 
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Here, we over-expressed XBP-1s exogenously in PELs both singly and dually 
infected, such as Cro-Ap6 (CRO6) and JSC-1 cells respectively. TPA, a phorbol 
ester, is known to be able to induce lytic reactivation of both KSHV and EBV 
and is used as a positive control (figure 3.3.A lane 4, and B, C lane 2) to ensure 
that both viruses can be induced into lytic cycle. K-RTA, in both singly and 
dually infected PELs, was expressed after XBP-1s expression but not in the 
vector control (Figure 3.3.A and B, lane 2 and 3). However, in JSC1 cells, no 
protein expression of BZLF1 was detected, despite the ability of TPA to induce 
the expression of both K-RTA and BZLF1 simultaneously (figure 3.3.B). As 
described in chapter 3.2.2, Daudi treated with TPA, DG75, and HEK 293 cells 
transiently transfected with RTA were used as a Western blot control. 
Since little is known about the EBV genome in dually infected PELs, it is 
possible that the EBV is somehow defective and non-responsive to XBP-1s. 
Therefore, we repeated the experiment on BC3 clone 6 (BC3 cl6) and CRO6 
cone 2 (CRO6 cl2). These two cell lines were created by superinfecting KHSV 
positive only PEL cell lines (BC3 and CRO6) with replication-competent EBV-
GFP virus (Xu et al., 2007) and selected with G418. Western blot analysis 
showed identical results for K-RTA and BZLF1 expression as JSC-1 cells 
(figure 3.3.B, C), K-RTA was induced after XBP-1s expression but not BZLF1. 
As before, TPA treatment confirmed that both KSHV and EBV can be induced 
into lytic cycle in these dually infected PELs. In these experiments, 60-80% of 
PELs in culture were transduced with XBP-1s expressing lentivirus, and the 
protein expression of XBP-1s is also confirmed by Western blot analysis (figure 
3.3.A, B).  
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Figure 3.3. XBP-1s does not activate EBV lytic gene expression in PEL cell lines. (A) JSC-1, a 
KSHV and EBV double positive PEL cell line, expressed K-RTA and BZLF1 after treatment with 
TPA, but only K-RTA was expressed following XBP-1s transduction. VecCon indicates the 
vector control. B) CRO6 cl2, and C) BC3 cl6 are EBV superinfected KSHV positive PEL cell 
lines and showed a similar pattern with XBP-1s transduction only resulting in K-RTA expression. 
TPA was able to induce both K-RTA and BZLF1. The Daudi cell line treated with TPA and 
KSHV RTA (K-RTA) transfected HEK 293 cells acted as positive control for the BZLF1 and K-
RTA antibody staining respectively. XBP-1s expression was detected using an XBP-1s specific 
antibody. 
 
 
A 
B 
C 
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3.2.4. Over-expression of XBP-1s in BL cells does not induce EBV BZLF1 
expression 
It is possible that the presence of KSHV interferes with the ability of EBV to 
enter the lytic cycle and a previous study has suggested possible antagonistic 
interaction between KSHV and EBV (Miller et al., 1997). To investigate the 
effect of expression of XBP-1s on EBV lytic reactivation, without the presence of 
KSHV, we decided to over-express XBP-1s in BL cell lines which are singly 
infected by EBV. The transduction rate of BL cell lines was between 10-25%, 
Despite this not being as high as in PEL cell lines, inducing EBV lytic cycle 
should still be observable. Previous reports have suggested that XBP-1s binds 
to the Zp1 site on the Zp, and therefore transactivate the promoter, resulting in 
expression of BZLF1 and initiation of the lytic cycle (Sun & Thorley-Lawson, 
2007).  However, over expressing XBP-1s in two different BL cell lines, Mutu I 
and Akata, failed to induce BZLF1 expression (Figure 3.4.A and B). The ability 
of EBV to enter lytic cycle in these cells was investigated by using BCR 
crossing linking. Under these conditions BZLF1 expression can be detected by 
Western blot analysis. These results suggested that XBP-1s does not 
transactivate the BZLF1 promoter in B-cell lymphomas, regardless of the 
presence of KSHV. 
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Figure 3.4. Burkitt’s Lymphoma cell lines do not express BZLF1 after transduction with XBP-1s. 
A) Mutu I and B) Akata, both EBV positive Burkitt’s lymphoma cell lines, were transduced with 
XBP-1s and vector control (VecCon) but BZLF1 expression was not detected. B-cell surface 
cross-linking (BCR) with human Ig is used as positive control to induce BZLF1 expression. A) 
Mutu I, with Ig-M. B) Akata, with Ig-G.  
 
 
3.2.5. Over-expression of XBP-1s in BL or PEL cells does not induce EBV 
BRLF1 and BMRF1 expression 
BZLF1 is the first protein that is expressed for the initiation of the lytic cycle of 
EBV. Nevertheless, there are two immediate early (IE) proteins for EBV 
reactivation. BZLF1 protein expression transactivates the BRLF1 promoter, 
leading to the expression of BRLF1, the second IE protein. Together, these two 
proteins can induce the full EBV lytic cycle cascade. We therefore examined the 
expression of BRLF1 after transducing XBP-1s in both BL (Akata) (Figure 3.5.A) 
and PEL (JSC-1) (Figure 3.5.B) cell lines. In both cell lines, both BZLF1 and 
BRLF1 expression can be detected after either treating the cells with BCR-
crosslinking (Akata) or TPA (JSC1). However, after transducing both cell lines 
with XBP-1s, neither BZLF1 nor BRLF1 expression can be detected. 
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We also examined the expression of BMRF1, an EBV early protein also known 
as diffused early antigen (EA-D) (Bayliss & Wolf, 1981). BMRF1 transcription is 
activated by BZLF1 (Kenney et al., 1992). The expression of BMRF1 was 
examined using Western blot analysis, however, in both BL and PEL cell lines, 
over-expressing XBP-1s did not induce BMRF1 expression. Therefore, over-
expression of XBP-1s in both PEL and BL cell lines does not induce the 
expression of either the IE proteins: BZLF1 and BRLF1, which are essential for 
inducing EBV lytic cycle; nor the expression early protein BMLF1. This indicates 
that XBP-1s over-expression does not induce EBV lytic cycle in PELs and BLs. 
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Figure 3.5. Expression of XBP-1s does not induce BZLF1 and BRLF1 protein expression in 
either BL or PEL cell lines. A) Akata and B) JSC-1 cell lines were transduced with XBP-1s and 
vector control with MOI of 5 and 2 (MOI measured in JSC-1 cells) respectively. Neither BZLF1, 
BRLF1 nor BMRF1 expression were detected in either cell lines. BCR cross-linking was used as 
positive control for Akata to induce EBV lytic gene expression and TPA was used for JSC-1 cell 
lines to induce KSHV and EBV lytic gene expression. Both positive controls show strong BZLF1 
expression, weaker BRLF1 expression, and but only (A) Akata with BCR cross-linking 
expresses BMRF1. B95.8 cell line was used as positive control for EBV immediate early and 
early protein expression. 
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3.2.6. EBV lytic cycle promoters do not respond to XBP-1s.  
Previously we showed that XBP-1s can transactivate the K-RTA promoter 
(Wilson et al., 2007) which induces the full KSHV lytic cycle. Despite showing 
that over-expression of XBP-1s in PEL and BL cell lines does not induce BZLF1 
and BRLF1 protein production, we examined the effect at the promoter level of 
XBP-1s expression. A construct containing the BZLF1 promoter region fused 
with a luciferase reporter gene (McDonald et al., 2010) (a kind gift of Prof. Paul 
J. Farrell) was used to determine the response of XBP-1s in HEK 293 cells. We 
failed to see any strong XBP-1s activity on the BZLF1 promoter (Zp) (figure 
3.6.A), especially compared to the strong response to BZLF1 protein. This weak 
response was also statistically insignificant (P> 0.05, two tailed T-test). Also, the 
BZLF1 promoter only responded to the positive control (BZLF1 protein 
expression) when the construct was methylated (black bar). BZLF1 protein 
expression failed to transactivate the Zp while it was unmethylated (data not 
shown). During thesse stages of EBV life cycles, the DNA is heavily methylated 
during latency but unmethylated at the lytic cycle (Robertson & Ambinder, 
1997). BZLF1 is the first IE protein that is expressed in the lytic cycle and as 
EBV DNA remains methylated during latency, prior BZLF1 expression. 
Therefore, it is not surprising that Zp is only responsive to BZLF1 only when 
methylated. 
These experiments were repeated using the BRLF1 promoter (Rp) (Bhende et 
al., 2007). Again, the experiments were carried out with BRLF1 promoters either 
methylated (black bar) or unmethylated (white bar). Both forms of the promoter 
were able to be transactivated by BRLF1, unlike the BZLF1 promoter. We were 
also able to detect, but to lesser level, a response to XBP-1s (figure 3.6.B). 
Therefore BRLF1 promoter activity is independent of the promoter methylation 
state and XBP-1s was able to weakly transactivate BRLF1 promoter in HEK 293 
cells. All results were statistically confirmed by using two-tailed T-test, to 
confirm the increase in relative light units (RLU) was not due to statistical error. 
The activity of XBP-1s in this assay was confirmed using a KSHV RTA promoter 
luciferase construct, a gift from Dr. Sam Wilson. This reporter construct showed 
a positive response to both KSHV RTA and XBP-1s expression (figure 3.6.C). 
The expression of XBP-1s in the transformed cells used for luciferase assay 
was confirmed by using Western blot analysis (figure 3.6.A and B inserts). 
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Figure 3.6. BZLF1 and BRLF1 promoter response to XBP-1s. RLU is the relative light units, 
indicating changes of luciferase activity compare with the vector control. The black bar 
represents methylated promoter luciferase construct, and the white bar represents 
unmethylated promoter luciferase construct. A) XBP-1s weakly transactivates the Zp in 
luciferase reporter assay in HEK 293 cells, although the weak response is statistically 
insignificant (P>0.05, two tailed T-test). BZLF1 over-expression transactivates the Zp as a 
positive control. B) BRLF1 and XBP-1s expression transactivate the Rp. The response is lower 
than the positive control, but statistically significant (P<0.05, two tailed T-test). The XBP-1s 
expression level in Zp (4A, insert) and Rp (4B, insert) transfected cells co-transfected with 
BZLF-1, BRLF-1 or XBP-1s was determined by Western blot. C) The K-RTA promoter was used 
as positive control for XBP-1s expression and activity. The promoter is transactivated 
significantly (P<0.05, two tailed T-test) by both K-RTA and XBP-1s. The results show the mean 
of three or more experiments with the error bars showing the standard deviation of these 
results. 
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3.2.7. XBP-1 is unspliced in different B-cell lymphomas, and splicing is not 
induced by TPA or VPA 
XBP-1 is expressed retaining a 26 nucleotide (nt) intron (XBP-1u, unspliced), 
resulting in a frame shift preventing the translation of the active transcription 
factor. The intron is then spliced to allow the translation of the active form XBP-
1s (XBP-1s, spliced) under ER stress or terminal differentiation into B-cells 
(Calfon et al., 2002). XBP-1u is expressed in both PEL and BL cell lines.  
Previously, Wilson et al (2007) had shown that DTT, a reducing agent, is 
capable of inducing the KSHV lytic cycle in HEK 293 cells, and causing splicing 
of inactive XBP-1u mRNA into active XBP-1s mRNA by promoting the unfolded-
protein response (UPR). As shown in the previous experiments, TPA can 
induce both KSHV and EBV lytic expression (shown by expression of KSHV 
RTA and BZLF1) (figure 3.3). Histone deacetylase inhibitors such as sodium 
butyrate (NaB) have also been shown to be able to induce EBV lytic cycle, 
although this is cell-line dependent (Countryman et al., 2008). We set out to 
determine whether when the reducing agent DTT induced EBV lytic cycle it did 
so by causing XBP-1 splicing. 
Unspliced XBP-1 is expressed in the two PEL cell lines: JSC-1 and BC3 cl6. 
Only DTT caused XBP-1 splicing, TPA, NaB and VPA did not cause XBP-1 
splicing, even though TPA induces both KSHV RTA and BZLF1 expression 
(figure 3.7.B. C and F). Splicing of XBP-1 was also examined in BL cell lines 
such as Akata and Mutu I. XBP-1 is expressed in BL cell lines as an unspliced, 
inactive form. Again, only DTT caused XBP-1 splicing, both TPA and VPA 
cannot induce XBP-1 splicing (figure 3.7.D. E). Therefore, XBP-1 splicing does 
not induce EBV lytic reactivation in BLs. VPA and TPA induce reactivation of 
EBV lytic cycle, but not via XBP-1 splicing. 
 
3.2.8. Induction of XBP-1 splicing by the UPR does not induce the KSHV 
and EBV lytic cycle. 
To further examing the role of DTT in inducing XBP-1 slicing in both PEL and 
BL cell lines, we examined the ability of DTT to induce KSHV and EBV into their 
lytic cycles using Western blot for KSHV-RTA and EBV BZLF1. DTT resulted in 
significant cell death in PEL cells. (figure 3.7.H); after treating JSC-1 cells with 
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DTT for 10 minutes, the cells lose membrane integrity. Using trypan blue 
staining, 48 hours after treating the cells with DTT, more than 50% cell death 
was observed. Because of the toxicity of DTT on PEL cells, it is not possible to 
determine the effect of XBP-1 splicing and EBV/KSHV reactivation in PELs 
(figure 3.7.H). However, the BL cell line Akata is more tolerant of DTT 
treatment. DTT treatment of BL cells induced XBP-1 splicing (figure 3.7.D. E); 
however the ability of DTT to cause XBP-1 splicing in BL cells did not result in 
induction of BZLF1 protein expression (figure 3.7.G). 
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Figure 3.7. NaB, TPA and VPA do not induce XBP-1 splicing in PEL and BL cell lines.  A) XBP-
1 is expressed as the unspliced (XBP-1u) form, but the spliced active form (XBP-1s) can be 
detected following ER stress induction by resistance to digestion by the Pst1 restriction enzyme 
of the XBP-1s PCR product. Treating the cells with DTT induces ER stress and XBP-1u splicing 
in all lymphoma cell lines (B-E). However, NaB, TPA and VPA treatment do not induce XBP-1 
splicing in the lymphoma cell lines (B-E) even though VPA induces K-RTA expression in the 
PEL JSC-1 (F) and TPA induces both K-RTA and BZLF1 in JSC-1 cells (F). VPA and DTT do 
not induce BZLF1 expression in the BL line Akata (G). DTT toxicity (H) results in PEL JSC1 cell 
death and the absence of detectable proteins (F). 
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3.2.9. Knocking down XBP-1s in BL cells  
McDonald et al. (2010) showed that cross-linking B-cell receptors (BCR) 
resulted in XBP-1u splicing within 10 minutes. As BCR cross-linking of BL cell 
line induces the EBV lytic cycle (figure 3.4 lane 4). We decided to knock down 
XBP-1s in BL cell lines and investigate the effect it had on EBV reactivation 
following BCR cross-linking. An shRNA construct targeting XBP-1 and 
luciferase had previously been used to knock down the expression and an 
irrelevant control respectively (Dalton-Griffin et al., 2009; Wilson et al., 2007). 
After transducing the Akata cell line with both hairpin lentiviruses, a Western 
blot analysis was performed to determine the level of XBP-1 protein expression 
in wild type, XBP-1 knock down (XBP-1 KD) and luciferase knock down (Luc 
KD) Akata cell lines (figure 3.8.A). No significant differences in the amount of 
XBP-1 protein expression in the three cell lines were detected. However, these 
results could be due to the low transduction rate of Akata cells, resulting in 
incomplete knock down. To further investigate, we cross-linked the BCR to 
induce EBV lytic reactivation. As shown in figure 3.8.B, after 1 hour cross-
linking the BCR, wild type Akata cells, in comparison to both XBP-1 KD and Luc 
KD cells, expressed less BZLF1. However, 4 hours after BCR cross-linking 
(figure 3.8.C), BZLF-1 expression changed between the wild type and knock 
down cells; with high BZLF1 expression in wild type but not in knock down cells. 
However no difference in BZLF1 expression between the XBP-1 KD and Luc 
KD cells was seen suggesting the effect was not due to knocking down of XBP-
1, but due to the transduction with shRNA lentiviral vectors. Since there is no 
difference between XBP-1 protein expression in the XBP-1 KD, wild type and 
Luc KD control, it is not possible to determine if BCR cross-linking induces EBV 
lytic cycle via XBP-1. 
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Figure 3.8. XBP-1 Knock down does not show different results compared to the irrelevant 
knocking down control. A) XBP-1 expression is slightly lower in XBP-1 KD akata cells, compare 
to wild type. However, it does not differ from the irrelevant control of luciferase knock down. B) 
one hour of BCR cross-linking with anti-IgG. BZLF1 expression is induced faster in XBP-1 KD 
Akata cells, compare to wild type. C) four hours after BCR cross-linking, BZLF-1 expression has 
been induced in wild type Akata cells, however, in both XBP-1 and Luc KD cell there is no 
BZLF1 expression. 
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3.2.10. Over-expression of XBP-1s or chemical agents do not induce 
expression of BZLF1 and BRLF1 mRNA in PEL or BL 
Although XBP-1s over-expression did not induce detectable BZLF1 and BRLF1 
protein expression in PEL or BL cell lines, the promoter based luciferase assays 
showed weak transactivation response between XBP-1s and Zp and Rp in HEK 
293 cells. Therefore, we used quantitative real-time PCR (Q-RT-PCR) to 
determine the mRNA level of BZLF1 and BRLF1 in both PEL and BL cell lines 
in response to XBP-1s over-expression. The effects of various chemical 
inducers of the KSHV and EBV lytic cycles on the mRNA level of BZLF1 and 
BRLF1 were also determined in this experiment. 
In Akata cells, the BZLF1 and BRLF1 mRNA level did not increase after XBP-1s 
over-expression, nor following TPA, VPA or DTT treatment (figure 3.9.A). BCR 
cross-linking with anti-human IgG was used as positive control and BZLF1 
mRNA level increased significantly (p<0.05, two tailed T-test). However, despite 
the increase of BRLF1 mRNA level after BCR cross-linking, this was not 
statistically significant (p> 0.05, two tailed T test). This is consistent with the lack 
of BRLF1 protein expression (figure 3.5.A), and also a previous study (Amon et 
al., 2004) where BCR cross-linking only transactivated Zp, but not Rp.  
The same experiments were carried out in JSC-1 cells. The EBV BZLF1, 
BRLF1 and KSHV K-RTA mRNA expression were determined using Q-RT-PCR 
(figure 3.9.B). After XBP-1s over-expression, or VPA or DTT treatment, the 
expression level of BZLF1 and BRLF1 mRNA did not increase significantly 
(p>0.05, two tailed T-test). The K-RTA mRNA level increased significantly after 
overexpressing XBP-1, DTT or VPA treatment. TPA is used as positive control, 
and compared to the negative control, the BZLF1 and K-RTA mRNA level both 
increased significantly (p<0.05, two tailed T-test) consistent with ZTA and K-
RTA protein expression (figure 3.5.B). These data confirmed that XBP-1s alone 
does not transactivate the EBV Zp or Rp in PEL or BL cell lines. 
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Figure 3.9. Over-expression of XBP-1s in PEL and BL cell lines does not increase the mRNA 
expression level of BZLF1 and BRLF1. Quantitative real time PCR was used to determine the 
expression of BZLF1 mRNA (open bars), BRLF1 mRNA (grey bars) and K-RTA mRNA (black 
bars) after transduction with XBP-1s lentivirus or treatment with chemical inducers for A) Akata 
and B) JSC-1 cell lines. A two-tailed T-test was performed to determine the possibility of false 
results. A) Neither XBP-1s over-expression or TPA, VPA or DTT treatment was able to increase 
BZLF1 or BRLF-1 mRNA expression. BCR cross-linking induced BZLF1 mRNA expression 
significantly compared to the vector control (P>0.05, two tailed T-test). B) In JSC-1 cells 
expression of XBP-1s only increased K-RTA mRNA expression. TPA, VPA and DTT also 
increased the K-RTA mRNA expression significantly (P<0.05, two tailed T-test). TPA treated 
JSC-1 cells expressed BZLF1 mRNA compared with negative control significantly (P<0.05, two 
tailed T-test).  The two tailed T-test analysis indicates that the increase of mRNA levels, as 
described above, are due to either the effect of overexpressing XBP-1s or chemical treatment. 
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3.2.11. XBP-1s and Protein Kinase D together do not induce BZLF1 
expression in PEL cell lines 
Previous results showed that XBP-1s alone does not transactivate the EBV 
BZLF1 promoter and therefore does not induce the EBV lytic cycle in either PEL 
or BL cell lines. Other studies indicated that despite the inability of XBP-1s to 
induce EBV into the lytic cycle that, in combination with protein kinase D, XBP-
1s was able to induce EBV BZLF1 expression (Bhende et al., 2007).  
We used the luciferase assay to examine the effect of PKD in combination with 
XBP-1s on Zp, Rp and K-RTA promoter activity. A constitutively active PKD 
(pPKDm-IG) was used in the study. In HEK 293 cells, XBP-1s and PKD 
combined together weakly transactivated Rp but not Zp (figure 3.10.A). In order 
to ensure that this result was not cell line specific, we also carried out the 
BZLF1 promoter luciferase assay in HeLa cells. XBP-1s and PKD together 
weakly transactivated the Zp in HeLa cells (figure 3.10.B). However the weak 
increases in promoter activity in both HEK 293 cells and HeLa cells were not 
statistically significant (P>0.05, two tailed T-test). BZLF1 and BRLF1 were both 
able to transactivate their respective promoters in both cell types. 
Over-expressing either PKD or XBP-1s alone or together in JSC-1 cells also did 
not induce BZLF1 and/or BRLF1 protein expression (figure 3.10.C), which 
confirmed the luciferase assay. K-RTA protein expression was induced 
whenever XBP-1s was over-expressed, with or without PKD. This indicates that 
PKD does not affect transactivation of K-RTA by XBP-1s. PKD alone did not 
induce K-RTA expression. Using Q-RT-PCR we further confirmed that the 
BZLF1 and BRLF1 mRNA level did not increase when PKD was expressed 
alone or in combination with XBP-1s (figure 3.10.D). K-RTA mRNA expression 
increased significantly whenever XBP-1s was overexpressed (P<0.05, two 
tailed T-test) (figure 3.10.D). Overexpressing PKD prior to XBP-1s also 
increased the K-RTA mRNA level more than XBP-1s expression alone or at the 
same time as PKD. Therefore, over-expression of PKD alone does not induce 
EBV BZLF1, BRLF1 and KSHV K-RTA expression. Additionally, over-
expression of active PKD and XBP-1s does not induce EBV BZLF1 and BRLF1.  
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Figure 3.10. Co-expression of XBP-1s and active PKD does not transactivate Zp or induce 
BZLF1 expression. RLU indicates the relative light unit of luciferase activity. A) HEK 293 cells 
were transfected with Zp (black bars) or Rp (open bars) luciferase reporter vectors with either 
active PKD or XBP-1s together with active PKD. Active PKD alone shows weak Zp activity and 
together with XBP-1s weak Rp activity compared to the control empty vector (VecCon) and 
BZLF1 or BRLF1 expression vectors. However, the increase of luciferase activity was not 
statistically significant compared to the vector control (P>0.05, two tailed T-test) B) The Zp 
promoter assays were repeated in HeLa cells where only XBP-1s and PKD together showed 
weak promoter activity compared to BZLF1 over-expression. However, this was not statistically 
significant compared to the vector control (P>0.05, two tailed T-test). C) Transduction of JSC-1 
cells with XBP-1s and active PKD either alone, in combination, or sequentially (arrows) does not 
induce BZLF1, BRLF1 and BMRF1 expression in PEL, but all combinations that include XBP-1s 
induce K-RTA expression. D) The mRNA expression, measured by quantitative real time PCR 
after XBP-1s and/or active PKD transduction for BZLF-1 mRNA (open bars), BRLF1 mRNA (grey 
bars) and K-RTA (black bars). Only K-RTA mRNA expression increased significantly (P<0.05, two 
tailed T-test) after XBP-1s transduction with or without PKD expression. Two tailed T test analysis 
was performed to determine the possibility of the results being statistically significant. 
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3.2.12. Examing genetic variation in the Z promoter sequences from 
mature B-cell lymphomas and wild type EBV 
The sequence of the Z promoter in both PEL and BL cell lines was not known. 
We therefore sequenced the promoter region of these cell lines to determine if 
polymorphism in the promoter could affect the ability to induce BZLF1 
expression. We also sequenced the Zp region from the luciferase reporter 
construct to ensure that the sequence did not differ from that found in the cell 
lines. The Zp sequence was compared with the EBV type 1 and type 2 
(Genbank ref. NC_007605 and NC_009334 respectively) Zp region from the 
Genbank database.  
There are three nucleotide differences between the EBV type 1 and type 2 in 
the Zp sequences (figure 3.9). The Z promoter luciferase construct that was 
used originated from the B95.8 cell line. The Zp region, from B95.8, Mutu I and 
Raji cell lines, were all identical to the Zp sequence of type I EBV; Akata, HBL6 
and have this type 2 EBV Zp sequence. 
A previous study carried out by Sun and Thorley Lawson (2007) indicated that, 
though computational prediction, Zp contains two putative XBP-1 binding motifs 
designated Zp1 and Zp2, at the ZII and ZID regions of the Zp (figure 3.11), with 
GTCA and ACGT motifs respectively. They have also shown that XBP-1s only 
binds to the Zp1 but not to the Zp2 region. However, using computational 
prediction software Jasper, ACGT is predicted to be the binding site for XBP-1s. 
In addition, previous studies using MD scanning program have also predicted 
ACGT to be an XBP-1s binding site (Acosta-Alvear et al., 2007). As mentioned 
earlier in this chapter, XBP-1s is able to bind and transactivate KSHV 
immediatel early protein K-RTA. It has been shown that XBP-1s binds to the 
XRE element in the K-RTA promoter, containing the ACGT motif (Dalton-Griffin 
et al., 2009). It is unclear why XBP-1s does not bind to the ACGT motif in the 
Zp. 
There are three single nucleotide differences between the type 1 and type 2 
EBV Zp sequences. However, the three single nucleotide base differences are 
not located in either the Zp1 or Zp2 regions. Therefore the lack of response to 
XBP-1s seen in the Zp is not caused by mutation in the Z promoter. 
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Figure 3.11. Schematic diagram of the a) BZLF1 promoter Zp, with the regulatory elements; and B) K-RTA promoter. A) The nucleotide sequences of the ZIC and 
ZIIIB/ZID region, indicating the difference between EBV type 1 and type 2. The nucleotide sequence of the ZID/ZII region is also shown, which contains the two 
putative XBP-1 binding motifs Zp1 and Zp2. Zp2 contains ACGT motif. This diagram indicated that the difference in nucleotide sequence between EBV type 1 and 
type 2 should have no effect in interacting with XBP-1s. B) XBP-1 response element (XRE) in the K-RTA promoter contains ACGT binding motif. Computational 
program JASPER has been used to determine the binding motif for XBP-1, which contains the sequence ACGT. 
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3.3. Discussion 
Plasma cell terminal differentiation and the associated expression of XBP-1s 
are linked to EBV and KSHV lytic cycle induction (Bhende et al., 2007; Laichalk 
& Thorley-Lawson, 2005; Sun & Thorley-Lawson, 2007; Wilson et al., 2007; Yu 
et al., 2007a). Recently this has been extended beyond human gamma 
herpesviruses with the demonstration that plasma cells account for most of the 
lytic reactivation of murine herpesvirus 68 in mice (Liang et al., 2009). It is 
known that XBP-1s transactivates and induces the expression of KSHV IE 
protein K-RTA in PEL cells, which initiates the rest of KSHV lytic cycle (Wilson 
et al., 2007). However, the role of XBP-1s in EBV lytic cycle induction is less 
well defined. In this chapter, we investigate the mechanism that underlines the 
initial induction of KSHV RTA and EBV BZLF1. XBP-1s alone induces KSHV 
into lytic cycle by transactivating the KSHV RTA promoter (ORF50 promoter) in 
PEL cell lines. However, this pathway of reactivation does not induce EBV 
BZLF1 and BRLF1 protein expression in either PEL or BL cell lines. Over-
expressing XBP-1s also does not induce the production of BZLF1 or BRLF1 
mRNA. Additionally, XBP-1s does not transactivate BZLF1 promoter in either 
HEK 293 cells or HeLa cells. Furthermore, XBP-1s and constitutively activated 
PKD together do not induce BZLF1 protein expression or mRNA production. 
The BZLF1 promoter sequences between different cell lines contain no 
mutations that could affect the transactivation. These results suggest that XBP-
1s does not activate EBV lytic cycle in either PEL or BL cells, despite being able 
to activate KSHV lytic cycle in PELs 
Previous reports have shown various effects of XBP-1s in EBV reactivation. 
Sun and Thorley-Lawson (2007) have shown that XBP-1s is able to 
transactivate BZLF1. Bhende et al. (2007) have shown that XBP-1s alone does 
not transactivate BZLF1 but can in combination with PKD expression, although 
the mechanism of reactivation is unclear. However, these reports did not carry 
out experiments in either a mature B-cell background, or used murine XBP-1s 
that differ from human XBP-1s. Sun and Thorley-Lawson (2007) have carried 
out studies in an multiple myeloma cell line MM1.S, which constitutively express 
XBP-1s. Sun et al. (2007) have shown that in HeLa cells XBP-1s cannot 
transactivate Zp; whereas Bhende et al. (2007) showed, also in HeLa cells, that 
XBP-1s weakly transactivates Zp and Rp and the effect of Zp could be 
130 
enhanced by co-expression of constitutively active PKD. Our data in HEK 293 
cells supports the observations that XBP-1s alone can weakly transactivate Zp 
and Rp. Similarly we showed co-expression of XBP-1s and PKD weakly 
transactivates Rp in HEK 293 cells although not to the magnitude described 
previously. This may reflect differences in assay sensitivity or may reflect the 
fact that we have used human XBP-1s in our studies rather than murine XBP-1s 
used by Bhende et al. (2007). Despite the weak transactivation of the Zp and 
Rp in these two cell lines, the relevance of these observations in HEK 293 and 
HeLa cells and the response of EBV to XBP-1s and PKD in B-cell tumour lines 
is questionable. We have also carried out the study on mRNA level and 
immediate early protein expression in B-cell lineages. More evidence has 
suggested that EBV undergoes different pathways of infection and reactivation 
in epithelial cells and B-cells. It is possible that the differences in results are 
also due to the type of cell lines used in the studies. 
The ability of XBP-1s to transactivate either Zp or Rp most likely depends on 
both the cell type and on the nature of individual cell lines. This is supported by 
the observation that distinct chemical inducing agents have different effects on 
the induction of EBV and KSHV lytic cycles in various lymphoma lines 
(Countryman et al., 2008; Miller et al., 1997), suggesting that the reactivation of 
EBV by XBP-1s can vary depending on cell line. In a lymphoblastoid and an 
NPC cell line XBP-1s and PKD clearly activated EBV BZLF1 protein expression, 
but BL or PEL cell lines were not tested (Bhende et al., 2007). In an unusual 
multiple myeloma cell line latently infected with EBV, only low levels of BZLF1 
transcript could be induced by XBP-1s. This observation contrasts with recent 
data indicating EBV can latently infect multiple myeloma cell lines in vitro, and in 
these circumstances the endogenous, active XBP-1s that is expressed by 
multiple myeloma cell lines, does not drive the EBV lytic cycle (Anastasiadou et 
al., 2009). Here we show that despite weak transactivation of Zp and Rp by 
XBP-1s in HEK 293 cells, there are no detectable levels of BZLF1 and BRLF1 
mRNA or proteins after XBP-1s over-expression in B-cell tumour lines.  
Why EBV Zp is refractory to XBP-1s in PEL and BL even when PKD is co-
expressed is not clear, although the role of the chromatin structure on Zp 
promoter is likely to be important. Indeed, the binding of myocyte enhancer 
factor 2D (MEF2D) to Zp recruits class II histone deacetylases (HDACs) 
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presumably promoting a repressed chromatin structure on Zp in lymphoma cell 
lines (Gruffat et al., 2002; McDonald et al., 2010). It has been suggested that 
methylation and histone acetylation of Zp are involved in maintaining viral 
latency in BL (Bergbauer et al., 2010; Flower et al., 2011; Murata et al., 2012). 
De-repression of Zp associated chromatin by PKD was suggested as the 
mechanism that allows XBP-1s to activate Zp (Bhende et al., 2007). PKD is a 
member of the serine/threonine protein kinase family (Rey et al., 2006) which 
can be activated by protein kinase C (PKC) (Zugaza et al., 1996), a cellular 
target of phorbol esters such as TPA (Wang, 2006). PKD can also be activated 
by B-cell receptor cross-linking via PKC pathway (Matthews et al., 2000). In our 
hands TPA induces both K-RTA and BZLF1 in PEL and BCR cross-linking 
induces BZLF1 in BL. It indicates that both TPA and BCR cross-linking can 
activate PKD via PKC pathway. Activated PKD can phosphorylate and therefore 
inactivate class IIa HDACs, similar to the effect of HDAC inhibitors (HDACi), 
such as trichostatin A (TSA) (Chang and Liu 2000), valporic acid (Feng & 
Kenney, 2006) and sodium butyrate (NaB). As HDACi are also capable of 
inducing EBV lytic reactivation in various cell lines (Gradoville et al., 2002), we 
investigated if XBP-1s is also induced by any of these chemical inducers. Here 
we show that NaB, VPA or TPA does not induce activation of XBP-1s in PEL 
and therefore the effects of HDACi and TPA on the Zp is independent of XBP-
1s. 
BCR cross linking induces the EBV lytic cycle and can also transiently induce 
XBP-1s production. However, this transient XBP-1s production cannot 
unambiguously be linked to BZLF1 expression (McDonald et al., 2010). Here 
we used DTT to chemically induce XBP-1s in PEL and BL cell lines. Although 
DTT is able to induce XBP-1 splicing and induce K-RTA in an XBP-1s 
dependent manner in HEK 293 cells (Wilson et al., 2007), it causes significant 
cell death in PEL cells making it impossible to determine K-RTA, BZLF-1 or 
BRFL-1 protein expression. Nevertheless, K-RTA mRNA expression was 
detected following DTT treatment of PEL (Figure 6B) and DTT, which does not 
cause cell death in BL cells, induces XBP-1s production, but does not induce 
BZLF1 expression. Taken together these data suggest that induction of EBV 
lytic cycle in the lymphoma cell lines of PEL and BL is not linked to XBP-1s 
activity, although the effects in B-cells in vivo may be different. 
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In the dually infected PEL cell backgrounds, other studies showed that a 
selective induction of one viral lytic cycle cross represses the other viral lytic 
cycle and co-expression of both KSHV and EBV immediate early proteins 
results in mutual inhibition (Jiang et al., 2008; Miller et al., 1997; Xu et al., 
2007). This suggests a selective lytic switch that induces only one virus is 
required for successful EBV or KSHV lytic replication in PEL. Here we show that 
XBP-1s is able to induce KSHV lytic replication alone in either singly or dually 
infected PEL, but does not induce the expression of EBV BZLF1 and BRFL1 IE 
proteins or transcripts in PEL or BL. XBP-1s with PKD also does not induce the 
expression of BZLF1 and BRFL1 IE or transcripts in PEL. This indicates that 
XBP-1s specifically induces only KSHV into lytic reactivation even in the 
presence of EBV, therefore it is possible that XBP-1s is acting as the “switch” to 
induce reactivation of specific viruses. 
Collectively, our results show that XBP-1s does not reactivate EBV lytic cycle in 
mature B-cells, with or without constructively activated PKD. The known 
reagents that can successfully induce EBV reactivation, such as TPA and 
HDACi, do not induce XBP-1 splicing. With recent study showing ER stress 
induces EBV lytic reactivation (Taylor et al., 2011), and ER stress being part of 
the plasma cell differentiation, it is possible other factors involved in the ER 
stress pathway are playing important roles in EBV reactivation in B-cells. 
133 
Chapter 4 
Results: Establishing methods for EBV whole genome 
sequencing 
4.1. Introduction 
Little is known about the genome variation of EBV, despite the high prevalence 
of EBV infection worldwide. There are currently five EBV genome sequences in 
Genbank of which two are from Burkitt’s lymphoma cell lines; one from a 
marmoset cell line (B95.8), which was infected by EBV originating from an 
Infectious mononucleosis sample; and two from nasopharyngeal carcinoma 
(NPC) cell lines GD1 and GD2. Within these five genome sequences, there is 
only one EBV type 2 genome sequence. The reference genome of EBV type 1 
is an artificial fusion between the B95.8 genome sequence with the deletion 
filled in by the Daudi (BL) cell line EBV sequence. There is no primary isolate 
wild type (WT) EBV whole genome sequence. WT EBV whole genomes in this 
study indicate the EBV whole genomes which are not associated with 
transformed B-cells. Additionally, there is no whole genome sequence of EBV 
present in dually infected PEL cell lines, or from other diseases that is 
associated with EBV.  
It is well established that the genomes of RNA viruses vary extensively. It is 
also established that genome variation is less extensive for DNA viruses. 
However, a recent study has shown that Human cytomegalovirus (HCMV), a 
member of the !-herpesvirus family, is more variable at both the genome and 
amino acid level than expected (Renzette et al., 2011). Previous studies carried 
out by Kelly et al., (2002) have showed that in BL samples, both cell lines and 
primary clinical samples, contain EBV genome variants known as Wp-restricted 
EBV that contain a deletion in the EBNA2 gene of the genome. More studies for 
another herpesvirus, varicella zoster virus (VZV), also showed variation 
between viruses. Samples taken from volunteers who had been vaccinated 
against the same strain of VZV vaccine have shown varied VZV genomes 
compared with each other and the vaccine strain (Breuer et al., 2007). 
Due to the small number of EBV genome sequences that are available 
currently, it is difficult to determine the extent of genetic variation in the EBV 
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genome either between infected people, within a person over time, or in 
different diseases associated with EBV. Here we establish the sequence of EBV 
from different clinical sources using Next Generation Sequencing and methods 
to assemble whole EBV genomes.  
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4.2. Results 
4.2.1. Assays for measuring EBV viral load (qPCR) 
To date sequencing large DNA virus genomes has involved either sequencing ! 
phage genome libraries, bacterial artificial chromosomes or multiple PCR 
products covering the whole genome. With large viral genomes such as 
herpesviruses, the quantity of PCR products required to cover the whole 
genome became too large, increasing costs and time and also increasing the 
possibility of errors during the process. 
Sequencing herpesvirus genomes by Next Generation Sequencing is also 
difficult due to the small amounts of EBV DNA relating to the host DNA. Direct 
deep sequencing from patient samples, such as the tumour tissue from a NPC 
patient (Liu et al., 2011), resulted in 94% of the reads matching human DNA 
and 0.027% of the reads matching viruses and, within that, only 17% (or 
0.0142% of total reads) matching to EBV. With these small percentages of 
reads that are positive to EBV, it is both time consuming and expensive to 
sequence EBV genomes from clinical samples, which prevents sequencing 
EBV whole genomes in large numbers. To routinely sequence EBV using high 
throughput Next Generation Sequencing therefore requires samples with high 
EBV genome copy number. 
In order to determine the amount of EBV in the samples, a quantitative PCR 
(qPCR) assay was established and used prior to the sequencing to determine 
the EBV genome copy number in the samples. Primers and probes were 
designed against the EBNA-LP gene. The sensitivity of this assay allowed the 
detection of EBV genome copy to 102 genomes. GAPDH is used to determine 
amount human DNA in the samples. The EBV qPCR assay was linear over four 
orders of magnitude of EBV copy number (figure 4.1). The qPCR of GAPDH is 
more efficient in comparison to the EBV qPCR, since the gradient of GAPDH 
standard curve is about 30% higher than the EBV qPCR standard curve, 
indicating the ability to detect the gene more efficiently. 
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Figure 4.1. Standard curve of A) EBV B) GAPDH quantitative PCR. The primers and probes of 
EBV qPCR target the EBNA-LP region. Each point has been carried out in duplicate while 
setting up the assay. This qPCR standard curve had been carried out in duplicate when 
quantification of EBV and GAPDH genome copy is required during the study. The copy number 
of EBV and GAPDH genome in different samples has been calculated using the equation 
inserted in the figure. Y is the Ct number from the qPCR result and X is the log EBV or GAPDH 
copy number.  
 
4.2.2. Identifying the source of wild type (WT) EBV sample used for 
sequencing 
To date, the EBV genome sequences that are in Genbank are all from tumours 
associated with transform cells, with majority from either NPC or BL. However, 
the vast majority of EBV infections are asymptomatic and in addition to NPC 
and BL, EBV infection has been associated with diseases such as glandular 
fever or post transplant lymphoproliferative disease (PTLD). Sequencing an 
EBV whole genome not associate with any type of tumour would increase the 
understanding of the virus genome. Polymorphisms have been associated with 
aggressiveness of tumour progression. An EBV genome with no tumour 
association can provide information to determine whether any polymorphisms in 
EBV are associated with tumour formation. 
EBV remains latent in memory B-cells, and transmits via saliva. Previous 
studies showed positive EBV detection in samples such as blood, buccal swap 
and saliva (Decker et al., 1996; Hadinoto et al., 2009). It is unclear which type of 
samples contain maximum EBV copy number for use in deep sequencing.  
Table 3.1 showed the EBV copy number from different sample types. Samples 
from two volunteers showed an undetectable (UD) amount of EBV. With one 
!" #"
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volunteer showing the presence of EBV in all three types of samples, it is clear 
that saliva contains the highest level of EBV. Moreover, it has been shown that 
EBV is shed via saliva constantly through time with high copy number (Hadinoto 
et al., 2009).  Although no EBV presence as detected in the saliva samples from 
volunteers 1-3, it is possible that the qPCR sensitivity is not sufficient to detect 
EBV from these three samples. The primers used for the qPCR were unable to 
detect EBV when there was fewer than 102 copies per µl. Also, the method of 
collecting and processing saliva, such as if the cells have been removed prior to 
processing, could also affect the EBV copy numbers in these samples. 
 
Table 4.1. EBV copy number in different types of sample 
 PBMC Buccal Swap Saliva 
Volunteer 1 UD UD UD 
Volunteer 2 UD UD UD 
Volunteer 3 3952 UD UD 
Volunteer 4 835 3947 7.6 x 106 
 
Further saliva samples were obtained from 26 volunteers and EBV genome 
load was measured using qPCR (table 4.2). 16 samples contained detectable 
amounts of EBV. The samples with more than 106 EBV copies per µl 
(highlighted in table 4.2) were directly sequenced as stranded Illumina libraries 
at the Wellcome Trust Sanger Institute (WTSI). However, the sequencing read 
pairs did not produce matches to the EBV genome. Rather all reads matched 
salmon sperm DNA, which as added as a carrier at DNA extraction. Further 
saliva DNA was collected and extracted with no carrier DNA and sequenced at 
WTSI. Despite there being greater than 106 copies of EBV genome in the 
sample, the Illumina sequencing still failed to detect any EBV reads. This is 
most likely due to high human DNA content of either host or other organisms 
such as bacteria, resulting in majority of the read pairs not matching EBV. To 
overcome this problem, EBV genome will therefore need to be either separated 
from other DNA, especially the host DNA; or enriched, before deep sequencing 
can take place.  
138 
 
Table 4.2. EBV genome copy number from 26 saliva samples 
Sample 
number 
Copy no. 
/µl 
Sample 
number 
Copy no. 
/µl 
Sample 
number 
Copy no. 
/µl 
1 4996 10 9257 19 3.9x106 
2 4310 11  UD 20 1.1x106 
3 UD 12 4.1x108 21 794 
4 UD 13 28825 22 1488 
5 UD 14  UD 23 5x104 
6 UD 15  UD 24 9.9x104 
7 5.3x107 16 3.7x106 25 2317 
8  UD 17  UD 26 132 
9  UD 18 1.2x108   
 
4.2.3. Using Gardella gel to extract episomal genome from latently 
infected cell lines 
To date, no EBV whole genome sequences have been produced from PEL 
which is dually infected with KSHV. EBV remains in latency in both PEL and BL 
cell lines, indicating the EBV episomal DNA associates with the human DNA in 
the nucleus. Gardella gels were used to separate EBV genome from human 
DNA. The Gardella gel was designed in 1984 (Gardella et al., 1984) for 
detecting herpesvirus episomes in latently infected cells. Figure 4.2 shows an 
illustrated diagram of a Gardella gel. With two sequential layers of agarose gels, 
the cell samples are lysed in the first tier with the virus episomal and human 
linear DNA being size separated in the second tier. 
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Figure 4.2. Schematic diagram of a Gardella gel. The Gardella gel separates the episomal and 
linear DNA from lysed cells. 1x106 cells have been suspended in sample buffer and loaded into 
each well. Sections of the gel containing the episomal DNA were cut into 0.5cm pieces and 
soaked in distilled water to elute the DNA. 
 
Here we adopted a method based on the Gardella gel used by Decter et al 
(1996), to separate the herpesvirus episomes from both JSC-1 and HBL-6 cell 
lines. Both of the PEL cell lines used are dually infected with KSHV and EBV, 
however this method cannot separate these two viral genomes. After gel 
electrophoresis, the gel was sliced into 0.5cm length sections, and the episomal 
DNA was eluted from the gel. The proximal distance from the well of episomal 
DNA was estimated according to previous literature (Decker et al., 1996; 
Gardella et al., 1984). PCR was performed to confirm EBV DNA was eluted 
from the gel (figure 4.3). The PCR result indicated that EBV genome could be 
detected spreading 6 cm from the loading well. Gel slices taken from other 
location of the Gardella gel were used as negative control. However the 
negative control also shows low level of EBV indicating the difficulty of 
estimating the discrete location of EBV within the gel. Also, it is unclear whether 
either the episomal or linear form of EBV genome is in the samples.  
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Figure 4.3. Determining the presence of the EBV genome after elution of the Gardella gel from 
A) HBL-6 and B) JSC-1 cell lines. Each PCR indicates the distance of the gel slice from the well. 
Random areas of the Gardella gel were also sliced and eluted and tested by PCR to ensure no 
contamination occurred during electrophoresis and the elution process, dH2O was used as 
negative control for the PCR. 
 
4.2.4. Using DNA polymerase phi29 with EBV specific primers to increase 
the viral copy number. 
The total number of EBV genomes extracted from the cell lines using Gardella 
gels is between 10,000 and 23,000 copies, which is low in comparison to the 
other samples that had failed when sequencing directly from saliva. With 106 
cells being loaded per well, and multiple episomes per cell, the recovery 
efficiency of EBV genomes from the Gardella gel is low. Phi29 DNA polymerase 
was used to increase the copy number of EBV with target specific primers. 
Phi29 is a proof-reading DNA polymerase, able to perform a rolling circle DNA 
amplification in vitro (Dean et al., 2001). Since the DNA extracted from Gardella 
gel is episomal, Phi29 is ideal for increasing copy number with minimal 
introduction of DNA induced errors. 
Initially, 6 EBV specific 20mers spaced evenly across the EBV genome were 
used in the PCR, which only increased the EBV copy number by 2-3 fold (figure 
4.4). An additional 12 primers were added and the PCR repeated. This resulted 
in the EBV copy number increasing by 10 fold relative to input DNA. These 
samples were sent to WTSI for sequencing, but again failed. 
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Figure 4.4. Comparison of the EBV genome copy number before and after Phi29 PCR. DNA 
from the Gardella gel slices was eluted, and the original copy number was determined by 
qPCR.  Phi29 PCR was performed to increase the copy number to the concentration required 
for sequencing. Using 18 primers, the Phi29 PCR could increase the copy number of EBV by 10 
fold. 
 
4.2.5. Extracting EBV from PEL and BL cell lines by reactivation. 
Other than separating the latent EBV episome from the cells by Gardella gel, 
EBV can also be amplified and enriched by reactivation of the lytic cycle. 
Chemical reagents such as VPA and BCR cross-linking were used to reactivate 
EBV into the lytic cycle. Viral DNA from the supernatant was extracted and 
concentrated.  Two dually infected PELs, JSC-1 and HBL-6, and two BLs, Mutu 
I and Akata, were treated with VPA and BCR cross-linking respectively to 
reactivate EBV. By using VPA to reactivate EBV in the dually infected PELs, 
KSHV is also reactivated. EBV and KSHV copy number of these samples were 
determined by qPCR (Table 4.3). We calculated the relative amount of virus 
genome to host genome in base pairs. Despite the high copy numbers of EBV 
and/or KSHV, in comparison to a typical human genome (which is about 3Gbp), 
the total amount of virus DNA per sample was equivalent to 103 to 104 of human 
genome. This highlights the affect of even a small copy number of human 
genome will cause in the sequencing project. The human genome can dominate 
the total amount of DNA in the sample due to the sheer size, resulting in the 
majority of the NGS reads being non-EBV, decreasing the depth of sequencing 
and also increasing the difficulty of analysis. These EBV lytic stage samples 
were sequenced as multiplexed reaction with 6 per lane using a Genome 
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Analyser IIx (Illumina) at the WTSI. The samples were sequenced successfully 
and will be discussed in chapter 5 in detail. 
 
Table 4.3. Copy number of EBV and KSHV from PELs and BLs  
Cell 
line 
Sample 
no. 
EBV copy 
no./µl 
KSHV 
copy 
no./µl 
Total 
volume 
Total EBV 
Genome 
equivalent 
(Gbp) 
Total KSHV 
Genome 
equivalent 
(Gbp) 
JSC-1 1 2.9x106 1.7x107 20µl 1.0x104 5.8x104 
  2 2.2x106 1.2x107 20µl 7.7x103 4.1x104 
  3 2x106 3x106 40µl 1.4x104 2.0x104 
  4 1.7x106 1.1x106 40µl 1.2x104 7.5x103 
HBL-6 1 1.4x106 8.5x106 20µl 4.8x103 2.9x104 
  2 9x105 6.5x106 20µl 3.1x103 2.2x104 
  3 1x106 9.6x105 40µl 6.9x103 6.5x103 
  4 1.9x106 8x105 40µl 1.3x104 5.4x103 
Akata 1 1.8x106 N/A 20µl 6.2x103 N/A 
  2 2.9x106 N/A 20µl 1.0x104 N/A 
  3 6x106 N/A 40µl 2.1x104 N/A 
Daudi 1 1.1x107 N/A 20µl 3.8x104 N/A 
  2 1.5x107 N/A 20µl 5.5x104 N/A 
  3 1.1x107 N/A 40µl 3.8x104 N/A 
 
4.2.6. Using Agilent SureSelect enrichment system  
As mentioned previously, enriching or separating viral genomes from host DNA 
can result in a higher success rate of sequencing using Illumina. Earlier 
sections of this chapter have described separating the viral genome from the 
host DNA.  However, the copy number of viral genome remained low despite 
using Phi29 DNA polymerase to enrich the separated viral DNA from each cell 
line. In addition, Phi29 DNA polymerase enrichment can only be used efficiently 
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on episomal samples. To sequence EBV from clinical samples, another method 
would therefore be required. 
The Target Enrichment system (referred to as SureSelect) (Tewhey et al., 2009) 
developed by Agilent is currently used to sequence all human exons. Figure 4.5 
illustrates the process of the SureSelect process. By adapting the procedure, 
this process was used to enrich and separate the EBV genome from other DNA 
in the sample. The SureSelect procedure can be divided into three stages. 
Firstly, the sample is sheared to desirable length, which is between 200-300bp 
long in this study, and mixed with target specific biotinylated “baits” (further 
detail in chapter 4.2.6), allowing the target DNA to hybridise with the baits. 
Secondly, the non-target DNA is removed from the sample by repetitive 
washing. And finally, the target DNA is enriched using a minimal number of 
PCR steps. This enrichment process removes the majority of the non-target 
DNA, and through minimal rounds of PCR, increases the target DNA further. 
The samples after the enrichment process can be sequenced as multiplexed 
reactions with 6 per lane using a Genome Analyser IIx (Illumina, Inc) at the 
WTSI.  
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Figure 4.5. Flow diagram illustrating the Agilent SureSelect target enrichment process. DNA 
samples were sheared to 200-400bp length using the covaris, and ligated with Illumnina 
adapters, which then hybridised with the biotinylated baits, which was designed against the EBV 
type 1 and 2 reference genome from Genbank. The non-target DNA fragments were then 
removed by washing, post hybridisation by using streptavidin coated magnetic beads.  Minimal 
PCR has then been carried out to amplify the DNA before sequencing the samples (adapted 
from Agilent SureSeclect website http://www.halogenomics.com/sureselect). 
 
4.2.7. Bait design 
One important feature of the SureSelect enrichment method is that there must 
be a reference sequence to enable the “bait” design. Currently there are five 
EBV genome sequences in Genbank, with two reference sequences 
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representing both type 1 and type 2 EBV genomes. Two sets of “baits”, one 
based on EBV type 1 (NC_007605) and another on EBV type 2 genome 
(NC_009334) were designed using Agilent eArray XD software. The baits were 
designed to be 120mer RNA probes, tiling five times across the whole genome. 
Each base in the genome is covered by five different probes, with a 24bp 
overlap between each probe. A total of 7154 and 7193 baits were designed and 
synthesised for EBV type 1 and type 2 respectively. Each library contains four 
sets of baits; two sets of EBV type 1 and type 2 each, which allows enrichment 
of either type 1 or 2 EBV genomes from the samples without prior determination 
of the virus type. 
 
4.2.8. Whole Genome Amplification (WGA) before the SureSelect 
procedure 
One disadvantage of using the SureSelect target enrichment methodology is 
that large quantities (3µg) of DNA template are required. For many clinical 
samples, the total amount of DNA available is less than 3µg. Phi29 DNA 
polymerase with primers specifically designed for EBV was used previously, to 
specifically enrich the copy number of EBV viral genomes. However, many 
clinical samples are stored as DNA, which has been sheared during the 
extraction process, therefore EBV specific primers cannot be used. Here, 
random primers (Genomiphi) were used instead to allow us to carry out whole 
genome linear amplification (WGA), resulting in an increase in the total quantity 
of DNA within the sample regardless the type, before processing the samples 
through SureSelect. The details of sample process are illustrated in the flow 
chart in figure 4.9. 
 
4.2.9. Analysis - Computational 
Large numbers of pair-end reads can be generated from second generation 
sequencing. In this study, the EBV DNA, purified from the cell line samples, was 
sequenced on an Illumina GAIIx system, while the PTLD samples were 
sequenced on an Illumina HiSeq system. Using Illumina GAIIx, the number of 
paired-end reads (which are 2 x 76bp long reads) returned from these samples 
were between 4.5 to 7 x 106 (table 4.4); however, this is the number of total 
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reads which includes both EBV and non-relevant reads, of which the majority 
are human DNA.  
Figure 4.6 illustrates the computational pipeline that was developed to obtain 
EBV genome consensus sequences. Firstly, duplicate paired end reads were 
removed from the data set since the duplicates may skew mapping and affect 
the calling of polymorphisms. The read pairs were subsequently quality 
controlled (QC) (discussed in more detail later in this chapter) using QUASR v7 
(figure 4.7). For samples sequenced with Illumina HiSeq, the percentage of 
read pairs passing QC is between 50 to 80% whilst the percentages of read 
pairs passing QC generated by GAIIx is higher, at around 85% (table 4.4). The 
difference in passing QC could be due to the type of samples that have been 
deep sequenced by these two Illumina machines. The cell line samples were 
sequenced using the GAIIx and the PTLD samples were sequenced using 
HiSeq. The DNA of PTLD blood samples had been stored in -20oC for a period 
of time and may therefore have been more degraded than the DNA from the cell 
line samples. After the QC step, the read pairs were mapped to both EBV type 
1 and 2 reference sequences. For the samples that were HiSeq sequenced, 
due to the large number of read pairs after QC, only a subset of the read pairs, 
selected randomly, were to aligned against the reference genomes using 
Burrows-Wheeler Aligner (BWA) (Chou et al., 2010). Using the percentage 
coverage across the genome on both type 1 and type 2 genomes, the type of 
EBV genome in the samples is readily determined. The EBNA2 region, which 
contains large differences between type 1 and type 2 EBV sequences and has 
been generated in both type 1 and 2 mapping, was used to confirm the EBV 
type. The read pairs were then assembled to the correct consensus sequence 
according to the type of EBV selected. The mapping of read pairs back to the 
reference sequences were carried out using the Burrows-Wheeler Aligner 
(BWA) (Chou et al., 2010). The QC process, and generation of majority 
consensus sequences, was carried out using QUASR v7 
(http://sourceforge.net/projects/quasr). Finally, single nucleotide polymorphisms 
(SNPs) were determined by aligning the majority consensus sequences back to 
the reference sequence, and using VarScan v2.2.7 (Koboldt et al., 2009) to 
determine the allelic frequencies. 
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Figure 4.6. Flow chart of the computational analysis of read pairs generated by Illumina 
sequencing. Raw data were firstly processed through the quality control stage, which removes 
duplicate and trims low quality reads. Small percentages of the read-pairs were then assembled 
against both type 1 and type 2 EBV genomes. The type of EBV was determined depending on 
the percentage of mapping against these two genomes. All read-pairs were assembled to the 
correct EBV type and a majority consensus sequence obtained. The sequence was then 
aligned against the reference genome using Base-by-Base (Brodie et al., 2004). All SNPs were 
identified using the Base-by-Base multi-genome comparison feature, and confirmed by QUASR 
7, VarScan, and Sanger sequencing. 
 
Figure 4.7 illustrates the process of QC. After removing the duplicate reads from 
the dataset, the dataset was divided into several smaller read sets from which 
the Illumina adaptor primers were removed. Read pairs generated from the 
Illumina carried a quality score (Phred score) on each individual base after the 
read pairs were generated. Phred scores were used to assess the quality of the 
sequence. Firstly, developed to assess the read quality in the Human Genome 
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Project, q Phred score is defined as a property that is logarithmically related to 
the base-calling probabilities. It works on the score system of 1-40 with 
exponential relationship to the probability. For example a Phred score 20 
indicates a 1 in 100 probability of incorrect base call, and a Phred score 30 
indicates 1 in 1000 probability of incorrect base call. Each base in a sequence 
had an associated Phred score, and the score of the total sequence was 
calculated according to all the Phred scores in the sequence. Phred score cut 
off during the assembly of consensus sequences was 30, indicating a 99.9% 
possibility of the reads and sequence being correctly called. The median of the 
Phred score of the last 10 bases of the read was calculated; if the median 
Phred score was below 30, the end base of the sequence was systematically 
removed and new median Phred score of the sequence recalculated. If the 
Phred score of the sequence reached 30 before the sequence became shorter 
than 50 base, the read was used in further assembly, otherwise the read and its 
pair were removed from the dataset.   
 
 
149 
 
 
Figure 4.7. Flow chart illustrating the details of Quality control step after the read pairs had 
been generated from Illumina. The Phred score was set at 30, which means a 99.9% probability 
that the base is called correctly.  The read length cut off point was set at 50 bases. The median 
Phred score of the last 10 bases of a read was used to determine the quality of the read, if it 
was below the cut off (30), the last base of the read was trimmed off and the median 
recalculated. This process was repeated until the median of the Phred score exceed the cut off, 
at this point if the trimmed read length was below the specific cut off (50 bases in this 
investigation), the read and its pair were discarded. Otherwise it was retained for mapping. 
 
Once the majority consensus sequence was generated, it was aligned against 
the reference sequence according to the type. The location of single nucleotide 
polymorphisms (SNPs) and the polymorphic loci were called after the alignment 
using Base-by-Base software (Brodie et al., 2004). The SNPs were further 
confirmed by using VarScan v2.2.7 and QUASR v7 software (Koboldt et al., 
2009) (http://sourceforge.net/projects/quasr) by investigating further into the 
depth and coverage of the read pairs of that particular base. Further analysis of 
the SNPs and polymorphisms will be discussed in chapter 5. SureSelect and 
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the computational analysis have been carried out in previous studies by 
Depledge et al., (2011). 
 
4.2.10. Confirmation of genome enrichment 
A pipeline for sequencing EBV whole genomes from both clinical and culture 
samples containing small amounts of EBV DNA has been established in this 
chapter. The samples which contained less than 3 !g of total DNA were whole 
genome amplified using Phi29 DNA polymerase and random primers, which 
then underwent the SureSelect process to enrich the target genome before 
deep sequencing. One of the sample types processed through this pipeline was 
the clinical blood samples of patients with post-transplant lymphoproliferate 
disease (PTLD). The detailed analysisof this data will be discussed in Chapter 
5. We carried out qPCR on EBV and human GAPDH genome at various stages 
during this pipeline to investigate the degree of enrichment. The viral and 
human genome content was determined at five stages: the original sample after 
purification, after whole genome amplification (WGA), during the SureSelect 
process, pre hybridisation and also post hybridisation before PCR. Figure 4.8 
shows the ratio between EBV and human DNA. Surprisingly, after WGA the 
ratio has lowered; indicating that WGA is apparently biased to amplify the 
human genome. The pre-hybridisation stage shows the same ratio as the WGA 
stage. Post hybridisation, three samples have an EBV to human DNA ratio 
increased to a maximum at seven logs. The last sample, despite not having as 
high increase in the ratio, also showed a log two increases. Depledge et al., 
(2011) also show similar results in the enrichment of the VZV samples. This 
indicates that the SureSelect process is successful in enriching the EBV 
substantially in the samples. However, WGA could be removed from the 
pipeline, as its effect to be seems detrimental.  
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Figure 4.8. The ratio between EBV and human genome DNA during various stages of 
preparation prior deep sequencing. The blood samples are from the same patient, taken from 
four different time points. Original samples indicating the DNA sample, WGA after whole 
genome amplification by using Genomiphi. Pre and post-hybridisations are two stages in the 
SureSelect enrichment protocol, before the final PCR stage.  
 
4.2.11. Illumina sequencing results 
As discussed in chapter 4.2.8, Next Generation Sequencing such as Illumina 
generates a large amount of data. Two types of sequencing machines were 
used in this study, the Illumina GAIIx was used for all cell line samples, and 
Illumina HiSeq was used for the clinical PTLD data that had also been 
processed through the SureSelect process. Figure 4.9 illustrate the process by 
the type of sample and all the sample preparation procedures before the 
sequencing machines were used.  A higher percentage of reads had passed 
QC from cell line samples (>70%) compared to the clinical samples (between 
55-60%), for reasons that are unclear. With all the samples, over 163,000 bases 
of the EBV genome are covered at least once and at 10 times coverage, still 
over 160,000 bases of EBV are covered except for the PTLD T1 sample (where 
at 10x and 1x coverage is of 90% of the genome). The average depth of all 
samples, i.e. the number of times a base is sequenced on independent reads 
ranges between 87 to 1,000x for the clinical samples, to over 2,000x for the cell 
line samples. This is possibly due to the quality of the DNA in the different types 
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of samples. This is much higher than was seen using Sanger capillary 
sequencing (depth = 1), or in other next generation Illumina sequencing by Liu 
et al., (2011) (average depth= 17). High depth coverage allows more accurate 
calling of SNPs, and also allowed us to study the evolution of EBV in more 
detail (further discussion in Chapter 5). 
 
 
Figure 4.9. Flow chart illustrates the sample preparations before sequencing.  Both cell line 
samples (lysate and supernatants) have DNA extracted using the Qiagen DNA extraction kit 
prior to processing through the Sureselect process. The samples were sequenced on the 
Illumina GAIIX machine. The PTLD blood samples were obtained as DNA samples which had 
been extracted previously.  The DNA samples were processed with whole genome amplification 
and followed by the Sureselect process prior to sequencing on the Illumina HiSeq machine. 
 
!"# 
 
Table 4.4. Statistics of number of read-pairs post Illumina sequencing.  
EBV reads only 
Sample Sequencer Total reads 
Post-
duplicate 
removal 
Post QC 
% reads 
post 
QC 
Uniquely 
mapped 
reads 
Mean 
Read 
Depth 
Coverage 
(1x) 
Coverage 
(10x) 
Coverage 
(100x) 
PTLD T1 Illumina HiSEQ 150000 97731 88059 59% 76434 87 163225 152326 54225 
PTLD T2 Illumina HiSEQ 393500 257000 229878 58% 198267 224 165588 161856 120638 
PTLD T3 Illumina HiSEQ 845500 542857 491461 58% 418711 469 167260 162966 144381 
PTLD T4 Illumina HiSEQ 1941750 1185264 1067767 55% 901910 1008 167564 164884 157419 
PTLD 2035 Illumina HiSEQ 377500 220057 209680 56% 154475 179 165417 159524 112533 
JSC1 SN Illumina GAIIx 6836067 5161388 4868370 71% 3052570 2623 171686 169154 162931 
JSC1 LYS Illumina GAIIx 6864461 5140591 4835122 70% 3526008 3040 171542 167686 158791 
HBL6 SN Illumina GAIIx 4751548 3978809 3765969 79% 2767361 2378 171689 167796 160894 
HBL6 LYS Illumina GAIIx 6747765 5134756 4746384 70% 2666926 2306 171053 167210 154362 
Daudi SN Illumina GAIIx 4351267 3507323 3301960 76% 2740415 2411 167739 164075 159841 
Akata SN Illumina GAIIx 4516373 3835862 3637931 81% 3144703 2721 171149 168433 160955 
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Figure 4.9. Flow chart of sample processing prior to next generation Illumina sequencing. The 
DNA of the cell line samples was extracted before the SureSelect process. The DNA from the 
PTLD blood samples was extracted and stored at -20oC after the samples were taken. The DNA 
was whole genome amplified prior to the SureSelect process. After the SureSelect process, the 
cell line samples were sequenced using the Illumina GAIIx, with the PTLD samples sequenced 
using Illumina HiSeq.   
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4.3. Summary 
Sequence variability of large DNA viruses has not been investigated in great 
detail due to difficulties in obtaining full genome sequences.  Recent studies on 
HCMV (Renzette et al., 2011) and VZV (Breuer et al., 2010) have established 
that the mutation and polymorphisms occur more commonly in large DNA 
viruses than previously assumed. With five complete genomes in Genbank, it is 
difficult to determine the extent of polymorphisms in EBV. Previously the 
sequences of EBV have been generated by Sanger capillary sequencing 
(Sanger et al., 1977b) and long PCR, which is time consuming and does not 
cover the genome in depth.  A recent EBV genome GD2 has been generated 
using Next Generation Sequencing from clinical samples. However, with the 
host DNA intact in the sample, the result shows over 99% of the reads returned 
to be negative of EBV; therefore removing non-relevant DNA from the samples 
would reduce the time taken for, and cost of EBV sequencing and analysis.  
In this chapter, several methods have been used to extract EBV for sequencing 
from various samples ranging from saliva to PBMCs. Both Phi29 DNA 
polymerase and the Agilent SureSelect target enrichment systems have been 
used to increase the copy number of the EBV. For sequencing samples 
containing large amounts of host DNA a pipeline has been established. The 
total DNA was increased by WGA, and target enriched by SureSelect prior to 
sequencing. However, after further investigation, it became apparent that WGA 
appear to be biased towards host DNA amplification and decreases the ratio of 
EBV to host DNA within the samples.  WGA was therefore removed from our 
current pipeline.   
Next Generation Sequencing generates large amounts of data. Careful 
computational procedures are required to sieve through the data and assemble 
the EBV genomes. Duplication and quality control process were carried out to 
reduce the possibility of sequencing error and remove low quality read pairs 
prior to assembly. Majority consensus sequences were generated using BWA 
software, mapping back to the reference genomes. De novo assembly was 
considered during the process of generating consensus sequencing; however, 
currently there is no ideal software for assembling EBV genome de novo. EBV 
contains many repetitive regions within the genome; it is difficult to assemble 
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the repetitive regions accurately with the BWA algorithm. Therefore the 
sequence of these repeated regions will require further investigation. 
Nevertheless, a complete assay for sequencing clinical samples has been set 
up in this chapter.  
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Chapter 5 
Results: EBV Whole Genome Analysis  
5.1. Introduction 
DNA viruses are known to be less polymorphic than RNA viruses such as 
Human Immunodeficiency Virus (HIV) and the influenza viruses. HIV evolves at 
an extremely fast rate due to a high replication error rate and a large effective 
population size, together with high recombination level and fast replication rates 
(Mansky & Temin, 1995; Perelson et al., 1996). The high mutation rates leads 
to many variants of HIV in a single infected individual in the course of one day 
(Robertson et al., 1995a). Many of the polymorphisms and mutations have been 
linked to different selective pressures on HIV, for example immune evasion, 
disease progression and development of drug resistance. 
Genetic variation in DNA viruses has not been studied extensively. Two 
herpesviruses have recently shown higher than expected genome variation in 
humans.  Human cytomegalovirus (HCMV) is a member of the !-herpesviruses 
and, with a 236 Kb genome, is the largest human herpesvirus (Dolan et al., 
2004). A recent study suggested that every open reading frame (ORF) of HCMV 
showed levels of intra-host diversity, and quantify this variability by measuring 
nucleotide diversity shows the intra-host diversity of HCMV is comparable to 
RNA viruses such as HIV, with the frequency of variants in coding region 
sequence (CDS) being lower than in non-CDS. Although the source of diversity 
was unclear, the variation of HCMV also indicates selection within the 
population. Evidence of both positive and negative selection was determined 
suggesting positive selection contributes to the divergence across HCMV 
species, and negative selections occurs to maintain the genetic stability of the 
viral species (Renzette et al., 2011).  
Varicella-zoster virus (VZV) is a human "-herpesvirus which causes chickenpox 
(primary infection) and Shingles (reactivation). Of all the herpesviruses, VZV is 
the one with the highest number of whole genome sequences in GenBank. 
Excluding the variable regions, there are between 30-200 single nucleotide 
polymorphims (SNPs) between any two genomes, indicating a SNP every 4,000 
!!
158 
to 600 bases. Around 30% of these SNPs result in amino acid changes, with 
uneven distribution across the genome (Tyler et al., 2007). 
Numerous studies have investigated the variation in EBV genes, the association 
with the geographical distribution and the affect on malignancy (See Chapter 
1.5). Since there are limited numbers of EBV whole genome sequences, little is 
known regarding the variation and polymorphisms of EBV. In Chapter 4, we 
have discussed the method and the pipeline that were used to conduct Next 
Generation Sequencing (NGS) of EBV, resulting in whole EBV genomes being 
assembled from cell lines and clinical samples. In this chapter we concentrate 
on the investigation of the variation of the EBV whole genome majority 
consensus sequences (MCS), especially focusing on variant EBV type 1 
sequences.  
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5.2. Results   
5.2.1. EBV whole genome sequences   
Following on from the computational analysis discussed at Chapter 4, a total of 
11 EBV whole genome majority consensus sequence (MCS) were assembled. 
These include two BL cell lines: Akata and Daudi and two PEL cell lines: JSC1 
and HBL6, with EBV from either the lytic cycle or latency. The other five 
sequences are from the whole blood samples of two Post Transplant 
Lymphoproliferative disorder (PTLD) patients. PTLD T1, 2, 3 and 4 are 
sequenced from the same patient at four different time points (table 4.4) during 
the development of the disorder with an increasing amount of viral load. These 
four samples were collected over a two months period, with the T3 and T4 
samples taken 4 days apart (table 5.1).  
 
Table 5.1. Time and viral load of the PTLD blood samples taken from the same patient 
Sample 
number 
Sample 
type 
Date sample 
taken 
Viral load 
(copies/ml) 
PTLD T1 Blood 18.04.2008 362,000 
PTLD T2 Blood 02.05.2008 2,352,720 
PTLD T3 Blood 02.06.2008 6,300,000 
PTLD T4 Blood 06.06.2008 13,100,000 
 
All of the samples other than HBL6 and PTLD 2035 were assembled to the EBV 
type 1 reference sequence; HBL6 and PTLD 2035 were assembled to the EBV 
type 2 reference genome. This is dependent on the percentage of read pairs 
matching to either the type 1 or 2 reference sequences (details discussed in 
Chapter 4). Additionally, five EBV whole genome sequences from the saliva 
samples (Saliva 5, 5G, 7 and 7G) (Chapter 4), and another PEL sample BC1, 
were assembled at the WTSI using the same method. All but the BC1 
sequences were assembled to the EBV type 1 genome. These sequences will 
not be discussed in detail, except in the phylogenetic studies later on in this 
chapter.  
Both PTLD T1-4 and PTLD 2035 are sequenced from clinical blood samples.  
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The PTLD 2035 blood samples originated from a two-years-old male PTLD 
patient, and the PTLD T1-4 samples were from a one-year-old male PTLD 
patient at the first time of sampling.  Both patients underwent renal transplants 
after renal failure, with the PTLD 2035 patient forming a tumour at the gut 
region and the PTLD T1-4 patient forming a tumour at the lung regions.  It is 
unclear if either of the patients was sero-positive with EBV prior to the organ 
transplant. 
 
5.2.2. Single Nucleotide Polymorphisms (SNPs) of the EBV genome 
The EBV genome contains large numbers of nucleotide repeat sequences 
within the genome. Sequencing over these repeated regions (RDs) is difficult 
with both Sanger capillary sequencing (SCS) and Next Generation Sequencing 
(NGS). During genome assembly, it was apparent that the coverage across the 
RDs is low, with in some cases no reads mapping across the region. Previous 
studies have shown cell line type specific variation in the number of repeats in 
the EBV genome, however, the number of repeats cannot be correctly identified 
in the MCS constructed after NGS. As the reads from Illumina were aligned 
against an EBV reference sequence; the number of repeats in the newly 
assembled sequence will therefore be identical to the reference genome used. 
Therefore the variations that occurred over RDs are ignored as unreliable to 
ensure a more accurate understanding of the rest of the EBV genome. 
Single nucleotide polymorphisms (SNPs) are called by comparing the majority 
consensus sequence against the relevant reference genome. Since the PTLD 
T1-T4 samples are from the same source over a short period of time, the SNP 
analysis is carried by comparing all four EBV sequences with the type 1 
reference genome, therefore the number of SNPs of PTLD here refer to any 
variation that occurred in any of the four PTLD sequences combined. Table 5.2 
shows the summary of the number of SNPs across the type 1 EBV assembled 
genomes, with the SNPs over RDs being discounted. Akata contains the 
highest number of SNPs in these samples, and JSC1 the fewest. All four 
samples contain higher number of SNPs within the CDS than the non-CDS; with 
more synonymous SNPs than non-synonymous SNPs (NS-SNPs). 
Synonymous change results in changes of nucleotides but does not result in 
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amino acid change; whereas non-synonymous change results in changes of 
both nucleotide and amino acid. The number of total SNPs from these samples 
indicates a SNP occurs between every 170-360bp in EBV genome, a much 
higher rate than seen in VZV suggesting EBV is more variable than previously 
expected. Between 26-30% of SNPs in CDS result in amino acid change.  
 
Table 5.2. Number of Single Nucleotide Polymorphisms (SNPs) in coding (CDS) and non-CDS 
region of EBV genome of different disease background. 
Type of SNPs PTLD T1-4 JSC1 Akata Daudi 
CDS  
Synonymous 
412 284 638 471 
CDS 
Non-synonymous 
(amino acid change) 
161 124 245 169 
Non-CDS 273 237 358 245 
Total number 683 521 996 716 
 
5.2.3. Latent and Lytic EBV genome from PELs 
Both the lytic virus genome and the latent virus genome of EBV were 
sequenced from JSC1 and HBL6 cell lines by sequencing the EBV genome 
from supernatant post stimulating EBV reactivation (lytic) or directly from the 
lysate of the latent cells (latent) (see Chapter 4 for detail). The majority 
consensus sequences of these two types of EBV genome were aligned using 
Base-by-Base (Brodie et al., 2004). Following removal of RDs, there was no 
difference between the latent and lytic EBV genomes in either JSC1 or HBL6 
cell lines. This indicates our method is robust and that there is no observable 
genetic variation in EBV genomes at the consensus level during lytic 
reactivation. The latent virus genomes of EBV from the BL cell lines Akata and 
Mutu were not sequenced, therefore the BL cell lines were not included in this 
analysis. 
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5.2.4. Non-Synonymous SNPs of cell lines distribute unevenly across the 
genome 
The hundreds of non-synonymous (NS)-SNPs in the EBV type 1 sequences 
show uneven distribution across the genome. Comparing the distribution of NS-
SNPs of the cell line sequences, it is clear that the distributions show a similar 
pattern between the three cell lines, especially between Daudi and JSC1 EBV 
sequences (figure 5.1). The amount of difference between the genomes 
suggests the reference genome is not representative, with EBV from JSC1 and 
Daudi revealing the unrepresentative regions. The Akata EBV genome showed 
a different NS-SNPs distribution. JSC1 and Daudi EBV sequences are more 
similar to the type 1 reference genome than the Akata EBV sequence. From the 
pattern of NS-SNPs distribution, it is clear that regions of the genome contain 
either higher numbers of NS-SNPs or no NS-SNPs, suggesting  there are 
regions that are more variable or conserved in the genome (figure 5.2).  
The EBV genomes of Daudi and JSC1 cell lines show no or low numbers of NS-
SNPs in certain regions across the genome, such as regions between BHRF1 
and BFRF1 genes, BLLF2 and BZLF1 genes, and BGLF4 and BGLF2 genes. 
The EBNA 3A, B, C and BZLF1 genes in the two genomes are identical to the 
reference gene. The majority of the highly polymorphic genes are located in the 
first 50% of the EBV genes (starting from the TR region at the 5’ end of the 
genome and excluding the W repeat region), such as at the BNRF1, EBNA2, 
BPLF1, BOLF1, BRRF2, EBNA1 and BBLF1 genes. The BLLF1 and BSLF1 
genes are also highly polymorphic in the EBV genome of Daudi origin, but not in 
that of JSC1 origin. EBNA2 is the major protein for determining the type of EBV, 
and differs by 55% in the protein sequences of the two EBV types. Here we 
show that within the same type of EBV genome the sequence of EBNA2 gene 
also varies. The EBNA1 gene is known to be highly polymorphic in the EBV 
genome, and has been studied extensively previously. Here we confirmed the 
highly variable nature of EBNA1 and showed more genes of the EBV genome 
that are highly polymorphic. It is unclear what selective pressures resulted in the 
conserved and variable genes and regions in the EBV genome or the functional 
significance of these polymorphisms.  
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Figure 5.1. Circos plot showing polymorphisms of EBV in PEL (JSC1,) and BL (Akata and 
Daudi) cell lines in comparison to the EBV type 1 reference genome. The outermost ring 
represents the reference genome, with the three inner rings representing Akata (yellow), Daudi 
(orange) and JSC1 (red) respectively. The lines in each of the three rings represent non-
synonymous (NS)-SNPs in the coding region, with the NS-SNPs located at the repeat regions 
removed prior to this analysis. The distribution of NS-SNPs shows a similar pattern in the EBV 
genomes of JSC1 and Daudi. There are clearly more NS-SNPs in the EBV genome of Akata, 
which shows a wider distribution of NS-SNPs across the genome.  
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!!
164 
 
 
 
Figure 5.2. Number and distribution of non-synonymous SNPs of EBV type 1 genomes from cell line samples: JSC1 (black) and Daudi (red), compared to the EBV type 1 
reference genome. The NS-SNPs occurring at the repeat regions have been discounted. The genes are listed in order on the EBV type 1 reference genome with the 
number of NS-SNPs on the Y-axis. The general distribution of NS-SNPs in these two cell lines are similar across the genome. Both the EBV of JSC1 and Daudi show 
regions of low variation (low or no NS-SNPs in the region), such as between BHLF1 and BFRF1 and between BLLF2 and BRLF1 (containing all the EBNA3 genes).  
!!
165 
5.2.5. Non-Synonymous SNPs distribution in PTLD samples 
We wished to determine if EBV genome variation could be observed over time 
in an infected individual. The study of the samples from the same PTLD case 
over four time points by full EBV genome sequencing (PTLD T1-4) is the first 
longitudinal EBV whole genome study. Over the two months period of sampling, 
a total of 682 SNPs occurred through the four consensus whole genomes with 
161 NS-SNPs resulting in amino acid changes when compared against the type 
1 reference genome. These NS-SNPs either occured only at one time point or 
at multiple time points. As with analysis of the EBV cell line sequences, the NS-
SNPs were not distributed evenly across the genome, but again show more 
conserved and variable regions of the genome (figure 5.3). The majority of the 
NS-SNPs occur in the first half of the genes starting from the 5’ end, excluding 
the RDs. In the EBV genome, BNRF1, EBNA2, BFRF2, BPLF1, BOLF2, BLLF1, 
BRRF2, EBNA1 and LMP1 were highly polymorphic, showing a similar pattern 
as the EBV genomes from cell lines. The distribution of the NS-SNPs in EBV 
sequences from the PTLD samples also shows highly conserved regions with 
little or no NS-SNPs. The distribution of S-SNPs follows similar pattern as the 
NS-SNPs; with few exceptions, such as BcLF1, which contains a high number 
of S-SNPs but very low number of NS-SNPs. 
Table 5.3 shows the number of SNPs occurring in each gene of the EBV 
genome of the PTLD EBV sequence. The SNPs occurring in the repeated 
regions have been removed prior to this analysis. The majority of the NS-SNPs 
occur at the genes encoding tegument proteins and glycoproteins. The 
tegument proteins and glycoproteins also contain a higher number of NS-SNPs 
(>five) (highlighted in orange), although EBNA1, 2, LMP1 and BFRF2 genes 
also contain >five NS-SNPs. Interestingly, EBNA2, which is the most highly 
variable gene between the EBV type 1 and 2 genomes, only contains 9 NS-
SNPs. The most highly polymorphic gene of the PTLD EBV sequence is 
EBNA1. Despite the fact that EBNA1 contains a large repeat region within the 
gene; there are 17 NS-SNPs within the non-repeat region of the gene. 
Subsequently, the second most polymorphic gene, BRRF2, contains 14 NS-
SNPs within the non-repeat region of the gene. The highly polymorphic 
phenotype of EBNA1 is the same as the EBV from cell lines and also has been 
observed previously (Bell et al., 2008); although it is the first time that other 
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genes especially the tegument and glycoproteins, have been also shown to be 
highly polymorphic in the genome. All the EBV genomes that have been 
sequenced from either PTLD or cell line backgrounds have shown that the 
majority of the variation occurs in the first half of the EBV genome (first half of 
the EBV genes starting from terminal repeat (TR)), although the reason and 
evolutionary pressure behind this phenotype is unclear.  
!!
167 
 
 
Figure 5.3. The NS-SNPs (black) and S-SNPs (red) distribution across the PTLD EBV genomes in comparison to the EBV type 1 reference sequence. The repeated 
regions have been removed from the genome prior the analysis. The number of NS-SNPs is on the Y-axis. The SNPs occurred at either a single time point multiple time 
points throughout the two month sampling period. This shows the uneven distribution of both NS and S-SNPs across the PTLD EBV genome. The genes are listed in order 
of the distance from the TR in the linear format. NS-SNPs occur more frequently in genes such as BNRF1, EBNA2, BFRF2, BPLF1, BOLF2, BLLF1, BRRF2 and EBNA1. 
The distribution of S-SNPs in the genome occur in a similar pattern to the NS-SNPs, with the exception of BcLF1 gene which encodes for major capsid protein, showing 
the highest number of S-SNPs. The distribution of SNPs also showed more variable (high number of SNPs) and conserved (low or no SNPs) regions of EBV genome.   
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Table 5.3. Details of the number of the NS-SNPs in each EBV gene of the PTLD whole 
genomes at either one or multiple time points throughout the 2 month sampling period. 
Genbank 
name Functions 
Number of 
NS-SNPs 
 
Number of 
S-SNPs 
LMP_2B Latent membrane protein 2A/B 2 2 
BNRF1 Tegument protein 9 14 
BCRF1_ Viral intreleukin (IL) 10 0 1 
EBNA_LP 
Glycoprotein L (Ubiquitin specific cystein 
protease) 0 0 
EBNA_2 
Glycoprotein L (Ubiquitin specific cystein 
protease) 9 5 
BHLF1 
Glycoprotein L (Ubiquitin specific cystein 
protease) 0 0 
BHRF1 Bcl-2 1 3 
BFLF2 Capsid maturation protein (AD169-UL53) 0 3 
BFLF1 DNA packaging protein (AD169-UL52) 3 6 
BFRF1A DNA packaging protein (AD169-UL51) 0 8 
BFRF1 Tegument protein (HHV4-BFRF1) 4 3 
BFRF2 Capsid protein (AD169-UL49) 8 2 
BFRF3 Capsid protein (C500-ORF65) 1 1 
BPLF1 Tegument protein 12 18 
BOLF1 Tegument protein (B95-8-BOLF1) 9 4 
BORF1 Assembly/DNA maturation protein 2 1 
BORF2 Ribonucleotide reductase large subunit 0 1 
BaRF1 (UL40) Ribonucleotide reductase small subunit 0 0 
BMRF1 DNApol processivity subunit (GammaHerpes) 0 0 
BMRF2 Unknown (B95-8-BMRF2) 0 1 
BSLF2_BMLF
1 Immediate-early phosphoprotein (B95-8-BMLF1) 0 0 
BSLF1 Helicase/primase complex (AD169-UL70) 3 1 
BSRF1 Unknown (AD169-UL71) 0 2 
BLLF3 dUTPase 1 0 
BLRF1 Envelope glycoprotein (AD169-UL73) 0 0 
BLRF2 Unknown (C500-ORF52) 0 1 
BLLF1 pp150 Tegument protein (AD169-UL32) 12 6 
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BLLF2 Unknown (B95-8-BLLF2) 4 0 
EBNA_3A HHV-4-B95_8-BLRF3 0 1 
EBNA_3B 
Glycoprotein L (Ubiquitin specific cystein 
protease) 0 0 
EBNA_3C 
Glycoprotein L (Ubiquitin specific cystein 
protease) 5 3 
BZLF2 Glycoprotein gp-12 0 1 
BZLF1 Immediate early protein 0 0 
BRLF1 Replication and Transcription activator 2 8 
BRRF1 Unknown (B95-8-BRRF1) 0 1 
BRRF2 
Glycoprotein L (Ubiquitin specific cystein 
protease) 14 11 
EBNA_1 Episome maintenance protein 17 8 
BKRF2 Glycoprotein L (GammaHV) 1 0 
BKRF3 Uracil-DNA glycosylase 1 3 
BKRF4 Immediate-Early Phase Viral Replication 0 0 
BBLF4 Helicase/primase complex (AD169-UL105) 5 17 
BBRF1 DNA packaging protein (AD169-UL104) 2 9 
BBRF2 Unknown (AD169-UL103) 1 2 
BBLF2_BBLF3 DNA helicase/primase complex (C500-ORF40) 2 10 
BBRF3 Glycoprotein M 1 1 
BBLF1 Myristylated virion protein (AD169-UL99) 0 0 
BGLF5 DNase 1 0 
BGLF4 Serine/threonine protein kinase 0 1 
BGLF3_5 Unknown (C500-ORF35) 1 0 
BGLF3 Unknown (AD169-UL95) 1 5 
BGRF1_BDRF
1 DNA packaging protein/terminase (AD169-UL89) 0 5 
BGLF2 Tegument protein (AD169-UL94) 0 3 
BGLF1 DNA packaging protein (B95-8-BGLF1) 1 2 
BDLF4 Unknown (AD169-UL92) 0 0 
BDLF3_5 Unknown (C500-ORF30) 1 0 
BDLF3 pp150 Tegument protein (AD169-UL32) 3 4 
BDLF2 Intercellular Viral Spread 0 2 
BDLF1 Capsid triplex protein 0 7 
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BcLF1 Major capsid protein (AD169-UL86) 2 27 
BcRF1 Unknown (AD169-UL87) 2 2 
BTRF1 Unknown (B95-8-BTRF1) 1 0 
BXLF2 Glycoprotein H 0 0 
BXLF1 Thymidine kinase 0 0 
BXRF1 Fusion protein (AD169-UL76) 0 0 
BVRF1 DNA packaging protein (AD169-UL77) 0 0 
BVLF1 Unknown (AD169-UL79) 0 0 
BVRF2 Proteinase/capsid scaffold protein (AD169-UL80) 0 4 
BdRF1 Proteinase/capsid scaffold protein (AD169-UL80) 0 3 
BILF2 Unknown (B95-8-BILF2) 0 2 
LF3 
Glycoprotein L (Ubiquitin specific cystein 
protease) 0 0 
LF2 Unknown (C500-ORF11) 0 0 
LF1 Unknown (C500-ORF10) 4 3 
RPMS1 HHV-4-WT-RPMS1 0 0 
BILF1 Putative G-protein coupled receptor (C500-A5) 1 5 
BALF5 DNA polymerase catalytic subunit 2 7 
BALF4 Glycoprotein B 3 8 
A73 HHV-4-WT-A73 0 1 
BALF3 DNA packaging protein (AD169-UL56) 2 2 
BARF0 Unknown (HHV4-WT-BARF0) 2 0 
BALF2 ssDNA binding protein 1 4 
BALF1 Unknown (B95-8-BALF1) 0 0 
BARF1 Unknown (B95-8-BARF1) 1 3 
LMP_2A Latent membrane protein 2A/B 2 0 
BNLF2b Unknown (B95-8-BNLF2b) 2 1 
BNLF2a Unknown (B95-8-BNLF2a) 2 0 
LMP_1 
Glycoprotein L (Ubiquitin specific cystein 
protease) 7 7 
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5.2.6. EBV evolution in a PTLD patient 
The NS and synonymous (S)-SNPs of the PTLD EBV genome sequences have 
show uneven distribution, with the EBNA1 gene being the most highly 
polymorphic gene in the PTLD EBV genome in comparison to the reference 
genome. As the four PTLD samples were taken over two months, we decided to 
investigate the variation these samples accumulated through time. Figure 5.4 
shows both the NS-SNP (red line) and S-SNPs (black line) in CDS, that 
occurred compared with only the previous time point, not the reference genome. 
Despite the short time between samples, changes are observed throughout the 
two months. The largest amount of variation occurs between T1 and T2, despite 
the samples being taken only two weeks apart (table 5.1), with seven NS-SNPs 
occurring between these two sequences. The viral load of these two samples 
also showed the largest increase over the four time points. The lowest number 
of SNPs in CDS occurred between T3 and T4, with only one NS-SNP occuring. 
This is not surprising since the two samples were taken only four days apart. 
However, variability of EBV sequences over such short period of time is 
interesting. Throughout these four time points of PTLD sampling, the SNPs 
occured in similar regions of EBV genome, possibly indicating higher selective 
pressure on different genes. 
Despite EBNA1 gene being the most polymorphic gene in EBV genome, when 
comparing EBV genomes of PTLD and cell lines with the reference genome; it 
is not the gene with the highest variation rate over time. When we investigated 
the changes of genes through time, EBNA1 remains relatively constant in the 
two months of PTLD sampling (figure 5.4), showing little variation through time 
when compared to the sequence at the previous time point. The majority of the 
NS-SNPs between two time points of sampling occurred in the BOLF1 gene, 
with six NS-SNPs between T1 and T2, three NS-SNPs between T2 and T3 and 
one NS-SNP between T3 and T3 (table 5.4). A total of nine NS-SNPs occur 
over time and are located in the BOLF1 gene. Notably, at location 61412, the 
nucleotide changed from C at T1, to A at T2 and back to C at T3, resulting in 
the codon changing from glutamic acid to a stop codon and back, suggesting 
that the mutation introduced at T2 may be selected against and therefore 
reverts back to the original nucleotide. BOLF1 encodes for a tegument protein 
with the function being unclear, although it is suspected that it is involved in 
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virus assembly and budding. BOLF1 also shares homology with the HLA-DQw8 
beta chain (Sairenji et al., 1991). The total number of NS-SNPs that occurred 
reduced through time, indicating the rate of variation, slowed towards the end of 
sampling period. However, since the study only consists of one patient over a 
two month period, it is difficult to be confident about the alteration of the 
genome variation rate over time of EBV genome. 
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Figure 5.4. Circos plot representing the SNPs occurring between the time points for the PTLD 
patient. The red lines represent non-synonymous changes, and the black lines represent 
synonymous changes. The outer ring represents the reference type 1 EBV genome, and the 
second ring represents the SNPs between time point 1 (T1) and 2 (T2), the third ring represents 
the SNPs between time point 2 (T2) and 3 (T3). The most inner ring represents the SNPs 
between time point 3 (T3) and 4 (T4). The SNPs in the repeated region should be treated with 
caution since the coverage in these regions is low. 
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Table 5.4. The NS-SNPs occuring over time in the PTLD patient, showing the nucleotide change and the resulting amino acid change. 
Location Gene PTLD T1 PTLD T2 PTLD T3 PTLD T4 
  Nucleotide Amino acid Nucleotide Amino acid Nucleotide Amino acid Nucleotide Amino acid 
59336 BOLF1 G Aspartic acid A Tyrosine     
60452 BOLF1 G Proline A Serine     
60484 BOLF1 C Glycine A Valine     
61054 BOLF1 C Glycine A Valine     
61412 BOLF1 C Glutamic acid A Stop     
62653 BOLF1 A/G 
Aspartic acid/ 
Alanine G Alanine     
40031 BHLF1   A Leucine C Arginine   
61412 BOLF1   A Stop C Glutamic acid   
96649 EBNA1   A Serine G Glycine   
61573 BOLF1     T Glutamic acid C Glycine 
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5.2.7. Polyclonal origin of EBV in blood samples of PTLD patients 
Previous studies have shown that EBV in PTLD blood samples can be either 
poly- or oligoclonal in origin, with a very low probability of being monoclonal 
(Anderlini et al., 2004). We have assembled the majority consensus sequence 
from the blood samples of PTLD patients where any nucleotide over 50% of the 
post QC reads is called as the majority nucleotide. SNP calling can only 
therefore show the change in majority base over time. This masks fluctuations 
in minority nucleotides which may also be informative. Minority viral variants 
have been shown to be important in RNA viruses, which have been associated 
with disease progression, treatment failure and viral evolution (Vignuzzi et al., 
2006; Zagordi et al., 2010). However, the minority nucleotide variants in DNA 
viruses have not been extensively studied. 
Therefore we determined the changes in nucleotide frequency over time at the 
NS-SNPs that occurred on the EBV genome sequence from PTLD samples. 
Here we define the occurance of minor nucleotide being if it exceeds 5% of total 
reads at any time point. Figure 5.5 shows six examples of the minority 
nucleotide changes over time for the EBV genome. A total of ten locations with 
fluctuations in percentage of nucleotide expression were observed at any time 
point. The six examples shown were chosen as they have reads covering the 
genome position at all four times. The appearance of minority nucleotides 
occurred in the EBNA2, BOLF1, LMP1 and EBNA1 genes. These four genes 
have been shown to be highly polymorphic when compared to the reference 
genome, with BOLF1 not only highly polymorphic but also having the highest 
mutation rate. Figure 5.5.A and B, both located in the EBNA2 gene, showed the 
abundance of minority species increasing over time. Figure 5.5.C, D, and E are 
located in the BOLF1 gene. Figure 5.5.C shows fluctuation of percentage of 
minority species over time, with Figure 5.5.D, E and F showing abundance of a 
minor species at only one point and then not at other three. 
 
 
 
 
 
!!
176 
 
 
 
Figure 5.5. Minority species and the alteration of nucleotide abundance at different time points 
in the EBV PTLD genomes. Black bars represent the nucleotide in the reference sequence and 
white bars represent the alternative nucleotide in the samples sequenced. A base is called as a 
majority consensus sequence when the percentage of the nucleotide is over 50%. A) and B) 
both located in the EBNA2 gene, both show increase of nucleotide guanine (G) and adenine (A) 
expression respectively over time, but not sufficiently to alter the base calling. The large 
expression of thymine (T) in A) results in the amino acid changing from methionine to 
iosleucine, and in B) results in serine instead of Threonine. C), D) and E) are located in the 
BOLF1 gene, in C), the expression of G increased at T2, and caused the amino acid to change 
from serine to proline, and although the percentage of G flunctuate at T3 and T4, it remains 
over 50% of nucleotides in the sample. In D), expression of cytosine (C) at T1 caused the amino 
acid to change from valine to glycine, however, at T2,3 and 4, the expression of C cannot be 
detected. In E) a similar situation as D) occurred only the abundance of A is 50%, therefore 
there were 50% aspartic acid. At the later time point, the abundance of G returns to 100%, the 
amino acid remaining Alanine. F) is in the EBNA1 gene, with expression of A introduced at T2 
and causing the amino acid change from glycine to arginine. 
 
A B C 
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5.2.8. Phylogenetic analysis of whole EBV genomes and coding regions of 
the genome 
With the EBV whole genome sequences assembled from different diseases 
backgrounds, it is interesting to see the phylogenetic relationship using whole 
genomes. A total of 11 majority consensus sequences were assembled from 
PEL, BL and PTLD samples, with the additional five assembled at WTSI, from 
PEL and saliva samples (table 5.5). These included both type 1 and type 2 EBV 
genomes. Combined with the EBV whole genome sequences available from 
GenBank: GD1 and GD2, both of NPC origin and two reference EBV genomes, 
there are total 20 EBV sequences for analysis (table 5.5). As previously 
described, the EBV majority consensus sequence was assembled against 
either EBV type 1 or type 2 reference genome from GenBank, which is 
determined on the percentage of the reads that have been successfully mapped 
back to the reference genome. All EBV from the saliva samples, JSC1, Akata, 
Daudi, PTLD T1-4 were assembled to the EBV type 1 reference genome, with 
GD1 and GD2 from GenBank also being type 1 EBV. HBL6, BC1 and PTLD 
2035 EBV genomes have been assembled to the EBV type 2 reference 
genome. 
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Table 5.5. EBV samples in phylogenetic study. Genomes 1-16 were generated using NGS, with 
genomes 17-20 from Genbank. 
 
 
 Name EBV type Disease associated 
1 JSC1 SN 1 PEL 
2 JSC1 Lysate 1 PEL 
3 HBL6 SN 2 PEL 
4 HBL6 Lysate 2 PEL 
5 BC1 2 PEL 
6 Akata 1 BL 
7 Daudi 1 BL 
8 PTLD 2035 2 PTLD 
9 PTLD T1 1 PTLD 
10 PTLD T2 1 PTLD 
11 PTLD T3 1 PTLD 
12 PTLD T4 1 PTLD 
13 Saliva 5 1 N/A 
14 Saliva 5G 1 N/A 
15 Saliva 7 1 N/A 
16 Saliva 7G 1 N/A 
17 GD1 1 NPC 
18 GD2 1 NPC 
19 EBV reference 1 1 IM and BL 
20 EBV reference 2 2 BL 
 
Repeat regions were removed and several methods were used to construct the 
phylogeny of the whole EBV genome (WG tree). Firstly, the Bayesian skyline 
coalescent model (Drummond & Rambaut, 2007; Drummond et al., 2005) 
(referred to as Bayesian model) is used, which was regarded as the model with 
least restriction. The most suitable heterogeneity site model was first examined 
using JModelTest (Posada, 2008), and GTR substitution model with both 
gamma and invariant heterogeneity model were used for the analysis. Two WG 
trees were built using either relax longitudinal or exponential clock models, with 
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the sampling length ranging between 20 and 50 million. We also generated a 
distance based tree using neighbour joining phylogeny, which is a bottom-up 
clustering method generating an unrooted tree if no out-group is used. All 
methods generated the same tree structure. Figure 5.6.A shows the WG 
phylogenetic tree constructed by Bayesian method, using relax longitudinal 
model. Recombination between the samples was also examined using RDP3; 
however we could find no consistent evidence of recombination within these 
samples. 
It has been reported that in HCMV variation occurs in higher rate at the CDS 
region in comparison to the non-CDS region (Renzette et al., 2011). We have 
observed a higher number of SNPs at the CDs in comparison to the non-CDS 
region in EBV genomes from both cell lines and PTLD samples. Another 
phylogenetic tree was constructed using the same method, but with coding 
region only (repeats removed) sequences from the 20 whole genome 
sequences. The location of the coding region is determined via the annotation 
of the EBV type 1 reference genome in GenBank. The EBV type 2 reference 
genome contains only 82 genes in comparison to the type 1 reference genome 
in Genbank; however, the CDS sequence of the type 2 samples were generated 
using annotation of EBV type 1, since the annotation of the repeated regions 
and CDS of type 2 are not as extensively studied. 
Figure 5.6.B shows the coding regions only of the EBV genomes phylogenetic 
tree (refer to as the CDS tree), constructed using the same methods as the WG 
tree. These two trees show the same grouping of the EBV genomes. Two major 
clades separate EBV type 1 and EBV type 2 samples. In the type 2 clade, 
unsurprisingly, BC1 EBV shows close association with HBL6 EBV sequences. 
BC1 and HBL6 are two independently established PEL cell lines from the same 
PEL tumor (Cesarman et al., 1995b; Gaidano et al., 1996). This further 
illustrates the robustness of our sequencing and analysis pipeline. In the type 1 
clade, there is no evidence of EBV sequences grouping by the disease. EBV 
sequences from saliva samples are in the same clade as EBV from PEL, BL 
and PTLD. GD1 and GD2 sequences show higher diversity and are clustered 
away from rest of the type 1 sequences, but together with the Akata EBV 
sequence. The Akata cell line is derived from tumour cells of a Japanese BL 
patient (Takada, 1984; Takada et al., 1991). Notably all three GD1, GD2 and 
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Akata EBV genomes were derived from samples originated from Asia, with GD1 
and GD2 derived from Chinese patients with NPC, suggesting the possibility of 
geographical association in this clade.  
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Figure 5.6. Phylogenetic tree of EBV A) whole genome sequences with no repeat regions, B) EBV CDS post removing the repeats. The tree is constructed using Bayesian 
skyline coalescent model, with relax longitudinal clock rooting of the tree. The EBV type 2 sequences: HBL6, BC1, PTLD 2035 and the type 2 reference genomes cluster 
together, away from other EBV type 1 sequences samples. For the EBV type 1 samples, there is no clear pattern of EBV sequences according to the type of diseases 
caused, especially with Akata within the same clade as GD1 and GD2. However, the numbers of samples is too small to draw any firm conclusion. PTLD samples T1 to T4 
shows progression in time, with T1 differing more than the other three samples. (SN = supernatant). The divergence scale (indicating numbers of substitution per site) is 
shown at the bottom of the tree. 
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5.2.9. Validation of the majority consensus sequence via PCR and Sanger 
capillary sequencing  
To validate the majority consensus sequence (MCS) assembled by QUASR v7, 
Sanger capillary sequencing (SCS) was carried out to sequence several regions 
across the EBV genome. The result of SCS was then compared to the MCS. 
Regions across two sections of BRLF1 gene, and one section each from 
BMRF1, BZLF1 and BDLF3.5 genes were cloned and table 5.6 shows the 
number of mis-matches between these two groups of sequences in these 
regions. SCS was also used to validate the EBV MCS of the PTLD samples 
across the EBNA2 gene. However, only PTLD T1 and T3 samples were 
sequenced due to the small volume of the original samples.  
 
Table 5.6. Numbers of mis-matched bases between the majority consensus sequence and the 
PCR sequence. 
 BRLF1 BMRF1 BZLF1 BDLF3.5 EBNA2 
  section 1 section 2         
Daudi 0 0 N/A 0 0 N/A 
Akata 0 1/843  0 29/611 0 N/A 
HBL6 0 0 0 0 0 N/A 
JSC1 0 N/A N/A 0 0 N/A 
PTLD T1 N/A N/A N/A N/A N/A 0 
PTLD T3 N/A N/A N/A N/A N/A 0 
 
For the cell line samples, a single clone of the PCR product was Sanger 
capillary sequenced (only one colony was picked for the cell line samples). 
There were no mis-matches between the DNA sequences generated by either 
SCS or MGC in EBV genomes of Daudi, HBL6 and JSC1 cell lines. However, 
there was a mis-match at the BRLF1 region that had been sequence in the EBV 
genome from the Akata cell line. The PCR product contains 843 bases of DNA 
sequence cloned from the supernatant of Akata cell line. The PCR sequence 
differs from the MCS by 1 substitution. Further inspection of the VarScan 
analysis of the MCS at the particular base indicates no minority population and 
adequate coverage.  
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Another difference between the SCS and MCS sequences also occurred in the 
Akata EBV genome, over the region of the BZLF1 gene (table 5.5). A total of 
611 bases of BZLF-1 were sequenced, and the cloned PCR sequence showed 
a 29bp insertion (figure 5.7). The BZLF1 gene consists of three exons and one 
intron, which contains a section of 29 bps repeats. Previous studies have shown 
that there are three copies of the 29bp repeats in the EBV of Akata cell lines, 
with only two copies in the B95.8 cell line. B95.8 forms the majority of the EBV 
reference genome (Packham et al., 1993). The primers designed to clone the 
BZLF1 region cover the intron including the repeats. This highlights a known 
problem in reference-based NGS assembly. As the majority consensus 
sequence of Akata EBV was produced by assembly against the EBV type 1 
(B95.8) reference genome, the mapping algorithm assigns the number of 
repeats of the reference genome, (two copies of the 29 bps repeats), rather 
than the correct number of repeats as determined by SCS, namely three 
repeats.  
Regions of the EBNA2 gene of PTLD T1 and T3 were also been cloned and 
sequenced by SCS. There were no mis-matches between the cloned sequence 
and the MCS of PTLD T1 and T3. Together this shows generating EBV 
consensus sequence from the Next Generation Sequencing product by 
reference based mapping has been effective and representative, but that care 
should be taken interpreting repeats in the genome.  
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Figure 5.7. Comparison between regions of majority consensus sequence (MCS) and the 
cloned PCR product sequence of the EBV from Akata cell line. MCS contains two copies of the 
29 bp repeats which resemble the EBV type 1 reference genome, with the PCR product 
showing three copies of the repeats. The difference was due to the reference based mapping 
method. MCS was constructed by mapping the NGS read pairs back to the B95.8 reference 
genome, therefore the number of repeats in the MCS is restricted to be the same as the 
reference genome, and does not represent the real number of repeats in the genome.  
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5.3. Conclusions 
EBV whole genome analysis has not been possible previously due to a lack of 
whole genome data and a robust and cheap method to generate whole 
genomes. As discussed in Chapter 4, a pipeline has been developed which 
allows sequencing of EBV whole genomes from various types of samples using 
Next Generation Sequencing. So far, we have successfully sequenced and 
assembled EBV genomes from both cell lines and blood samples, and of both 
EBV type 1 and type 2. 
Here, we investigate the difference between the EBV genomes. First EBV 
genomes from latency and the lytic cycle have been sequenced from both JSC1 
and HBL6 cell lines, both are PEL cell lines dually infected with KSHV and EBV. 
The EBV genomes, with the repeated region of the genome removed, show 
100% consistency between the latent and lytic cycle EBV sequences. This 
shows our method is robust and suggests that the EBV episomes in both cell 
lines are clonal.  
The numbers of SNPs in EBV genomes across different types of samples were 
examined. SNPs occur every 170-360bp on average, with between 26-30% of 
the SNPs being non-synonymous. Interestingly, all the samples show similar 
locations of the NS-SNPs. Further analysis of the non-synonymous SNPs with 
the PTLD EBV samples showed a more uneven distribution across the genes. 
The majority of the NS-SNPs for the PTLD EBV sequence occured at the 
tegument and glycoprotein encoded genes, with EBNA1, 2 and LMP1 genes 
also polymorphic. However, EBNA1 contained the highest number of NS-SNPs 
in the genome of both the PTLD and three EBV sequences from cell lines, 
indicating major diversity in EBNA1 genes. EBNA1 is a DNA binding protein 
responsible for maintaining episomal DNA during cell division, previously shown 
to be highly polymorphic. During latency I, EBNA1 was the only viral protein 
expressed. EBNA1 contains a central repeat region composed of glycine-
alanine repeats (GAr), which inhibits cytotoxic T lymphocyte (CTL) immune 
responses. The EBNA1 GAr domain inhibits proteasomal degradation of the 
EBNA1 protein (Levitskaya et al., 1995) although the mechanism is unclear. 
EBNA1 also inhibits CTL peptide antigen processing, with GAr domain delaying 
the translation of EBNA1 and increasing the stability and reducing unfolded 
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protein turnover (Yin et al., 2003). Further investigation of the mutations in the 
EBNA1 gene in the one PTLD is required to understand their cause. It is 
possible that immune deficiency in PTLD allows CTL escape variants to 
replicate that would normally be actively controlled. The EBV whole genome 
sequenced from PTLD patients were from blood samples, it would be 
interesting to see the EBV whole genome sequences in the PTLD tumour tissue 
sample. Other highly polymorphic genes from EBV genomes include the 
BFLF2, BNRF1, EBNA2, BPLF1 and BOLF1 genes. The functions of the 
majority of these genes are unknown and further investigation is required to 
understand the relationship between the genes and polymorphisms. BNRF1 
encodes a tegument protein, and has been shown to activate early viral gene 
transcription (Lopez et al., 2005), and also to allow efficient transfer of the viral 
DNA from endosomal compartments to the nucleus in B-cells (Tsai et al., 2011). 
However, it is unclear what the effect of the variations of BNLF1 are on its 
function. BPLF1 shares structure homology with HSV1 VP16 protein which is a 
structural tegument component and is important for HSV replication and a trans-
activator of viral immediate-early genes (Schmaus et al., 2004). HSV VP16 
protein forms a transcriptional regulatory complex with two cellular proteins: 
Oct-1, a POU-domain transcription factor, and HCF-1, a cell-proliferation factor 
upon infection, to activate the transcription of the first set of expressed viral 
genes (Wysocka & Herr, 2003). Recent studies have suggested that Oct-1 
interacts with EBV BRLF1 protein and acts as a positive regulator of EBV lytic 
gene expression (Robinson et al., 2011). Another POU-domain transcription 
factor Oct-2 has also been shown to maintain EBV latency by inhibiting EBV 
BZLF1 activation, possibility via direct binding to the BZLF1 protein (Robinson 
et al., 2012). It is possible that BPLF1 gene, through sharing functional similarity 
to HSV VP16, also plays important role in EBV reactivation and infection. 
We also investigated the changes of EBV sequences in a PTLD patient over a 
two month period. There has been no previous study showing the changes of 
EBV genome sequences through time. The EBV whole genomes assembled 
are the majority consensus sequences, where SNPs are called when there is a  
100% change of base relative to the reference. We also examined the alteration 
of relative nucleotide levels between different EBV samples. EBNA1 and other 
highly polymorphic genes remain constant and do not change much over the 
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two month period of sampling. The BOLF1 gene that encodes a tegument 
protein is the most variable gene through the time course. The function of the 
BOLF1 gene is unclear, although it is suspected that the protein is responsible 
for virus assembly and budding. The reason for a high variation rate of one 
gene is not known. 
After closer examination of the PTLD majority sequences over time, we have 
also observed alteration in the percentage of nucleotides present as NS-SNPs, 
indicating changes in minority species over time. The majority of the minority 
species of NS-SNPs occur in the BOLF1 gene. Since EBV is polyclonal in most 
of the PTLD patients, the alteration of minority species provides evidence of 
virus evolution throughout disease progression. The variation in minority 
species could also indicate the polyclonal virus population in the PTLD blood 
samples. However, with EBNA1 being the most polymorphic gene in the EBV 
genome, and remaining constant in this study, this suggests the variation of 
minority species in PTLD blood samples is due to evolutional pressure other 
than changes of virus population. However, further analysis of minority species 
in PTLD patients is required and since the samples were processed with WGA 
and also SureSelect process prior to NGS, it is unclear if these combined 
processes introduced a bias.  
Phylogenetic trees have been constructed based on both whole genome and 
the CDS sequences. In both cases the phylogeny is identical and shows distinct 
separation between EBV type 1 and type 2 sequences. No clear separation 
relating to EBV disease can be seen from the tree, indicating no evolutionary 
differentiation of EBV genomes leading to different malignancies. However, the 
numbers of samples are too small for any firm conclusions. Liu et al., (2011) 
had shown that for the EBNA1, BZLF1 and LMP1 genes, GD1 and GD2 
consistently clustered together and share the same ancestor as the AG876 EBV 
sequence (EBV type 2 reference genome). Here we show that using every CDS 
of the EBV genomes, GD1 and GD2 indeed cluster together, but are more 
closely related to EBV type 1 genomes than the EBV type 2 reference genome. 
The close grouping between GD1, GD2 and Akata EBV genomes in the 
phylogenetic tree, although not indicating the association of EBV genomes 
according to the type of disease, does suggest grouping by geographical origin. 
The Akata cell line was derived from a Japanese patient with BL, with both GD1 
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and GD2 sequenced from Chinese patients with NPC, these three EBV 
genomes therefore represent EBV originating from Asia. Further studies with 
more EBV sequences from different diseases and different geographical 
regions is required to understand more about the relationship between the virus 
and the diseases it is associated with. 
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Chapter 6 
General Discussion 
EBV is one of the most widely distributed virus infections with 95% of the world 
population infected. EBV is linked to several different types of diseases, but little 
is known about virus reactivation in vivo and the diversity of whole EBV genome 
sequences. 
The different latent and lytic cycles are one of the most important features of the 
herpesvirus life cycle. Latency allows EBV to remain hidden from the immune 
system and maintain a persistent infection, whilst lytic replication allows viruses 
to amplify and infect more target cells. The balance between these two phases 
is maintained and facilitated by many cellular factors to ensure the virus only 
reactivates under the correct conditions.  
B-cell terminal differentiation into plasma cells has been associated with the 
reactivation of gamma herpesviruses. XBP-1, a transcriptional factor that is 
important for the UPR response during plasma cell differentiation has been 
shown to transactivate the ORF50 promoter and initiate the lytic cycle of KSHV 
(Dalton-Griffin et al., 2009; Wilson et al., 2007). Reactivation of other 
herpesviuses have also been linked to plasma cell differentiation, such as the 
murine gamma-herpesvirus 68 (Collins et al., 2009) and EBV (Laichalk & 
Thorley-Lawson, 2005). However, studies on EBV lytic reactivation by XBP-1s 
have shown different results, with XBP-1s alone apparently able to transactivate 
the EBV BZLF1 gene and induce the lytic cycle (Sun & Thorley-Lawson, 2007); 
in contrast to another study indicating that XBP-1s requires PKD to be able to 
induce EBV BZLF1 protein expression and initiate the EBV lytic cycle (Bhende 
et al., 2007). 
Here we have shown that XBP-1s does not transactivate EBV IE gene 
promoters and does not induce BZLF1 or BRLF1 mRNA and protein 
expression, with or without PKD expression in tumour cell lines. The chemical 
inducing agents TPA and NaB are able to induce EBV lytic reactivation; 
however, they do not do so by inducing XBP-1 splicing in B-cells. Multiple 
myeloma cell lines constantly express XBP-1s, and in a recent study 
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superinfection of multiple myeloma cell lines by EBV showed no signs of 
constant lytic replication of EBV (Anastasiadou et al., 2009). These results all 
indicate that XBP-1s expression does not induce EBV lytic reactivation in B-
cells, contradicting the previous literature. The differences could be due to the 
cell type used in the experiments, and also the different strains of XBP-1s. 
Murine XBP-1s were used in previous studies (Bhende et al., 2007; Sun & 
Thorley-Lawson, 2007), whereas human XBP-1s were used in this PhD study. 
EMSA were performed previously to identify the putative XBP-1s binding site on 
the Zp (Sun & Thorley-Lawson, 2007). Two putative binding sites Zp1 and Zp2 
were identified using computational program, with Zp1 showing interaction with 
XBP-1s in the EMSA.  However, Zp1 does not contain a similar sequence to the 
XBP-1 binding site on KSHV RTA promoter, whereas Zp2 shows homology.  A 
CpG motif was identified in the Zp2 region. Zp does not interact with BZLF1, the 
protein that is able to self-activate, unless in the methylation status. The 
methylated state of Zp therefore is a factor in reactivation and may be the 
reason for the XBP-1s binding site in Zp being non-functional. 
EBV has been associated with many different types of diseases. However, the 
whole genome sequences of EBV in both disease and health have not been 
studied. As with all other viruses it is important to study the diversity of the EBV 
genome across different diseases and geographical areas. Whole EBV genome 
sequencing has been difficult to carry out due to the nature of host DNA 
association of gamma herpesvirus. We have used the Agilent SureSelect 
enrichment system to enrich the viral DNA and remove the non-viral DNA from 
the samples. A pipeline to sequence EBV using NGS and computational 
assembly of the majority consensus sequence has been established, allowing 
faster and cheaper methods of generating EBV whole genome sequences. In 
this thesis, we have generated the majority consensus sequences of EBV from 
BLs and PEL cell lines and from clinical blood samples from PTLD patients. 
Here we have shown that the EBV genome contains more variation than 
previously recognised. DNA viruses have not been linked to a high rate of 
variation; however, we have shown that the SNPs in EBV occur every 170-
360bp within the genome, excluding the repeat regions. With the high variation 
between the genomes, it is debatable that the current reference sequence of 
EBV is the best representative of the virus genome. The non-synonymous 
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SNPs of EBV occur mostly in the glycoprotein and tegument proteins, although 
also in EBNA1, 2 and LMP1 genes. The EBNA1 gene is known to contain high 
amount of variation, and here we also shown it contains the highest amount of 
non-synonymous SNPs in different EBV majority consensus genomes. The 
effect of the SNPs in the EBNA1 gene is unclear. Other highly polymorphic 
genes that have not been identified previously include BOLF1, BPLF1 and 
BNRF1. BPLF1 shares structural similarity with HSV VP16 protein, which is 
important for HSV replication and transactivates the HSV IE gene. BNRF1 has 
recently been shown to activate early viral gene transcription and allows viral 
DNA to be transferred from the endosomal compartment to the nucleus. BOLF1 
has been shown to be highly polymorphic in both EBV from cell lines and also 
PTLD samples, and also has a high mutation rate over the two months of the 
longitudinal EBV study. However, little is known about BOLF1 and the role it 
plays in the EBV life cycle and infectivity is unclear.  
The phylogenetic study shows no clear association between the EBV 
sequences and their associated disease, despite a clear separation between 
type 1 and type 2 EBV genomes. The EBV genomes originating in Asia form a 
sub-group within the EBV type 1 clade, indicating a possibility of geographical 
clustering. However, the sampling number and geographical origin is too small 
to draw any firm conclusion from the study.  
EBV whole genome sequences analysis has shown interesting variations 
throughout the genome. The variations highlighted in this study serve as a 
beginning of understanding EBV evolution and the difference between EBV 
populations in different geographical regions and diseases.  
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Chapter 7 
Future Experiments 
The thesis can be divided into two sections, in the first section we have 
examined the reactivation of EBV in the tumour B-cell background and in the 
second section we have developed a pipeline of sequencing EBV whole 
genome sequence using Next Generation Sequencing and investigated 
variation of between EBV genomes. 
Further investigation of EBV reactivation in mature B-cells is required to 
understand the process fully. A recent study has shown ER stress induces EBV 
reactivation (Taylor et al., 2011). During terminal differentiation, the germinal 
centre B-cells expand the secretary apparatus in preparation for producing large 
amount of antibodies, which induce ER stress. Other cellular factors involved in 
the ER stress response should be investigated in relation to EBV reactivation. 
TPA can reactivate both KSHV and EBV in B-cells into the lytic cycle via an 
XBP-1 independent pathway since TPA does not induce XBP-1 splicing. Recent 
studies have shown TPA dependent KSHV reactivation uses MEK/ERK, JNK 
and p38 signally pathways (Ford et al., 2006; Xie et al., 2008). As TPA also 
induces EBV reactivation, it would be interesting to carry out further 
investigations on these pathways and their effect on EBV reactivation. 
EBV can be induced into lytic reactivation by histone deacetylate inhibitors such 
as sodium butyrate and valporic acid. MEF2D is known to recruit type II histone 
de-acetylase to the Zp and prevent EBV reactivation. Oct-2, a POU family 
protein has also recently been shown to be important for maintaining EBV 
latency in B-cells. It would be interesting to investigate if EBV sould enter lytic 
replication if these two proteins were disrupted, which could be achieved by 
knocking down these two proteins by using RNA interference (RNAi).  
The second part of the thesis concentrates on the EBV whole genome 
sequencing. A pipeline of generating EBV whole genome majority consensus 
sequence has been established in this thesis. This pipeline can be used to 
generate large numbers of EBV whole genome sequences. However, there are 
several aspects of this pipeline that can be improved. We have shown that 
using the SureSelect system allows us to capture the target EBV DNA 
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fragments successfully. With more understanding of the EBV genome, the 
probes used in the capturing process could be re-designed to ensure higher 
efficiency. The WGA process has been shown to bias towards amplifying host 
DNA and therefore this step should be removed from the pipeline. Samples with 
low DNA content should either be processed by hand or using a carrier DNA to 
increase the total DNA content of the sample, which would allow the samples to 
be processed in the SureSelect procedure. 
Currently the EBV whole genome is assembled against the reference 
sequences, resulting in a majority consensus sequences. Further investigation 
of compiling these sequences using de novo assembly is required, and the 
comparison between these two methods is necessary to ensure the accuracy of 
the EBV sequences. 
With the highly variable EBNA1 genes from the PTLD samples, further analysis 
of the protein structure is required to understand, firstly if the variations alter the 
ability of EBNA1 to bind DNA, and therefore affect its ability of associating EBV 
episome with human DNA; and secondly if the variations affect the ability of 
EBNA1 to evade immune surveillance. Further investigation of the two genes 
that vary the most during the PTLD time series study are also needed, 
especially the BPLF1 and BOLF1 genes. Since BPLF1 shares structural 
homology with the HSV VP16 protein, it would be interesting to investigate the 
high rate of variation over time. Since limited studies have been carried out, 
further investigation of BPLF1 and the role it plays in EBV reactivation are 
required, especially its association with Oct-1. Limited studies have also been 
carried out on the BOLF1 gene, which encodes for a tegument protein. Since 
the BOLF1 gene shares structural homology with HLA-DQw8 beta chain, it 
would be interesting to further investigate the role of BOLF1 in host immune 
response.  
To understand the link between EBV whole genome variation and the diseases 
associated with EBV, more EBV genome sequences from different diseases 
and healthy individuals in different geographical regions are needed. 
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Cells of primary effusion lymphoma (PEL), a B-cell non-Hodgkin’s lymphoma, are latently infected by
Kaposi’s sarcoma-associated herpesvirus (KSHV), with about 80% of PEL also co-infected with
Epstein–Barr virus (EBV). Both viruses can be reactivated into their lytic replication cycle in PEL by
chemical inducers. However, simultaneous activation of both lytic cascades leads to mutual lytic
cycle co-repression. The plasma cell-differentiation factor X-box binding protein 1 (XBP-1)
transactivates the KSHV immediate–early promoter leading to the production of the replication and
transcription activator protein (RTA), and reactivation of KSHV from latency. XBP-1 has been
reported to act similarly on the EBV immediate–early promoter Zp, leading to the production of the
lytic-cycle transactivator protein BZLF1. Here we show that activated B-cell terminal-differentiation
transcription factor X-box binding protein 1 (XBP-1s) does not induce EBV BZLF1 and BRLF1
expression in PEL and BL cell lines, despite inducing lytic reactivation of KSHV in PEL.We show that
XBP-1s transactivates the KSHVRTA promoter but does not transactivate the EBVBZLF1 promoter
in non-B-cells by using a luciferase assay. Co-expression of activated protein kinase D, which can
phosphorylate and inactivate class II histone deacetylases (HDACs), does not rescue XBP-1 activity
on Zp nor does it induce BZLF1 and BRLF1 expression in PEL. Finally, chemical inducers of KSHV
and EBV lytic replication in PEL, including HDAC inhibitors, do not lead to XBP-1 activation. We
conclude that XBP-1 specifically reactivates the KSHV lytic cycle in dually infected PELs.
INTRODUCTION
The human gammaherpesviruses Epstein–Barr virus (EBV)
and Kaposi’s sarcoma-associated herpesvirus (KSHV) are
associated with B-cell lymphomas and tumours of epithelial
and endothelial origin, respectively. EBV and KSHV co-
infection occurs in approximately 80% of the non-
Hodgkin’s B-cell lymphoma, primary effusion lymphoma
(PEL); the remainder being infected by KSHV alone. KSHV
and EBV dually infected PEL have a subtly different pattern
of B-cell gene expression compared with KSHV singly
infected PEL (Fan et al., 2005). In addition, the presence of
EBV appears to potentiate the tumourigenicity of dually
infected PELs in SCID mice (Trivedi et al., 2004). How
dually infected PEL arise is not understood, however, both
KSHV and EBV latently infect PEL and normal B-cells.
EBV establishes a latent infection in memory B-cells in vivo
(Babcock et al., 1998, 1999; Souza et al., 2005; Thorley-Lawson,
2001). A model for EBV infection suggests that, following
saliva transmission, EBV infects IgD-positive antigen-naı¨ve
B-cells in the nasopharyngeal lymphoid tissue (Joseph et al.,
2000) and induces B-cell proliferation through the expres-
sion of virus latent growth programme genes (Thorley-
Lawson & Gross, 2004). The EBV-positive lymphoblasts
subsequently express the default/latency II gene-expression
programme (Thorley-Lawson, 2001; Thorley-Lawson &
Gross, 2004), finally entering the memory B-cell repertoire,
where the virus silences its gene expression allowing lifelong
persistence (Gires et al., 1997; Panagopoulos et al., 2004).
The type of B-cell and the mechanism of latent colonization
by KSHV are not known.
Horizontal virus transmission requires either EBV and/or
KSHV to reactivate from latency with infectious EBV and
KSHV being transmitted by saliva. The molecular events
that lead to virus reactivation have been studied extensively.
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For EBV the reactivation of the lytic cycle is mediated by two
viral proteins, BZLF1 (ZTA) and BRLF1 (RTA) (Amon et al.,
2004; Chang & Liu, 2000; Yuan et al., 2006). BZLF1 is the
key immediate–early protein in EBV (Bryant & Farrell, 2002;
Countryman & Miller, 1985), with B-cell receptor (BCR)
cross-linking able to activate the BZLF1 promoter (Zp) but
not the BRLF1 promoter (Rp). Induction of Zp is therefore
the first event of EBV lytic reactivation (Amon et al., 2004),
and BZLF1 expression alone is sufficient to initiate the entire
EBV lytic cycle (Countryman & Miller, 1985; Rooney et al.,
1989). For KSHV, the virus immediate–early replication and
transcription activator protein (RTA) is both necessary and
sufficient to activate the virus lytic cycle. RTA is able to
transactivate its own promoter and those of many viral
genes, leading to the KSHV lytic gene expression cascade
(Lukac et al., 1998).
The authentic cellular mediators that lead to the induction
of EBV BZLF1 (ZTA) and KSHV RTA (K-RTA) are less
clear. Previously, we and others showed that the activated
B-cell terminal-differentiation transcription factor X-box
binding protein 1 (XBP-1s) is sufficient to initiate the lytic
cycle of KSHV in PEL cell lines (Dalton-Griffin et al., 2009;
Sun & Thorley-Lawson, 2007; Wilson et al., 2007). XBP-1s
binds to and transactivates the promoter of KSHV RTA.
XBP-1s expression is essential for terminal differentiation
of plasma cells (Reimold et al., 2001). XBP-1 retains a 26 nt
intron when expressed (XBP-1u, unspliced) that results in
a frame shift preventing the translation of an active
transcription factor. Under endoplasmic reticulum (ER)
stress or B-cell terminal differentiation, the 26 nt intron of
XBP-1u mRNA is removed to allow the translation of the
active form, XBP-1s (XBP-1 spliced) (Calfon et al., 2002).
EBV lytic replication is induced in plasma cells (Laichalk &
Thorley-Lawson, 2005); however, EBV infection of mul-
tiple myeloma cell lines does not result in lytic EBV
replication even though XBP-1s is abundantly expressed in
these cells (Anastasiadou et al., 2009). Interestingly, other
studies have also suggested that XBP-1s is able to bind to
and transactivate the EBV BZLF1 promoter (Bhende et al.,
2007; Sun & Thorley-Lawson, 2007). Although XBP-1 can
be transiently activated following BCR cross-linking
(McDonald et al., 2010), XBP-1s alone may not be
sufficient to induce expression of EBV ZTA as protein
kinase D (PKD) may also be required (Bhende et al., 2007).
In dually infected PEL a selective lytic switch has been
proposed that leads to the induction of one virus over the
other (Miller et al., 1997). Indeed K-RTA can only induce
the KSHV lytic cycle and BZLF1 can only induce the EBV
lytic cycle in PEL. The selective switch can be maintained
by the induced virus blocking the lytic replication of the
other latent virus (Xu et al., 2007). If both K-RTA and
BZLF1 are expressed at the same time, physical interactions
promote mutual inhibition of the two transcription factors
(Jiang et al., 2008). Here we investigate the mechanism that
underlies the initial induction of K-RTA and BZLF1 in
dually infected PEL (Miller et al., 1997). We show that
XBP-1s alone induces the KSHV lytic cycle but does not
induce either EBV BZLF1 or BRLF1 in PEL cell lines; it also
does not induce either of the EBV immediately–early
proteins in EBV-positive Burkitt’s lymphoma cell lines
(BLs). Additionally, we show that XBP-1s does not activate
the BZLF1 promoter of EBV in HEK 293T and HeLa cells.
Overexpressing XBP-1s in both PEL and BLs does not
increase the level of BZLF1 and BRLF1 mRNA. These
results suggest that XBP-1s activates the KSHV lytic cycle
alone in EBV co-infected PEL cells.
RESULTS
XBP-1s overexpression in PEL cell lines results in
KSHV RTA expression but not EBV BZLF1
expression
In order to examine the ability of XBP-1s to induce the
EBV lytic cycle, we used lentiviral vectors for the transient
delivery of XBP-1s into different PEL cell lines. The effect
of XBP-1s overexpression on both KSHV and EBV were
evaluated by Western blotting against the KSHV imme-
diate–early gene K-RTA and the EBV immediate–early
gene BZLF1 (ZTA), respectively. Overexpressing XBP-1s in
JSC-1 cells, a KSHV and EBV co-infected PEL, induced K-
RTA expression. However, no EBV BZLF1 protein
expression was detected, despite the ability of O-tetradeca-
noyl-phorbol 13-acetate (TPA) to induce the expression of
K-RTA and BZLF1 in JSC-1 simultaneously (Fig. 1a).
It is possible that EBV in PEL cell lines is in some way
defective or non-responsive to XBP-1s. Therefore, we
repeated the experiment with BC3 clone 6 (BC3 cl6) and
CRO6 clone 2 (CRO6 cl2); two cell lines that were
produced by superinfecting KSHV single-positive PEL cell
lines with replication-competent EBV–GFP virus (Xu et al.,
2007). Western blot analysis showed identical results with
the induction of K-RTA but no expression of BZLF1 (Fig.
1b, c) after overexpressing XBP-1s in these cells. TPA
treatment again resulted in induction of K-RTA and
BZLF1. In all cases, 60–80% of PEL cells were transduced
by the XBP-1s-expressing lentivirus (data not shown).
Expression of XBP-1s was confirmed by using Western blot
analysis (Fig. 1a, b). Therefore, XBP-1s induces K-RTA
expression in PELs, but does not induce BZLF1 expression.
Overexpression of XBP-1s in BL cells does not
induce EBV BZLF1 expression
It is possible that the presence of KSHV in PEL affects the
ability of XBP-1s to induce BZLF1 expression. We
therefore expressed XBP-1s in BLs, which are only EBV
positive. Using BCR cross-linking we could induce BZLF1
expression (Fig. 2). However, overexpressing XBP-1s in
two different BL lines, Mutu and Akata, did not induce
BZLF1 expression despite good transduction efficiencies of
10–25%. This suggests that XBP-1s does not transactivate
the BZLF1 promoter in B-cell lymphomas regardless of the
presence of KSHV.
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Overexpression of XBP-1s in BL or PEL cells does
not induce EBV BRLF1 and BMRF1 expression
BRLF1 is a second EBV immediate–early protein whose
expression is induced by BZLF1 during the EBV lytic cycle.
Together these two proteins induce the rest of EBV lytic
cascade. We examined the expression of BRLF1 after
overexpressing XBP-1s in both BL (Akata) (Fig. 3a) and
PEL (JSC-1) (Fig. 3b) cells. The expression of the EBV
early protein BMRF1, also known as diffused early antigen
(EA-D) (Bayliss & Wolf, 1981), was also examined by
using Western blot analysis. BMRF1 transcription is
activated by BZLF1 (Kenney et al., 1992). However, in
BL or PEL cell lines, overexpression of XBP-1s did not
induce BZLF1, BRLF1 and BMRF1 expression. Inter-
estingly, co-induction of K-RTA, BZLF1 and BRLF1 by
TPA in PEL failed to induce BMRF1 expression, consistent
with mutual co-repression of the full virus lytic cycle
(Jiang et al., 2008).
EBV lytic-cycle promoters do not respond to
XBP-1s
Previously, we showed that XBP-1s can transactivate the K-
RTA promoter (Wilson et al., 2007), thereby inducing the
KSHV lytic cycle. We therefore determined whether the
Fig. 1. XBP-1s does not activate EBV lytic gene expression in PEL
cell lines. (a) JSC-1, a KSHV and EBV double-positive PEL cell
line, expressed K-RTA and BZLF1 after treatment with TPA, but
only K-RTA was expressed following XBP-1s transduction. (b)
BC3 cl6, and (c) CRO6 cl2 are EBV-superinfected KSHV-positive
PEL cell lines and showed a similar pattern with XBP-1s
transduction only resulting in K-RTA expression. TPA was able to
induce both K-RTA and BZLF1. The Daudi cell line treated with
TPA and K-RTA-transfected HEK 293T cells acted as positive
controls for the BZLF1 and K-RTA antibody staining, respectively.
XBP-1s expression was detected using an XBP-1s specific
antibody. VecCon, vector control.
Fig. 2. Burkitt’s lymphoma (BL) cell lines do not express BZLF1
after transduction with XBP-1s. (a) Mutu and (b) Akata, both EBV-
positive BL cell lines, were transduced with XBP-1s and vector
control (VecCon) but BZLF1 expression was not detected. B-cell
surface cross-linking (BCR) with human Ig is used as positive
control to induce BZLF1 expression: (a) Mutu, with Ig-M. (b) Akata,
with Ig-G.
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EBV BZLF1 or BRLF1 promoters can be transactivated by
XBP-1s. A construct containing BZLF1 promoter fused to a
luciferase reporter gene (McDonald et al., 2010) was used
to determine the response to XBP-1s in HEK 293T cells;
however, we were unable to show strong XBP-1s activity on
the BZLF1 promoter (Fig. 4a). The experiments were
repeated using the BRLF1 promoter (Bhende et al., 2007)
in either the methylated or unmethylated form. Both forms
of the BRLF1 promoter were transactivated by BRLF1 and
had a lesser but detectable response to XBP-1s (Fig. 4b).
The activity was therefore independent of the promoter
methylation status. The activity of XBP-1s in this assay
system was confirmed by using a KSHV RTA luciferase
promoter reporter that responded to both KSHV RTA and
XBP-1s (Fig. 4c). The expression of XBP-1s in the
luciferase assay was confirmed by Western blot analysis
(Fig. 4a, b insert).
XBP-1 is unspliced in different B-cell lymphomas
and splicing is not induced by TPA or valporic
acid (VPA)
XBP-1u is expressed in both PEL and BL cell lines. DTT, a
reducing agent able to induce the KSHV lytic cycle in
KSHV-infected HEK 293T cells, can cause the splicing of
inactive XBP-1u mRNA to active XBP-1s mRNA by
promoting the unfolded-protein response (UPR) (Wilson
et al., 2007). As TPA can induce K-RTA and BZLF1
expression, and previous reports show other chemical
agents can induce these viruses (Ye et al., 2007), we
determined whether they do so in part by inducing
XBP-1splicing. DTT, TPA, VPA and sodium butyrate
(NaB) (both histone deacetylase inhibitors) were used and
XBP-1 splicing was assessed in the PEL cell line JSC-1 and
BC3 cl6 cell line. Only DTT caused XBP-1 splicing in PEL
cell lines despite TPA being capable of inducing KSHV K-
RTA and EBV BZLF1 expression (Fig. 5b, c, f). We also
examined the splicing status of XBP-1 in the BL cell lines
Akata and Mutu. Again, XBP-1 is expressed as the
unspliced inactive form and this only undergoes splicing
in the presence of DTT (Fig. 5d, e).
Induction of XBP-1 splicing by the UPR does not
induce the KSHV and EBV lytic cycle
As DTT is capable of inducing XBP-1 splicing and the
KSHV lytic cycle in HEK 293T cells (Wilson et al., 2007),
we examined the ability of DTT to induce the lytic
reactivation of KSHV and EBV by Western blotting for the
expression of K-RTA and BZLF1. Despite being able to
cause XBP-1 splicing, DTT resulted in large amounts of cell
death in PEL (Fig. 5h) After treating the cells with DTT for
10 min, JSC-1 cells lose membrane integrity and stain with
trypan blue; after 48 h of incubation, more than 50% of
JSC-1 cells are dead (Fig. 5h). Therefore, and because of the
toxicity of DTT in PEL cells, it is not possible to access the
effect of XBP-1 splicing (Fig. 5f). The BL cell line Akata was
more resilient to DTT treatment; however, despite the
ability of DTT to induce XBP-1 splicing, BZLF1 was not
expressed (Fig. 5g).
Fig. 3. Expression of XBP-1s does not induce BRLF1 and BRLF1 protein expression in either BL or PEL cell lines. (a) Akata and
(b) JSC-1 cell lines were transduced with XBP-1s and vector control with m.o.i. of 5 and 2, respectively (m.o.i. measured in
JSC-1 cells). Neither BZLF1, BRLF1 nor BMRF1 expression were detected in either cell line. BCR cross-linking was used as a
positive control for Akata to induce EBV lytic gene expression and TPA was used as a positive control for JSC-1 cell lines to
induce KSHV and EBV lytic gene expression. Both positive controls showed strong BZLF1 expression, weaker BRLF1
expression, and, for Akata (a) only, expression of BMRF1 with BCR cross-linking. B95.8 cell line was used as a positive control
for EBV immediate–early and early protein expression.
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Overexpression of XBP-1s or use of chemical
agents does not induce expression of BZLF1 and
BRLF1 mRNA in PEL or BL
Although XBP-1s overexpression did not induce detectable
BZLF1 and BRLF1 protein expression in PEL or BL cell
lines, the luciferase assays showed that XBP-1s weakly
transactivated Zp and Rp in HEK 293T cells. We therefore
performed a quantitative real-time PCR (Q-RT-PCR) to
determine the mRNA levels of BZLF1 and BRLF1 in PEL
and BL cell lines in response to XBP-1s and various
chemical inducers of the KSHV and EBV lytic cycles.
In Akata cells, BZLF1 and BRLF1 mRNA expression did not
increase following XBP-1s expression or following TPA,
VPA and DTT treatment (Fig. 6a). BCR cross-linking used
as a positive control induced BZLF1 mRNA expression
significantly (P,0.05, two-tailed t-test). The increase of
BRLF1 mRNA is not statistically significant (P.0.05, two-
tailed t-test) and is consistent with the lack of BRLF-1
protein expression (Fig. 3a). This is also consistent with
previous work by Amon et al. (2004), showing that BCR-
cross-linking transactivates Zp, but not Rp.
EBV BZLF1, EBV BRLF1 and KSHV K-RTA mRNA
expression was determined in JSC-1 cells by using Q-RT-
PCR (Fig. 6b). After XBP-1s transduction or VPA and DTT
treatment, BZLF1 and BRLF1 mRNA expression was not
significantly different from control cells (P.0.05, two-
tailed t-test). However, the K-RTA mRNA level increased
significantly in response to XBP-1s, TPA, VPA and DTT
(P,0.05, two-tailed t-test). TPA induced a significant
increase in the BZLF1 mRNA level, compared with the
negative control (P,0.05, two-tailed t-test). These data
confirm that XBP-1s alone does not transactivate the EBV
Zp or Rp in PEL or BL cell lines.
XBP-1s and protein kinase D together do not
induce BZLF1 expression in PEL cell lines
Previously Bhende et al. (2007) showed that XBP-1s alone
was not sufficient to induce lytic reactivation of EBV and
that PKD was also required. We therefore performed
luciferase assays to investigate the effect of the combined
expression of XBP-1s and a constitutively active PKD
(pPKDm-IG). In HEK 293T cells, PKD alone weakly
transactivated the BZLF1 promoter but not the BRLF1
promoter (Fig. 7a). Conversely, XBP-1s in combination
with PKD weakly transactivated the BRLF1 promoter (Fig.
7a). In order to ensure that the lack of a robust effect from
PKD is not cell type specific, we performed the luciferase
assay in HeLa cells for the Zp. Here, XBP-1s and active
PKD alone do not transactivate Zp, but together weakly
transactivate Zp (Fig. 7b). However, these effects are not
statistically significant (P.0.05, two-tailed t-test). At all
times BZLF1 and BRLF1 were able to transactivate their
respective promoters.
Importantly, overexpressing either PKD or XBP-1s alone or
together in JSC-1 cells did not induce BZLF1 or BRLF1
protein expression (Fig. 7c), whereas K-RTA expression was
induced whenever XBP-1s was overexpressed. Q-RT-PCR
confirmed that the mRNA expression of BZLF1 and BRLF1
did not increase when PKD was expressed with and without
XBP-1s (Fig. 7d). K-RTA mRNA expression increased
significantly (P,0.05, two-tailed t-test) whenever XBP-1s
Fig. 4. BZLF1 and BRLF1 promoter responses to XBP-1s. (a)
XBP-1s weakly transactivates the Zp in a luciferase-reporter assay
in HEK 293T cells. BZLF1 overexpression transactivates the Zp as
a positive control. (b) BRLF1 and XBP-1s expression transactivate
the Rp. The XBP-1s expression level in Zp- (d, insert) and Rp- (e,
insert) transfected cells co-transfected with BZLF1, BRLF1 or
XBP-1s was determined by Western blotting. (c) The K-RTA
promoter was used as a positive control for XBP-1s expression
and activity. The promoter is transactivated by both K-RTA and
XBP-1s. RLU, Relative light units.
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was overexpressed (Fig. 7d). Therefore, active PKD alone
does not lead to EBV BZLF1 and EBV BRLF1, or KSHV
K-RTA expression. Also, active PKD together with XBP-1s
does not induce EBV BZLF1 and BRLF1 expression.
DISCUSSION
Plasma cell terminal differentiation and the associated
expression of XBP-1s are linked to EBV and KSHV lytic
cycle induction (Bhende et al., 2007; Laichalk & Thorley-
Lawson, 2005; Sun & Thorley-Lawson, 2007; Wilson et al.,
2007; Yu et al., 2007). Recently this has been extended
beyond human gammaherpesviruses with the demonstra-
tion that plasma cells account for most of the lytic
reactivation of murine herpesvirus 68 in mice (Liang et al.,
2009). In EBV and KSHV co-infected PEL however,
selective induction of one viral lytic cycle cross-represses
the other viral lytic cycle and co-expression of both KSHV
Fig. 5. NaB, TPA and VPA do not induce XBP-1 splicing in PEL and BL cell lines. (a) XBP-1 is expressed as an unspliced
(XBP-1u) form, but the spliced, active form (XBP-1s) can be detected following ER stress induction by the resistance to PstI
digestion of the XBP-1s PCR product. Treating the cells with DTT induces ER stress and XBP-1u splicing in all lymphoma cell
lines (b–e). However, NaB, TPA and VPA treatment do not induce XBP-1 splicing in the lymphoma cell lines (b–e) even though
VPA induces K-RTA expression in the PEL JSC-1 and TPA induces both K-RTA and BZLF1 in JSC-1 cells (f). VPA and DTT do
not induce BZLF1 expression in the BL line Akata (g). DTT toxicity (h) results in PEL cell death and the absence of detectable
proteins (f).
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and EBV immediate–early proteins results in mutual
inhibition (Jiang et al., 2008; Miller et al., 1997; Xu et al.,
2007). This suggests that a selective lytic switch that
induces one or other virus is required for successful EBV or
KSHV lytic replication in PEL. Here we show that XBP-1s
is able to induce KSHV lytic replication alone in dually
infected PEL. XBP-1s does not induce the expression of
EBV BZLF1 and BRFL1 immediate–early–proteins or
transcripts in PEL or BL. XBP-1s with PKD also does not
induce the expression of BZLF1 and BRFL1 immediate–
early proteins or transcripts in PEL.
Previous studies have suggested XBP1s, either alone or in
combination with PKD, can activate the EBV lytic cycle
(Bhende et al., 2007; Sun & Thorley-Lawson, 2007);
however, the mechanistic detail is unclear. Sun &
Thorley-Lawson (2007) showed that, in HeLa cells, XBP-
1s cannot transactivate Zp. Whereas, Bhende et al. (2007)
showed, also in HeLa cells, that XBP-1s weakly transacti-
vates Zp and Rp, and the effect on Zp could be enhanced
by co-expression of constitutively active PKD (Bhende
et al., 2007; Sun & Thorley-Lawson, 2007). Our data in
HEK 293T cells supports the observations that XBP-1s
alone can weakly transactivate Zp and Rp. Similarly, we
show co-expression of XBP-1s and PKD weakly transacti-
vates Zp in HEK 293T and HeLa cells, although not to the
magnitude described previously. This may reflect differ-
ences in assay sensitivity or may reflect the fact that we
have used human XBP-1s in our studies rather than the
murine XBP-1s used by Bhende et al. (2007). Nevertheless,
the relevance of these observations in HEK 293T and HeLa
cells, and the response of EBV to XBP-1s and PKD in B-cell
tumour lines, is questionable.
The ability of XBP-1s to transactivate either Zp or Rp
probably depends on both the cell type and on the nature
of the individual cell lines. This is supported by observa-
tions that distinct chemical inducing agents have different
effects on the induction of EBV and KSHV lytic cycles in
various lymphoma lines (Countryman et al., 2008; Miller
et al., 1997). In a lymphoblastoid and a nasopharyngeal
carcinoma cell line XBP-1s and PKD clearly activated EBV
BZLF1 protein expression, but BL or PEL cell lines were
not tested (Bhende et al., 2007). In an unusual multiple-
myeloma cell line latently infected with EBV, only low
levels of BZLF1 transcript could be induced by XBP-1s.
This observation contrasts with recent data indicating that
EBV can latently infect multiple myeloma cell lines in vitro.
In these circumstances the endogenous, active XBP-1s does
not drive the EBV lytic cycle (Anastasiadou et al., 2009).
Here we show that despite transactivation of Zp and Rp by
XBP-1s in HEK 293T cells, there are no detectable levels of
BZLF1 and BRLF1 mRNA or proteins after XBP-1s
overexpression in B-cell tumour lines.
Why EBV Zp is refractory to XBP-1s in PEL and BL, even
when PKD is co-expressed, is not clear, although the role of
the chromatin structure at Zp is likely to be important.
Indeed, the binding of myocyte enhancer factor 2D to Zp
recruits class II histone deacetylases (HDACs), which
presumably promote a repressed chromatin structure on
Zp in lymphoma cell lines (Gruffat et al., 2002; McDonald
Fig. 6.Overexpression of XBP-1s in PEL and BL cell lines does not increase the mRNA expression levels of BZLF1 and BRLF1.
Q-RT-PCR was used to determine the expression of BZLF1 mRNA (open bars), BRLF1 mRNA (grey bars) and K-RTA mRNA
(black bars) after transduction with XBP-1s lentivirus or treatment with chemical inducers for (a) Akata and (b) JSC-1 cell lines.
(a) Neither XBP-1s overexpression nor TPA, VPA or DTT treatments were able to increase BZLF1 or BRLF1 mRNA expression.
BCR cross-linking induced BZLF mRNA expression (P,0.05, two-tailed t-test). (b) In JSC-1 cells, expression of XBP-1s only
increased K-RTA mRNA expression. TPA, VPA and DTT treatment also increased K-RTA mRNA expression significantly
(P,0.05, two tailed t-test). TPA-treated JSC-1 cells expressed BZLF1 mRNA compared with negative control (P,0.05, two
tailed t-test).
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et al., 2010). Derepression of Zp-associated chromatin by
PKD was suggested as the mechanism that allows XBP-1s
to activate Zp (Bhende et al., 2007). PKD is a member of
the serine/threonine protein kinase family (Rey et al., 2006)
which can be activated by protein kinase C (PKC) (Zugaza
et al., 1996), a cellular target of phorbol esters such as
TPA (Wang, 2006). PKD can also be activated by BCR
cross-linking via the PKC pathway (Matthews et al., 2000).
In our hands, TPA induces both K-RTA and BZLF1 in PEL
and BCR cross-linking induces BZLF1 in BL. Activated
PKD can phosphorylate and therefore inactivate class IIa
HDACs; this is similar to the effect of HDAC inhibitors
(HDACi), such as trichostatin A (Chang & Liu, 2000), VPA
(Feng & Kenney, 2006) and sodium butyrate (NaB). As
Fig. 7. Co-expression of XBP-1s and active PKD does not transactivate Zp or induce BZLF1 expression. (a) HEK 293-T-cells
were transduced with Zp (black bars) or Rp (open bars) luciferase-reporter vectors with either active PKD or XBP-1s together
with active PKD. Active PKD alone shows weak Zp activity and together with XBP-1s weak Rp activity compared to control
empty vector (VecCon) and BZLF1 or BRLF1 expression vectors. However, the increase of luciferase activity was not
statistically significant compared to vector control (P.0.05, two-tailed t-test). (b) The Zp promoter assays were repeated in
HeLa cells where only XBP-1s and PKD together showed weak promoter activity compared with BZLF1 overexpression.
However, this was not statistically significant compared to vector control (P.0.05, two tailed t-test). RLU, Relative light units.
(c) Transduction of JSC-1 cells with XBP-1s and active PKD either alone, in combination or sequentially (denoted by arrows)
does not induce BZLF1, BRLF1 or BMRF1 expression in PEL, but all combinations that include XBP-1s induce K-RTA
expression. (d) mRNA expression in JSC-1, measured by Q-RT-PCR after XBP-1s and/or active PKD transduction for BZLF1
mRNA (open bars), BRLF1 mRNA (grey bars) and K-RTA (black bars). Only K-RTA mRNA expression increased significantly
(P,0.05, two tailed t-test) after XBP-1s transduction with or without PKD expression.
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HDACi are also capable of inducing EBV lytic reactivation
in various cell lines (Gradoville et al., 2002), we
investigated whether XBP-1s is also induced by any of
these chemical inducers. Here we show that neither NaB,
VPA nor TPA induce activated XBP-1s in PEL, and
therefore the effects of HDACi and TPA on the Zp is
independent of XBP-1s.
BCR cross-linking induces the EBV lytic cycle and can also
transiently induce XBP-1s production. However, this
transient XBP-1s cannot be unambiguously linked to
BZLF1 expression (McDonald et al., 2010). In this study
we used DTT to chemically induce XBP-1s in PEL and BL
cell lines. Although DTT is able to induce XBP-1 splicing
and K-RTA in an XBP-1s dependent manner in HEK 293T
cells (Wilson et al., 2007), it causes a large amount of cell
death in PEL cells, making it impossible to determine K-
RTA, BZLF1 or BRFL1 protein expression. Nevertheless, K-
RTA mRNA expression was detected following DTT
treatment of PEL (Fig. 6b). Also DTT does not cause cell
death in BL cells; it induces XBP-1s production but does
not induce BZLF1 expression. Taken together these data
suggest that induction of the EBV lytic cycle in lymphoma
cell lines of PEL and BL is not linked to XBP-1s activity,
although the effects in B-cells in vivo may be different.
METHODS
Cell culture. The PEL cell line JSC-1 and the BL cell lines Mutu,
Daudi and Akata were grown in RPMI 1640 medium (Invitrogen)
with 10% FCS (BioSera), 100 units penicillin ml21 and 100 units
streptomycin ml21 (Invitrogen) at 37 uC in 5% CO2. All super-
infected PEL cell lines, CRO6 clone 2, BC3 clone 6 and BC3 clone 10
(a kind gift from Pankaj Treviti), were grown with G418 selection as
described previously (Xu et al., 2007). HEK 293T cells and HeLa cells
were grown in Dulbecco’s modified Eagle’s medium (Invitrogen)
with 15 and 10% FCS, respectively, 100 units penicillin ml21
and 100 units streptomycin ml21 (Invitrogen) at 37 uC in 10%
CO2. To induce BZLF1 and K-RTA expression, cells were cultured
with the following concentrations of inducing agents: DTT, 2 mM;
goat anti-human IgG antibody (Sigma), 5 mg ml21; 12-O-tetradeca-
noyl-phorbol 13-acetate (TPA; Sigma), 20 ng ml21; VPA (Merck),
1.5 mM.
Lentiviral vector construction and transduction. The lentiviral
vector construction of pXBP1sIG and pIG has been described
previously (Wilson et al., 2007). The lentiviral vector for activated
PKD, pPKDm-IG, was produced from the pHA.PKD.S738A/S742A
plasmid kindly supplied by Alex Toker (Storz & Toker, 2003)
(Addgene). Briefly, BamHI and XhoI were used to clone the
HA.PKD.S738A/S742A insert into the lentiviral vector pIG to produce
the pPKDm–IG construct. To produce lentiviral viruses, HEK 293T
cells were transfected with 1 mg pMDG, 1 mg p8.91 and 1.5 mg of
lentiviral vector, by using FuGENE-6 (Roche). The supernatants were
collected 48 and 72 h post-transfection and filtered. Both PEL and BL
cell lines (56104 cells per well in a 24-well plate) were transduced
with lentivirus vector at an input equivalent to an m.o.i. of 2 or 5 as
measured in JSC-1 cells. This resulted in an actual level of infection of
60–80% in PEL and 10–25% in BL cell lines. Lentiviruses were added
to the cells, spinoculated for 1 h, at 500 g and room temperature. No
selection for infected cells was used after the transduction. Forty-eight
hours after transduction the cells were analysed using flow cytometry.
RNA extraction and reverse-transcriptase PCR (RT-PCR). Total
RNA was purified from 8–106105 cells resuspended in TRIzol
(Invitrogen). The TRIzol mixture was first treated with chloroform
and RNA was isolated using an RNA extraction kit (Qiagen),
including an on-column DNase (Promega) digestion. Reverse
transcription was carried out using Ominiscript Reverse
Transcriptase (Qiagen) according to the manufacturer’s instructions
with 1–2 mg total RNA.
PCR and restriction digestion. Oligo-dT (Promega)-primed cDNA
was used for PCR amplification across the XBP-1 intron as described
previously by Wilson et al. (2007). The PCR product was then
digested with PstI for 1 h at 37 uC.
Q-RT-PCR for mRNA. Q-RT-PCR was performed with a QuantiTect
SYBR Green PCR kit (Qiagen) using the following primers: BZLF1
(59-CTATCAGGACCTGGGAGGGC-39 and 59-CACAGCACACAA-
GGCAAAGG-39) (Schelcher et al., 2005), BRLF1 (59-AATTTAC-
AGCCGGGAGTGTG-39 and 59-AGCCCGTCTTCTTACCCTGT-39)
(Chia et al., 2008), K-RTA (59-TTGGTGCGCTATGTGGTCTG-39
and 59-GGAAGGTAGACCGGTTGGAA-39) (Caselli et al., 2005) and
L32 (59-CAACATTGGTTATGCAAGCAACA-39 and 59-TGACGTTG-
TGGACCAGGAACT-39) (Schelcher et al., 2005). L32 is a cellular
ribosomal gene used to assess the preparation of cDNA and all the
mRNA levels were normalized with L32. The PCR was prepared
according to the manufacturer’s instructions and was performed by
using an ABI Prism 7000 (Applied Biosystems) with the following
programme: 50 uC for 2 min, 95 uC for 15 min, 95 uC for 15 s and
60 uC for 1 min; the third and fourth steps are then repeated for
40 cycles.
Luciferase promoter assays. HEK 293T cells or HeLa cells were
plated at a density of 26104 cells per well in 96-well plates. Cells were
transfected the next day with 20 ng of the appropriate reporter and
expression constructs by using fuGENE-6 (Roche). The ORF50
reporter plasmids were a kind gift from Erle Robertson (Robertson &
Ambinder, 1997). The BZLF1 promoter and expression vectors have
been described previously (Bryant & Farrell, 2002) and the BRLF1
promoter and expression constructs were a kind gift from Shannon
Kenney (Bhende et al., 2007). The pXBP1sIG and pIG plasmids were
described previously (Wilson et al., 2007). Co-transfection of 2 ng of
Renilla expression vector (a kind gift from Professor Gary Stein,
University of Massachusetts, MA, USA) was also used for monitoring
transfection efficiency. After 48 h, the relative light units (RLU) and
the expression of the Renilla construct were determined using
luciferase Stop & Glo reagents (dual-luciferase assay kit; Promega)
according to the manufacturer’s instructions. Data were read using a
GloMaz96 microplate luminometer (Promega) with a single injector.
All assays were performed in triplicate.
Methylation of promoter luciferase constructs. BRLF1 promoter
was methylated using CpG methyltransferase (New England Biolabs)
according to the manufacturer’s instructions. Methylation of the
plasmids was confirmed by performing restriction enzyme digestion
with methylation-sensitive enzymes. Rp was digested with BgII and
MlnI.
Immunoblotting. Forty-eight hours after transduction (with no
selection), the samples were lysed with a mixture of 1 M DTT and
sample buffer (1 : 3 ratio) (0.2 M Tris-HCL pH 6.8, 5.2% SDS, 20%
Glycerol and bromophenol blue) then sonicated and heated to 95 uC
for 5 min. Proteins were resolved on 10% polyacrylamide gels by
SDS-PAGE and transferred to a PVDF membrane. The membrane
was blocked with 5% non-fat dried milk powder (NFDM) in TBS
solution containing 0.1% Tween 20 (Sigma) (TBS-T) for 1 h. The
membrane was then probed with primary antibody as follows: BZLF1,
BZ-1 diluted 1 : 2000 (Bryant & Farrell, 2002); tubulin, anti-a-tubulin
XBP-1 only induces the KSHV lytic cycle in dually infected PEL
http://vir.sgmjournals.org 429
clone DM1A (Sigma) diluted 1 : 40,000; K-RTA polyclonal, kind gift
of Don Ganem (Lukac et al., 1998), diluted 1 : 40 000; PKD, PKC m(D-
20), sc-935 (Santa Cruz) diluted 1 : 2000; BRLF1, anti-EBV transcrip-
tion factor R (Argene) diluted 1 : 2000; BMRF1, EBV early antigen
diffuse (Vector Laboratories) diluted 1 : 2000; XBP-1s, a kind gift
from Giovanna Roncador, diluted 1 : 50 (Maestre et al., 2009), all in
1% NFDM in TBS-T solution at 4 uC overnight. The membrane was
then incubated with appropriate HRP-conjugated secondary anti-
bodies (GE Healthcare) in 1% NFDM TBS-T solution for 1 h at
room temperature. The blots were washed five times for 5 min
periods in TBS-T before developing, and were visualized using ECL
Western blotting detection reagents or ECL Advanced Western
blotting detection reagents (GE Healthcare).
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Abstract
Whole genome sequencing of viruses directly from clinical samples is integral for understanding the genetics of host-virus
interactions. Here, we report the use of sample sparing target enrichment (by hybridisation) for viral nucleic acid separation
and deep-sequencing of herpesvirus genomes directly from a range of clinical samples including saliva, blood, virus vesicles,
cerebrospinal fluid, and tumour cell lines. We demonstrate the effectiveness of the method by deep-sequencing 13 highly
cell-associated human herpesvirus genomes and generating full length genome alignments at high read depth. Moreover,
we show the specificity of the method enables the study of viral population structures and their diversity within a range of
clinical samples types.
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Introduction
Whole genome sequencing of viral genomes directly from
clinical samples is critically important for identifying genetic
variants which cause disease, including those that are under
positive selection pressure through interaction with the host [1].
Genetic variation defines virus population structures and is used
effectively in determining transmission chains [2]. In clinical
samples, viral genome copies per millilitre can number in the
billions yet the relative proportion of viral nucleic acid is minute in
comparison to host nucleic acid. Direct sequencing of mixed
human and viral nucleic acids yields representative proportions of
sequence reads that map to viral genomes [3], This represents a
significant issue when dealing with samples that contain low
proportions of viral nucleic acid and one that has limited such
studies from being carried out previously [4,5,6,7]. For this reason,
current methods for viral genome sequencing benefit significantly
from isolation of viral nucleic acid from host nucleic acid prior to
sequencing. The primary methods rely on the production of
microgram quantities of viral nucleic acid by either in vitro virus
culture or amplification of virus genomes by PCR [4,5,6,7].
However, both methods are known to alter virus population
structures either by replication advantages of subsets of viruses
during in vitro culture or through the introduction of nucleotide
mutations, gene deletions and genome rearrangements [8,9].
Moreover, the presence of PCR-inhibitory secondary structure
and the inability of many viral species to thrive in culture present
additional difficulties in generating sufficient quantities of viral
nucleic acid for whole genome sequencing. These factors all
impact on the accuracy of assembled genome sequences and the
interpretation of minority population structures.
Some of the hardest viral genomes to sequence are those of the
herpesviridae, a family of large highly cell associated (120–230 kilo
base pairs (kbp)) DNA viruses. The eight known human-infective
Herpesviruses are currently represented by 29 whole genome
sequences in GenBank. 18 of these represent Varicella-Zoster
Virus (VZV) strains, the causative agent chickenpox and shingles
while Epstein-Barr and Kaposi’s sarcoma-associated herpes viruses
(EBV and KSHV, respectively) are represented by only two strains
each. In all cases, these genomes were sequenced using viral
nucleic acid isolated from cultured material [7,10,11,12,13,
14,15,16,17,18]).
Target isolation by hybridisation and subsequent enrichment
has proven highly effective in exome sequencing studies [19],
enabling researchers to target and deep-sequence specific regions
within the human genome. This method uses overlapping 120-mer
biotinylated RNA baits, designed by tiling across targeted genomic
regions. Subsequent hybridisation of the RNA baits with sequence
library-prepared nucleic acid enables isolation and enrichment of
target material (using a minimal number of rounds of PCR) and
generating sufficient quantities for sequencing on second-genera-
tion platforms (Illumina, Roche, Abi). Moreover, while microgram
quantities of nucleic acid are still required for sequence library
preparation, the target genomes need only comprise a fraction of
the total nucleic acid [20].
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We describe here, the use of a solution-based target capture
methodology to separate and enrich for specific viral genomes
from low volume clinical samples comprising complex nucleic acid
mixtures (including excess human and bacterial nucleic acids). We
use a variety of approaches to determine the optimal method for
generating sufficient total nucleic acid for sequence library
preparation including whole genome amplification methods and
the use of carrier nucleic acid. The utility of the method is
demonstrated by directly sequencing 13 human herpesvirus
genomes from a range of clinical samples including blood, saliva,
vesicle fluid, cerebrospinal fluid and tumour cell lines.
Results and Discussion
Initially, total DNA was extracted from a range of VZV, EBV
and KSHV clinical and cultured samples (Table 1 and Table S1
online) and their viral loads determined. Due to the decreased
sensitivity of the qPCR assay (versus the PCR assay used to confirm
presence of viral DNA), no viral load data could be determined for
six VZV samples which were below the limit of detection. Five
samples underwent whole genome amplification (WGA) using the
high fidelity Phi29 DNA polymerase and random primers to
generate sufficient DNA for the library preparation step [21]. Viral
load assays, post-WGA, showed a large increase in viral nucleic acid
within the samples (Table S1). All remaining samples were prepared
without WGA, either directly (all culture samples and clinical
sample Vesicle I) or with the addition of carrier DNA (clinical
samples Blood I). Sequence library preparation, hybridisation and
subsequent enrichment were carried out on all samples using the
SureSelect Target Enrichment System (Agilent Technologies) [20]
and custom designed RNA baits. For comparison, two cultured
samples were amplified by overlapping long PCR and the products
mixed in equimolar ratios prior to sequence library preparation.
The viral load and human DNA content was determined for each
sample at the pre-hybridisation, post-hybridisation and post-
amplification stages and are expressed as a ratio (Table 1).
All samples were multiplexed (2-7 per lane) and sequenced using a
Genome Analyser IIx (Illumina, Inc) yielding between either
4.86107–7.26107 76bp paired-end reads per sample (clinical and
cultured samples) or 2.76107–3.36107 54 bp paired-end reads (long
PCR amplicons). Post-sequencing, read-pair quality control was
performed using QUASR (http://sourceforge.net/projects/quasr/),
and removing duplicate and low quality read-pairs. Consensus
genome sequences were produced by aligning read-pairs against a
reference genome using the Burrows-Wheeler Aligner [22] while
polymorphic loci (including SNPs) were reported using VarScan
[23]. The accuracy of SNPs identified in the assembled consensus
sequences for culture samples I and II and clinical samples Vesicle II
and CSF I was confirmed by either direct PCR and sanger
sequencing from the original material or prior reporting of the SNP
in peer-reviewed publications [24,25] (Table S2). In agreement with
previous studies, there was no evidence of error-induced substitutions
or indels in the consensus sequences of samples prepared using the
Phi29 DNA polymerase for WGA [26].
BLASTn [27] searches of unmapped read-pairs showed them to
of human or bacterial origin with minimal homology (,30%
identity) to the target enrichment probes, their presence attributed
to cross-hybridisation and insufficiently stringent post-hybridisa-
tion washes. For samples prepared using the SureSelect system,
34–99% of read-pairs mapped to the reference genomes enabling
the generation of full genome consensus sequences (Figure 1 and
Table S1). No correlation was observed between viral load and the
proportion of mapped reads. Several known short repetitive
sequences within the VZV, KSHV and EBV genomes could not
be accurately assembled with the BWA algorithm and are not
considered further. Genome coverage was lower for samples
prepared by long PCR than for target enriched sample. At
mapping depths of. 5x per nucleotide, genome coverage was 94–
98% for long PCR-prepared samples, compared with . 99% for
target enriched samples. At mapping depths of .100x per
nucleotide, genome coverage reduced to 88–92% for long PCR
samples and$ 94% for target enriched samples (Figure S1). These
differences are due to the presence of PCR-refractory regions
within the VZV genome which have no effect upon the target
separation and enrichment method. The specificity of the target
enrichment probe sets was confirmed by our ability to specifically
target and isolate either KSHV or EBV from a Primary Effusion
cell line lysate infected with both viruses using independent RNA
bait sets (Table 1). The successful enrichment of viral DNA in each
sample is shown by the significant increase in the ratio of
viral:human DNA post-hybridisation and is further evidenced by
the high proportion of sequence reads that map to the target
genome (Table 1).
Minority viral variants have been shown to be important in RNA
viruses and there is evidence that diverse population structures
among these viruses are strongly associated with viral evolution,
disease progression and treatment failure [28,29]. While large DNA
viruses are believed to exhibit minimal genetic variation, neither the
frequencies of minority variants, nor their biological importance, are
known. To examine this in VZV (one of the most stable of the
human herpesviruses), we defined polymorphic loci as positions at
which a minor allele was present at a frequency between 5–50%, the
total read depth exceeded 100 fold and a minimum of 5 independent
reads carry the minor allele (Figure 2). By plotting the frequencies of
each minority allele, relative to the consensus allele, we generated a
‘mutational spectrum’ for each sample showing that polymorphic
loci exist at between ,0.03–0.5% of positions in the genome
(Figure 3). The frequency of VZV genome positions with minority
bases was highest in two genomes (Culture III & IV) prepared by
long PCR and these also showed strong bias towards A to G and T to
C substitutions at minority variant positions, consistent with
sequence errors introduced by Taq–like polymerases [30]. In
contrast, no mutational pattern emerged in any samples prepared
by target enrichment confirming that no systemic bias was present.
For target enriched samples, those that underwent culture (Culture I
and II) had the lowest numbers of minority variant positions (, 40–
50) while the clinical samples were more variable. This likely reflects
a generalised tissue culture-related loss of diversity in culture samples
[8] while the relatively large proportion of polymorphic loci in CSF I
may be indicative of a more diverse population structure, the
significance of which is currently unknown.
These data demonstrate, for the first time, the suitability of
target capture technology for purifying very low quantities of viral
nucleic acid from complex DNA populations where the host
genome is in vast excess. This enables deep sequencing and
accurate alignment of full length viral genomes directly from
clinical samples using next generation technologies, making it far
superior to the culture and PCR–based methodologies. The
method is sample sparing (compared to traditional techniques),
compatible with WGA methods, automatable and applicable to a
range of other virus genome types, including RNA viruses. We
predict that the method is fully extendable to other pathogens
including bacteria and protozoa present in both clinical and
environmental samples. Moreover, the ability to recover multiple
viral genomes from a single clinical sample using pools of different
virus family capture probes offers the potential for next generation
multiplex genome sequence based diagnostic testing and studies of
host pathogen interactions.
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Figure 1. Coverage across sequenced genomes is highest using the target enrichment methods. Proportions of assembled genomes at
which read depth per base falls below 100 fold (lightest grey), 50 fold, 20 fold, 5 fold, 1 fold and 0 (indicated by increasing darkness).
doi:10.1371/journal.pone.0027805.g001
Figure 2. Total numbers of minority variant positions in all sequenced VZV samples. Each bar indicates the number of genome positions
at which multiple alleles are present (minor allele frequency 5–49.9%). Datasets are normalised (corrected for the total number of mapped reads per
sample) and showed no evidence that minority reads map to specific regions of the genome or that any bias between the proportions occurring in
coding and non–coding regions of the genomes is present. Viral genome copies, post-target enrichment could not be determined for some samples
(nd).
doi:10.1371/journal.pone.0027805.g002
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Materials and Methods
Ethics statement
Clinical specimens (diagnostic samples collected as part of
standard clinical procedures) were independently obtained from
patients with confirmed VZV infection and anonymised prior to
this study. Written consent was obtained in all cases. The use of
these specimens for research was approved by the East London
and City Health Authority Research Ethics Committee (P/96/
046: Molecular typing of cases of varicella zoster virus).
Repository of sequence read datasets
All VZV sequence datasets are available in the Sequence Read
Archive under the accession number SRA030888.1. All EBV and
KSHV datasets are available in the European Genome Archive
under the accession EGAS00001000141.
Sample preparation: VZV culture samples
VZV strains Culture I, II, III and IV were retrieved from the
Breuer Lab Biobank and cultured (2 passages) in Mewo cells
(MEM, 10% FCS, 1% Non-essential amino acids) at 34uC, 5%
CO2 until 70–80% cytopathic effect was observed. The
monolayer was scraped and centrifuged at 20 0g for 5 min and
DNA was extracted using a QiaAmp DNA mini kit (Qiagen)
according to manufacturer’s instructions.
Sample preparation: VZV diagnostic samples
Diagnostic samples from patients with confirmed VZV infection
were retrieved from the Breuer lab cryobank and included vesicle
fluid (Vesicle I, II, III and IV), Cerebro-spinal fluid (CSF I) and
saliva (Saliva I) and 2 samples adapted to culture (Culture I & II).
Total DNA was isolated from vesicle fluid, saliva and CSF using
a QiaAMP DNA mini kit according to manufacturer’s instruc-
tions. Peripheral blood mononuclear cells (PMBCs) were purified
from whole blood samples by centrifugation (1600 g, 15 minutes)
enabling separation of plasma (top layer) and PBMCs (middle
layer) from red blood cells (bottom layer) and total DNA extracted
using a QIAamp DNA Blood Mini Kit according to manufactur-
er’s instructions. Total DNA quantities were determined by
NanoDrop and those with a 260/280 ratio outside the range 1.9–
2.1 were further purified using the Zymoclean Genomic DNA
Clean & ConcentratorTM (Zymo Research Corp.).
Sample preparation: Primary effusion lymphoma cell
lines
PEL cell lines JSC-1 [31] and HBL6 [32] were cultured in
RPMI containing 10% FCS (Biosera) and pen/strep (100 units
ml21 penicillin and 100 mg ml21 streptomycin, Invitrogen). Lytic
reactivation of KSHV and EBV in PEL was induced by addition
of valproic acid (2.5 mg ml21) and 20 ml virus-containing
supernatant collected and 0.45 mm filtered after 72 hours. Viruses
were concentrated using 8% Poly(ethylene glycol) triphenylpho-
sphine (Sigma) and 0.15M NaCl. Samples were stored at 4uC for
12 hours before centrifuging (4uC, 2000 g for 10 min). The
supernatant was removed and discarded and the virus pellet re-
suspended into 200 ml PBS and DNA extracted using the QiaAmp
DNA Blood Mini Kit (Qiagen) according to manufacturer’s
instructions.
Whole genome amplification
5 clinical samples with very low total DNA quantities (with
variable viral loads) were amplified (10ng starting DNA) using
Genomiphi V2 (GE Healthcare) and purified using Zymoclean
Genomic DNA Clean & ConcentratorTM (Zymo Research Corp.),
both according to manufacturer’s instructions.
Figure 3. Mutational spectra of minority variants occurring within clinical samples. Each bar indicates the number of genome positions at
which specific allele combinations (see graphic) are present (minor allele frequency 1–10%). Datasets are normalised (corrected for the total number
of mapped reads per sample) and show a clear bias toward A to G and T to C substitutions in samples prepared by long PCR. No bias was observed in
samples prepared using target enrichment methods.
doi:10.1371/journal.pone.0027805.g003
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Viral load assays
The relative proportions of human and viral DNA within each
sample were determined by qPCR assays targeted at human
GTPase KRas (KRAS) and varicella-zoster virus ORF 29.
VZV DNA was measured by a real-time PCR assay used to
quantitatively detect viral DNA in clinical specimens. The PCR
targets a 78 bp region in ORF 29 of the VZV genome, a 78 bp
region in the EBV nuclear antigen leader protein and a 88 bp
region in KSHV ORF 73. For VZV, 1 ml of sample DNA was
diluted with 8 ml nuclease-free water and mixed with 12.5 ml of
Qiagen master mix (from Quantitect Multiplex PCR Kit
(Qiagen)), 0.94 ml (final concentration 0.94 mM) of the for-
ward primer 59 CACGTATTTTCAGTCCTCTTCAAGTG 39,
0.94 ml of the reverse primer 59 TTAGACGTGGAGTTGA-
CATCGTTT 39 and 0.1 ml of the FAM probe 59 FAM-
TACCGCCCGTGGAGCGCG -BHQ1 39 (final concentration
0.4 mM). For EBV, the EBNA-LP gene was targeted and samples
were prepared with the SensiMix dU kit (Bioline) using a 5 mM
MgCl2 concentration, forward and reverse primers at a 20 pmolar
final concentration (forward primer 59 GGCCAGAGG-
TAAGTGGACTTTAAT 39, reverse primer 59 GGGGACCCT-
GAGACGGG 39) and a probe at a 10 pmol final concentration
(59 FAM-CCCAACACTCCACCACACCCAGGC-BHQ1 39).
For KSHV, ORF 73 was targeted and samples were prepared
as for EBV using the following primers and probe (Forward
primer: 59 TTGCCACCCACGCAGTCT 39, Reverse primer: 59
GGACGCATAGGTGTTGAAGAGTCT 39, Probe: 59 FAM-
TCTTCTCAAAGGCCACCGCTTTCAAGTC-TAMRA 39) [33].
Quantitative PCRwas performed in a 96 well plate on an ABI 7300 or
a Masterplex thermocycler ep (Eppendorf) with an initial 15 minute
incubation at 95uC followed by 45 cycles at 95uC for 15 seconds and
60uC for 60 seconds. Ct values were compared to a standard curve
generated using a plasmid target to assign a copy number per
microliter. For human DNA, GTPase KRas was targeted using
forward (59 GCCTGCTGAAAATGACTGAATATAAAC 39) and
reverse (59 TGATTCTGAATTAGCTGTATCGTCAAG 39) prim-
ers at a 20pmolar final concentration. The relative proportion of
human and viral DNA copy numbers was subsequently calculated and
expressed as a ratio (Table 1).
SureSelect Target Enrichment: RNA bait design
Overlapping 120-mer RNA baits (generating a 2x coverage for
VZV and 5x coverage for EBV and KSHV) spanning the length
of the positive strand of the reference genomes were designed
using in house Perl scripts for VZV and Agilent eArray software
for KSHV and EBV. For VZV, a further 552 control baits were
designed against a 16 kbp region of the Salmo trutta trutta
mitochondrion (NC_010007). The specificity of all baits was
verified by BLASTn searches against the Human Genomic +
Transcript database. Bait libraries for EBV, KSHV and VZV
were uploaded to E-array and synthesised by Agilent Biotech-
nologies. All bait designs are available from the corresponding
author.
SureSelect Target Enrichment: Library preparation,
hybridisation and enrichment
DNA preparations of 3 mg, 500 ng and 250 ng (the latter
bulked with 2750 ng carrier DNA from MeWo cells) were sheared
for 6660 seconds using a Covaris E210 (duty cycle 10%, intensity
5 and 200 cycles per burst using frequency sweeping). End repair,
non-templated addition of 39-A, adaptor ligation, hybridisation,
enrichment PCR and all post- reaction cleanup steps were
performed according to the SureSelect Illumina Paired-End
Sequencing Library protocol (Version 1.0) observing all recom-
mended quality control steps.
Long PCR
Amplicons ranging from 1–6 kbp in size and spanning the
whole VZV genome were generated for culture strains 79A and
V110A. 30 overlapping primer pairs were designed against the
Dumas reference genome (NC_001348) as a template (Table S3).
All reactions were performed using the LongAmpH Taq PCR Kit
(NEB) and all PCR products size selected by gel purification with
the QIAquick Gel Extraction Kit (Qiagen) on 0.8% 1X TAE gels
stained with ethidium bromide. Cycling conditions were as follows:
Denaturation at 94uC for 3 min, followed by 45 cycles of
amplification (denaturation 94uC, 10 s; annealing 55uC, 40 s;
extension 65uC, 30 s – 5 m) and a final extension step at 65uC for
10 min. Gel purified amplicons were merged in equimolar ratios
prior to library preparation. Sequencing libraries were subse-
quently generated using the Nextera Tagmentation system
(Epicentre Biotechnologies). Here, 50 ng of each sample was
sheared and library prepped for paired end sequencing (2654 bp)
in a single reaction according to the manufacturer’s instructions.
Samples were tagged using the Nextera Barcode Kit and
multiplexed prior to flow cell preparation and cluster generation.
Illumina sequencing
Sample multiplexing (2 – 7 samples per lane on an 8 lane flow
cell) cluster generation and sequencing was conducted using an
Illumina Genome Analyzer IIx (Illumina Inc.) at UCL Genomics
(UCL, London, UK) or Wellcome Trust Sanger Institute
(Hinxton, UK). Base calling and sample demultiplexing were
performed using the standard Illumina pipeline (CASAVA 1.7)
producing paired FASTQ files for each sample.
Sequence data processing and alignment against
reference genomes
For each data set, all read-pairs were subject to quality control
using the QUASR pipeline (http://sourceforge.net/projects/
quasr/) to first trim the 39 end of reads (to ensure the median
Phred quality score of the last 15 bases exceeded 30) and
subsequently to remove read-pairs if either read had a median
Phred quality score below 30 or were less than 50 bp in length.
Duplicate read-pairs were also removed. All remaining read-pairs
were mapped to the reference genome using the Burrows-Wheeler
Aligner (maximum insert 50 bases, maximum distance between
paired ends 500) [34] generating SAM files containing all mapped
and unmapped reads. SAM files were subsequently processed
using SAMTools [35] to produce pileup files for consensus
sequence generation and SNP calling using VarScan v2.2.3 (--min-
coverage 3, --min-reads2 3, --p-value 5e-02) [23]. Unmapped
read-pairs were extracted from SAM files and BLASTn searches
used to determine the proportion mapping to the reference
genome [27]. Read-pairs with no significant hits were subsequent-
ly checked against the non-redundant database at NCBI to
determine their origin.
Supporting Information
Figure S1 Mean read depth across assembles genomes.
The mean read depth of each position in the assembled genome is
shown for (a) VZV culture samples, (b) VZV clinical samples
prepared without WGA, (c) VZV clinical samples prepared with
WGA, (d) VZV long PCR samples, (e) EBV and KSHV from
JSC1 cell lines and (f) EBV and KSHV rom HBL6 cell lines.
(TIF)
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Table S1 Deep sequencing of clinical samples prepared
using the SureSelect Target Enrichment System.
(DOCX)
Table S2 Confirmation of fixed SNPs identified in
assembled consensus sequences.
(DOCX)
Table S3 Primers used to generate overlapping ampli-
cons by long PCR for deep–sequencing of VZV.
(DOCX)
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